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This dissertation examines policy and individual barriers to behavioral health (BH) 
service utilization. The full reach of federal policies like the Affordable Care Act (ACA) and the 
Comprehensive Addiction and Recovery Act (CARA) may be limited by state policies and the 
supply of the workforce available to deliver these services. Further, individual factors, such as 
low health insurance literacy, may influence patterns of behavioral healthcare utilization. Despite 
efforts to increase access to behavioral health services, treatment rates remain low, suggesting 
that barriers remain. To explore the effectiveness of these policies and examine remaining 
barriers, this dissertation explores three main research questions:  
1. Does mental health services utilization increase more in Medicaid expansion states, and 
does MH workforce supply moderate this relationship? 
2. Does buprenorphine dispensing increase to a greater extent after CARA in states where 
nurse practitioners have a broad scope of practice relative to states with a narrow scope of 
practice? 
3. Does health insurance literacy affect subsequent behavioral health services utilization and 
self-reported unmet need for mental health services?  
We find evidence of greater increases in mental health (MH) service visits in Medicaid 
expansion states but little difference between counties with mental health workforce shortage and 
areas with adequate supply. However, MH Emergency Department (ED) visits appear to be 
higher in areas with adequate workforce supply. These findings may be limited by the workforce 
measure, which relies heavily on psychiatry supply. Following CARA, buprenorphine dispensing 
increases overall. Increases are greater in states where state laws grant nurse practitioners (NP) 





associated with an increased probability of reported unmet MH needs and less access to mental 
health specialist services. Research should explore other measures of workforce shortage and 
provider insurance acceptance, which may hinder access to mental health care in Medicaid 
expansion states. Further, policymakers should consider increasing nurse practitioner practice 
autonomy to increase access to treatment for individuals with opioid use disorder. Policymakers 
should consider health insurance literacy’s role in accessing behavioral health services and 
consider these potential general directions: (1) insurance-level efforts to increase the clarity and 
accessibility of health insurance terms/processes and (2) interventions to increase health 






Chapter I: Introduction 
Behavioral health (BH) conditions are prevalent, with approximately 20% of U.S. adults 
living with mental illness (AMI) and 7.4% with a substance use disorder (SUD).1 Untreated, 
symptoms can worsen, sometimes leading to more severe symptoms, additional diagnoses, or 
increased mortality risk.2–5 Despite the prevalence and consequences of untreated BH disorders, 
few receive treatment. Only 44.8% of those with AMI received mental health (MH) services in 
the past year, and only 10.3% of individuals 12 and older with a SUD received substance use 
treatment services.1 Further, less than 35% of adults with an OUD receive substance abuse 
treatment, and even fewer access effective and life-saving medications, such as buprenorphine, 
for OUD.6,7 Increases in opioid-related mortality and suicide are plausibly related to inadequate 
or unmet BH treatment needs.4,5,8  
Medicaid expansions in participating states, authorized by the federal Affordable Care 
Act (ACA), provided coverage for behavioral health services for 14.8 million new enrollees.9 
Despite increased coverage of BH services through ACA, there is little overall change in 
reported access to BH services.10  In 2019, 44.8% of those with AMI reported any outpatient MH 
service in the previous year, compared to 40.9% in 2008. Trends in access to SUD treatment 
services are flat, with 10.4% accessing SUD treatment in 2015 and 10.3% in 2019.1  Low 
treatment rates and slow growth in treatment rates suggest that other barriers remain.11  
Supply barriers may limit the full potential of reforms, such as Medicaid expansion and 
CARA, to improve access to behavioral health services. State-level legislation limiting the 
practice authority of mid-level practitioners may exacerbate workforce shortage problems. 
Supply shortages may be especially detrimental for public coverage, where provider participation 





behavioral health services coverage, individual factors may mitigate demand. Private insurance 
companies typically administer Medicaid benefits to low-income populations.13 Limited 
understanding of insurance jargon can increase confusion about covered services and providers, 
resulting in limited service utilization, particularly for those with little experience accessing 
healthcare services using insurance.14  
Figure 1. Overarching Conceptual Framework  
 
This research seeks to further our understanding of barriers that may reduce access to 
behavioral health services. Specifically, this dissertation will address three topics. The first paper 
explores the impact of Medicaid expansion on the utilization of mental health services and the 
role of the MH workforce. Although Medicaid expansion has increased health insurance 
coverage, literature showing improvements in access to MH treatment and outcomes is limited 
and mixed. Access to MH treatment may be further limited in areas with workforce shortages, 
where people experience greater difficulty finding MH providers to provide treatment. The 
current study will examine the impact of Medicaid expansion on access to MH services and MH 





providers. Medicaid expansion is expected to increase access to mental health services, with 
greater access increases in areas with an adequate mental health workforce. 
The second paper examines whether buprenorphine prescribing increases following the 
federal Comprehensive Addiction and Recovery Act (CARA) in states with broad SOP laws. 
Opioid use disorder is associated with a high risk of mortality, but medications—such as 
buprenorphine or methadone—reduce that risk.4,8 CARA extended prescribing authority to mid-
level providers, such as nurse practitioners (NP).15 However, state variations in practice 
autonomy may impact the supply of waivered nurse practitioners and buprenorphine prescribing. 
CARA is expected to increase buprenorphine distribution, with the greatest increase in states 
with broad SOP laws.  
The third paper explores whether an individual’s health insurance literacy (HIL), or 
understanding of health insurance and terms, leads to access to behavioral health services in a 
low-income population enrolled in a safety-net coverage program. Low HIL is associated with 
more emergency department visits, lack of adherence to prescription drug treatment, delays to 
care, and poorer overall health.16,17 Therefore, low health insurance literacy may be a direct 
barrier to receiving needed care, and this risk is more pronounced in groups with low HIL. Low 
HIL is expected to be associated with lower subsequent access to BH services and more unmet 








Chapter II: The Role of the Supply of Mental Health Workforce on Access and Outcomes 
of Mental Healthcare in Medicaid Expansion States 
In states that expanded Medicaid through the Affordable Care Act, millions of previously 
uninsured low-income populations gained healthcare insurance that included coverage for 
behavioral health services.9 ACA extended the reach of 2008 federal parity legislation to most 
health plans, including all Medicaid-managed care health plans with behavioral health carved-
in.10,18 Low-income populations experience a higher prevalence of mental health conditions than 
the general population.19 In Medicaid expansion (ME) states, where health coverage provides 
behavioral health service coverage to low-income adults with and without children, we expect to 
observe the most significant improvements in mental health services utilization and outcomes. In 
the general population, insured individuals are more likely to report receipt of needed mental 
health treatment than uninsured.20  
While the literature examining the effects of early Medicaid expansion in states or state 
experiments report promising improvements in mental health access and outcomes 
indicators,21,22 literature examining the 2014 Medicaid expansion is limited and mixed. Post-
expansion coverage gains are observed consistently in individuals with mental health conditions 
that live in Medicaid expansion states.23,24  Expansion states experience more reductions in poor 
mental health days, depression diagnoses, and psychological distress, but no improvements in 
unmet mental health need due to cost.25–27 Further, improvements in self-reported mental health 
findings are often sensitive to the population and not tied to the utilization of mental health 
services.25  
Limited evidence finds that mental health outpatient visits increased to a greater extent 





Hispanic Whites.28 Notably, this study finds no significant differences in the share of people who 
access MH services in Medicaid expansion states.28 However, a study using a different data 
source finds evidence of greater increases in mental health prescriptions in Medicaid expansion 
states.29  
Despite recent legislative attempts to improve access to mental health treatment, 
treatment rates remain low.1 Research from a mental health advocacy organization points to 
continued problems with access, with less than half of Americans reporting that mental health 
treatment is accessible and over a third of people reporting difficulty finding a behavioral health 
provider.30,31 The time from symptom onset to treatment is an indicator of unmet needs. On 
average, individuals with mood disorders experience symptoms for 6 to 8 years before accessing 
treatment, and that time is 9 to 23 years for individuals with anxiety disorders.32  
Provider Shortage 
To complicate matters further, a mental health provider shortage and inequitable 
geographic distribution of providers create additional barriers to treatment access for many who 
live with mental disorders.33 Workforce shortages, particularly acute in mental health, may be an 
underlying mechanism that helps explain continued challenges in access to mental health care, 
even in areas with higher insurance rates, such as Medicaid expansion states.34  
Low insurance acceptance among behavioral health providers exacerbates the MH access 
problems caused by workforce shortages.34  In 2010, approximately 38% of psychologists 
reported that they did not accept any insurance, and 45% of psychiatrists do not take any private 
insurance. This compares to about 89% of physicians in other specialties.35 Literature finds 
behavioral health facilities in expansion states are more likely to accept Medicaid post-





Although efforts in recent years have tried to increase the mental health workforce, the 
shortage of behavioral health providers impedes access to treatment.38 As of 2009, almost 20% 
of all U.S. counties had an unmet need for non-prescriber mental health professionals. Nearly all 
counties had an unmet need for prescribers of psychiatric medications.34 More recent estimates 
of provider supply suggest that this problem persists, particularly in rural regions.33 A recent 
analysis revealed that only 4 of 50 states had mental health prescriber levels at or above 50 
percent of the estimated need.11 The aging psychiatrist workforce will continue to exacerbate 
future workforce shortages.39,40 
Although Medicaid expansion has increased health insurance coverage, literature 
showing improvements in access to MH treatment and outcomes are limited and mixed. 28 25–27 
Access to MH treatment may be further narrowed in areas where there are workforce shortages, 
where people experience greater difficulty finding MH providers to treat them, regardless of their 
insurance coverage. The current study will examine the impact of Medicaid expansion on access 
to MH services and MH outcomes, focusing on differences between expansion states with and 














The conceptual framework pictured in Figure 2 is adapted from Donabedian’s structure, 
process, and outcome framework.41 This conceptual framework shows the hypothesized 
relationship between Medicaid expansion and mental health outcome measures. Under the 
“structure box” of the conceptual model pictured above, Medicaid expansion (implemented in 
2014 in most states) provided healthcare coverage to millions of the previously uninsured low-
income population in the U.S. The “process” box depicts how healthcare coverage through 
Medicaid expansion created an avenue for individuals with mental disorders to access needed 
mental health services and pharmacotherapy drugs. The “health outcomes box” shows health 
outcomes associated with access to needed mental health services, including decreases in the 
average levels of psychological distress. Also shown in the “structure box,” Medicaid 
expansion’s impact on process and health outcomes depends on the supply of the local mental 





expansion and MH access and outcomes and to determine whether the mental health workforce 
supply moderates mental health utilization and outcomes.  
Research Aims/Hypotheses 
Aim #1: Examine the impact of Medicaid expansion on mental health care access and outcomes. 
H1: Access to mental health services and pharmacotherapy will increase to a greater 
extent in expansion states in the post-expansion period, relative to non-expansion states. 
H2: Self-reported mental health outcomes will improve to a greater extent in expansion 
states in the post-expansion period, relative to non-expansion states. 
Aim #2: Examine whether counties in Medicaid expansion states with an adequate mental health 
workforce supply experience greater increases in mental health access and outcomes compared 
to counties in Medicaid expansion states that are designated mental health professional shortage 
areas.  
H3: Access to mental health services, pharmacotherapy, and self-reported mental health 
outcomes will improve to a greater extent in counties in expansion states that have a 
greater supply of mental health providers, relative to counties in expansion states that 
have shortages of mental health providers.  
Methods 
Overview of Design 
 This chapter will investigate the role of Medicaid expansion in (1) the utilization of 
mental health services, (2) associated mental health outcomes, and (3) how the supply of mental 
health providers in local areas moderates the effect of Medicaid expansion on access to services 





mental health outcomes, I used nationally representative survey data to conduct a quasi-
experimental difference-in-difference (DID) analysis.  
Data Sources 
Medical Expenditure Panel Survey. The primary source of information for this study 
was the Medical Expenditure Panel Survey (MEPS)42 data from 2010 to 2018. This national 
survey of the civilian non-institutionalized population, conducted annually on a nationally 
representative sample of the U.S. population, provides information about behavioral health visits 
and diagnoses and includes a psychological distress scale, Kessler 6. For the purposes of linking 
state and county level measures to the MEPS sample, I obtained access to MEPS restricted data 
files that include state and county encrypted identifiers, and I conducted the analysis at the 
Agency for Healthcare Research and Quality (AHRQ) data center, in Rockville, MD.   
Area Health Resource File. The Area Health Resource File, maintained by the Health 
Resources and Services Administration (HRSA), is created from a compilation of data sources 
that provide detailed county-level data about health care provider supply and area-level 
population characteristics.43 It contains area-level information about the percent of the population 
living under the federal poverty level (FPL), the physician workforce data, and the number of 
psychiatrists. It also includes county-level indicators to indicate mental health professional 
shortage area (HPSA).  
Identification of Study Sample 
Age. The sample was limited to individuals between the ages of 19-64, as individuals 
who are 65+ are eligible for Medicare.44 Medicaid was available to low-income individuals 
under 19 before the ACA through Children’s Health Insurance Program (CHIP).45 Therefore, we 





Income Levels. We examined the impact of Medicaid expansion across three income 
groups: (1) below 100% federal poverty level (FPL), (2) below 138% of FPL, and (3) below 
200% of FPL.46 Although most expansion states set Medicaid eligibility at 138% FPL, there is 
some variation across states in the populations impacted, particularly in early expander states and 
years.47  
Mental Health Subsample 
We conducted all analyses using the full sample and a subsample that was restricted to 
individuals with mental health symptoms. To identify the mental health subpopulation in the 
MEPS data, I included individuals with moderate or high levels of psychological distress. This 
variable is measured using the Kessler 6 scale, a 6-question scale with Likert-type responses that 
measures psychological distress. Respondents are asked to indicate how they felt the past four 
weeks using questions such as: "During the past four weeks, how much of the time did you feel 
so sad nothing could cheer you up," "During the past four weeks, how much of the time did you 
feel hopeless?" Response categories are as follows: "all of the time," "most of the time," "some 
of the time," "a little of the time," and "none of the time." The six items are summed to generate 
a total scale score, ranging from 0-24, with higher scores indicating higher psychological distress 
levels. This scale has high reliability and high internal consistency and is used for diverse 
populations.48,49 Studies that have used the Kessler 6 compared to clinical diagnostic interviews 
have found high specificity in detecting serious mental illness (SMI) at a cut point equal to 13 or 








Outcome Measures. A summary of measures is located in the appendix (Appendix A, Table 1). 
MH Pharmacotherapy 
We used prescribed medicines in the MEPS event files to generate a binary variable to 
indicate any MH pharmacotherapy and a continuous variable to count the number of 
prescriptions, conditional on having any prescriptions. MEPS classifies prescriptions into 
therapeutic class codes. We identified MH pharmacotherapy using the Multum therapeutic sub-
class #1 for TC1 including stimulants, anxiolytics, antidepressants, antipsychotics, and mood 
stabilizers (Appendix A, Table 2). Any use of MH prescriptions was coded as 1 and otherwise 0, 
and a continuous variable of the total number of prescriptions (conditional on any) was created. 
We used AHRQ documentation to use the relevant therapeutic sub-class codes, as codes change 
slightly across years.42 
Emergency Department and Outpatient MH Utilization 
 MEPS obtains detailed information on all health care encounters, including outpatient 
visits, emergency department visits, and acute inpatient stays. We followed AHRQ linking 
instructions to merge event files, conditions files, and appendix files to generate person-level 
utilization datasets for 2010-2018. Using the relevant ICD-9, ICD-10, and clinical classification 
software codes for each year, we created a variable to flag for any visit with an MH code. The 
number of visits, conditional on any, is summed for each person and year. This procedure 
identifies outpatient and emergency department visits. MEPS separates outpatient utilization into 
two categories (outpatient visits and office-based medical provider visits). We combined these 
two outpatient visits into one outpatient variable and summed the visits to generate the outpatient 







 We examined the severity of psychological distress using the Kessler-6 (K6) scale. This 
scale is administered to adults through the self-administered questionnaire. Although we used 
Kessler-6 as a cutoff for the MH subsample (above 5), there is variation in responses as the 
remaining scale ranges from 6-24. The K6 is analyzed as a continuous variable for all study 
years. 
 To examine the impact of the mental health symptoms on an indicator of functional 
outcomes, we used the question, “Accomplished less than you would like (due to emotional 
problems),” from the self-administered questionnaire as a self-reported measure of MH status. 
Responses “some of the time,” “most of the time,” and “all of the time,” were coded as 1. 
Responses “a little of the time” and “none of the time” were coded as 0.  
Primary Independent Variables 
Medicaid Expansion. We present study results using two specifications of the Medicaid 
Expansion variable: (1) a binary Medicaid expansion variable and (2) a time-varying Medicaid 
expansion variable.  
The first specification that uses a binary Medicaid expansion variable that only includes 
states that expanded in 2014. We excluded states with early ACA expansions with upper-income 
thresholds of at 75% FPL or above (CA, DC, MN, WA).47 Similar to Hoehn,51 we divided the 
study period into pre-Medicaid expansion (2010-2013) and post- Medicaid expansion (2016-
2018) periods. The years 2014 and 2015 are considered acclimation periods and were excluded 
from the analysis.  
We included all states and years in a two-way fixed effect DID regression in the second 





timing of the Medicaid expansion rollout by creating a single time-varying DID estimator 
variable.52 In this analysis, the DID variable of interest is a time-varying Medicaid expansion 
variable. State years with Medicaid expansion were coded as “1.” State years without Medicaid 
expansion were coded as “0.” For example, the DID variable for a state that expanded Medicaid 
in 2015 was coded as “0” for 2010-2014. It was switched to a “1” when the Medicaid expansion 
treatment started in 2015 and remained a “1” for the remainder of the study since the expansion 
status does not change after 2015. In instances when states expanded Medicaid late in the year 
(past July 1), the DID variable was coded as “0” for the current year and “1” for the following 
year and years thereafter. We always coded states that have never expanded Medicaid as “0.” 
Mental Health Workforce Measures 
We stratified models by mental health workforce shortage areas. The Health Resources 
and Services Administration (HRSA) designates shortage areas for mental health professionals, 
known as MH health professional shortages (HPSA). Counties are categorized into three groups 
based on the level of MH workforce shortage: (1) whole county is a shortage area, (2) part of the 
county is a shortage area, (3) or none of the county is a shortage area.53 The shortage area 
categorization uses the following information to create its designation: mental health 
professional workforce, the proportion of the population living in poverty, population age, and 
behavioral health disorder prevalence. It is important to note that the HRSA shortage area 
formula only systematically accounts for the supply of psychiatrists.12 Although other MH 
professionals provide MH treatment services (psychologists, social workers, counselors etc.), 
their inclusion in the HRSA designation is optional and often not reported.12,54   
Current HRSA methodology considers one psychiatrist per 30,000 residents adequate 





residents to 1 psychiatrist. 12,54 There are few counties with no shortages, so we combined non-
shortage and partial shortage areas. We created a binary variable and coded it as 1 to indicate a 
shortage area for the entire county and 0 if the area is considered “non-shortage area” or a 
“partial shortage area.”  
Covariates 
 To control for individual factors that may influence care-seeking behaviors, we included 
the following covariates: age (19-24, 25-35, 36-50, and 51-64), sex (male/female), number of 
chronic health conditions (0, 1-2, 3+), race (White, Black/African American, Alaskan/Native 
American, Asian, and Multiple races/Other), ethnicity (Hispanic/non-Hispanic), education (less 
than high school, high school, more than high school, other/unknown), marital status 
(married/not married), and the percent of the population residing in the county that lived under 
the FPL (continuous). In models that were not stratified, we controlled for the county-level 
supply of psychiatrists per 100,000 residents. 
Statistical Analysis 
The study examined the relationship between Medicaid expansion, MH treatment, and 
mental health outcomes. We stratified models by MH HPSA to examine the role of MH 
workforce supply. All models used a quasi-experimental difference-in-difference (DID) design. 
In all models, binary outcomes were estimated using linear probability models (LPM). Count 
utilization outcomes, conditional on any utilization, were estimated using Poisson regression 
models and reported as incidence rate ratios.  
In the first model, we estimated the impact of expansion in a reduced sample using a 2x2 
DID.   






Ysyi represents dependent variables for individual i in county c and year t. β1Expansions is a state-
level binary variable that was set to 1 for expansion states and 0 for non-expansion states. β2Postt 
is a binary variable to indicate post-expansion years, 2016-2018. β3Expansions*Postts is the DID 
term of interest and measured the relative change in dependent variables for expansion states in 
the post-period, relative to non-expansion states and the pre-period. B4Xic represents a vector of 
controls including individual characteristics and supply variables. State and  Year represent state 
and year fixed effects and εist the error term. All regressions incorporated survey weights and 
corrected the standard errors to account for the complex survey design.   
 To incorporate the MH workforce supply and following prior literature,56 we used the 
MH HPSA shortage designation at a county-level to stratify counties and ran the following three 
regression models: (1) Model (i) as shown above (2) Model (i.a) restricted samples to shortage 
areas, and (3) Model (i.b) restricted the samples to non-shortage or partial shortage areas. We 
generated DID estimates for the total sample and the MH subsample. We tested for differences 
of coefficients between stratified models, (i.a) and (i.b), using z-tests.57  
Sensitivity Analyses 
 We used a two-way fixed effect DID quasi-experimental design to incorporate all years 
and states in the analysis. This analysis allowed us to incorporate the differential timing of the 
Medicaid expansion rollout by creating a single time-varying DID estimator variable. In this 
analysis, the DID variable of interest was a time-varying Medicaid expansion variable, where 
state years with Medicaid expansion were coded as 1. State years without Medicaid expansion 
were coded as 0. 





Ysyi represents dependent variables for individual i in county c and year t.  β1Expansionst is a 
time-varying DID estimator, where states and years with Medicaid expansion present were coded 
as 1 and otherwise 0. B2Xic represents a vector of controls including individual characteristics and 
supply variables. State and  Year represent state and year fixed effects and εist the error term. All 
regressions incorporated survey weights and corrected the standard errors to account for the 
complex survey design. Estimates were generated for the full sample and the MH subsample. 
Results 
Descriptive Statistics 
 Table 1 reports descriptive measures for the states that expanded and never expanded 
Medicaid. Within both groups, results were broken into a pre- and post-expansion period (2010-
2013 and 2016-2018, respectively). Mirroring the primary regression analysis, early and late 
expanders were excluded in the years 2014 and 2015. Any MH access increased in both 
Medicaid expansion and non-Medicaid expansion states, with MH outpatient and MH 
prescriptions increasing to a greater extent in Medicaid expansion states (18.7% increase in 
Medicaid expansion for OP MH compared to 11.3 for non-ME; 13.1% increase in MH 
prescription in Medicaid expansion states compared to 7.2 for non-Medicaid expansion states). 
However, any ED visit increases were larger in non-Medicaid expansion states (28.9% increase 
in non-Medicaid expansion states compared to 7.7% increase in Medicaid expansion states). MH 
OP and ED utilization counts, conditional on any visit, fell in non-Medicaid expansion states and 
rose in Medicaid expansion states (10 and 14.4% decrease in non-Medicaid expansion states 
compared to a 25.8 and 30.8% increase in Medicaid expansion states, respectively). However, 
MH prescription counts decreased in both non-Medicaid expansion and Medicaid expansion 





mental health status improved from pre-to post periods in Medicaid expansion and non-Medicaid 
expansion states, with a larger improvement in non-Medicaid expansion states.  
Age distribution was similar across periods, with a decrease in individuals aged 19-24 
years across both groups. Educational, marital, and chronic health trends were similar across 
groups, except that Medicaid expansion states reported a greater decrease in those who reported 
zero chronic conditions over periods. Supply variables also trended together in Medicaid 
expansion and non-Medicaid expansion states. Notably, the proportion of people in counties 
located in a full MH HSPA decreased by about 30 percent in Medicaid expansion and non-



















Table 1.  
 
Characteristics and MH Outcomes by Expansion Status and Expansion Periods. 
 Non-ME States  ME States 
 2010-2013 2016-2018 Difference(%)  2010-2013 2016-2018 Difference(%) 
Sample 14,870 -  11,209 - 
Weighted population 98,817,195 -  84,627,906 - 
Any MH utilization        
   Any outpatient MH 10.6 11.8 11.3  13.9 16.5 18.7 
   Any MH Rx 20.9 22.4 7.2  24.5 27.7 13.1 
   Any MH ED visit 0.76 0.98 28.9  1.3 1.4 7.7 
Utilization count        
    Rx count 12.6 12.3 -2.4  14.1 12.9 -8.5 
    ED count 1.39 1.19 -14.4  1.3 1.7 30.8 
    MH outpatient count 6.11 5.50 -10.0  8.9 11.2 25.8 
Self-Reported        
   K6sum 4.93 4.05 -17.8  5.2 4.6 -11.5 
   Did less due to MH 46.0 35.2 -23.5  48.4 38.7 -20.0 
Age        
   Age 19-24 21.7 16.9 -22.1  20.1 16.2 -19.4 
   Age 25-35 26.5 28.2 6.4  25.7 28.8 12.1 
   Age 36-50 29.1 26.6 -8.6  28.6 28.3 -1.0 
   Age 51-64 22.5 28.2 25.3  25.5 26.6 4.3 
Sex        
  Male 43.0 39.9 -7.2  44.2 43.9 -0.7 
  Female 56.9 60.1 5.6  55.7 56.1 0.7 
Race/Ethnicity        
   White 70.1 65.2 -7.0  70.2 71.5 1.9 
   Black/African     
   American 24.6 25.9 5.3  21.4 18.9 -11.7 
   Alaskan/Native  
   American 1.7 1.9 11.8  0.74 0.76 2.7 
   Asian 2.6 2.9 11.5  4.0 4.5 -12.5 
   Other/Multiple .81 3.9 381.5  3.7 4.4 18.9 
   Hispanic 24.3 25.2 3.7  19.1 19.1 0 
Marital status        
   Married 30.1 28.6 -5.0  33.0 30.8 -6.7 
Education        
   Below high school 29.2 25.9 -11.3  27.4 22.7 -17.2 
   High school 34.3 38.1 11.1  35.5 41.8 17.7 
   Above high school 31.2 26.3 -15.7  32.2 27.2 -15.5 
   Other/Missing 5.3 9.7 83.0  4.9 8.3 69.4 
Chronic health conditions 
(no.)        
   0 48.9 48.7 -0.4  45.2 41.3 -8.6 
   1-2 32.7 31.1 -4.9  34.9 36.9 5.7 
   3+ 18.2 20.1 10.4  19.9 21.8 9.5 
Psychiatrist/100k  8.0 7.9 -1.3  14.8 13.4 -9.5 








 In adjusted DID models that examined the impact of ME on access to any MH utilization 
(OP, ED, and prescription), we did not observe any significant differences, and this was 
consistent across all income groups, the full sample, and the MH subsample. This means there 
were no statistically significant changes in utilization in ME states relative to non-Medicaid 
expansion states. Similarly, we did not find evidence that Medicaid expansion led to significant 
changes in self-reported outcomes. However, we did find evidence that Medicaid expansion 
increased the number of MH OP and MH ED visits, conditional on any visit. Specifically, 
estimates from the 138% FPL sample show the expected rate of MH OP visits was 1.41 times 
greater (p<0.05) in the post-period in ME states, relative to non-Medicaid expansion states. 
 Further, the expected rate of MH ED visits was 1.55 times greater (p<0.01) in the post-
period in ME states, relative to non-Medicaid expansion states. These results were consistent 
across all income groups, the full sample, and the MH subsample. Although we did not test 
differences in estimates across regressions, we observed that the expected rate of MH OP and ED 
counts were highest in the 100% FPL MH subsample (Table 2). Full results are reported in the 
appendix (Appendix A, Tables 2-7).  
To examine the parallel trends assumption, we plotted each outcome by ME status across 
years and observed acceptable parallel trends in the pre-period except any ED visits, number of 
ED visits, and number of MH prescriptions. Violations to the parallel trends assumption may 














Difference-in-Difference Analysis of the Impact of Medicaid Expansion on MH Utilization and Self-Reported 
MH Outcomes Among All Individuals and a MH Subsample Across Three Income Groups. Standard DID (ME 
* Post)  
100% FPL 138% FPL 200% FPL 
All levels of MH symptoms    
Any Utilization    
   Any MH Rx 0.011[-0.024, 0.047] 0.009[-0.021, 0.040] -0.004[-0.030, 0.021] 
   Any MH related ED -0.005[-0.014, 0.002] -0.001[-0.008, 0.004] -0.001[-0.006, 0.003] 
   Any MH outpatient 0.005[-0.023, 0.034] 0.010[-0.014, 0.034] 0.013[-0.007, 0.033] 
Utilization count , IRR 
   Conditional on Any   
 
    Rx count 0.897[0.749, 1.075] 0.946[0.810, 1.106] 0.978[0.848, 1.128] 
    ED count 1.837[1.303, 2.59] *** 1.55[1.181, 2.038]*** 1.599[1.272, 2.010]*** 
   MH outpatient count 1.594[1.155, 2.199]*** 1.410[1.036, 1.918]** 1.469[1.108, 1.948]*** 
Self-reported outcomes    
  Kessler 6 Scale (continuous)   0.230[-0.269, 0.729] 0.123[-0.264, 0.511] 0.094[-0.231, 0.419] 
  Accomplished less due to MH    0.004 [-0.038, 0.045] 0.004[-0.032, 0.040] 0.001[-0.028, 0.031] 
    
MH subsample    
Any Utilization    
   Any MH Rx 0.006[-0.059, 0.071] 0.012[-0.046, 0.072] 0.006[-0.045, 0.057] 
   Any MH related ED -0.007[-0.029, 0.015] -0.006[-0.023, 0.010] -0.005[-0.019, 0.008] 
   Any MH outpatient 0.017[-0.044, 0.079] 0.022[-0.034, 0.079] 0.027[-0.021, 0.075] 
Utilization count , IRR 
   Conditional on Any    
    Rx count 0.887[0.725, 1.085] 0.953[0.799, 1.138] 0.952[0.815, 1.112] 
    ED count 2.138[1.306, 3.501]*** 1.654[1.167, 2.344]*** 1.655[1.250, 2.191]*** 
   MH outpatient count 1.666[1.222, 2.271]*** 1.659[1.229, 2.240]*** 1.676[1.281, 2.192]*** 
Self-reported outcomes    
  Kessler 6 scale (continuous)   0.583[-0.090, 1.256]* 0.519[-0.074, 1.112]* 0.337[-0.140, 0.816] 
  Accomplished less due to MH    0.019[-0.036, 0.075] 0.020[-0.028, 0.070] 0.013[-0.028, 0.054] 













Regression Results, MH HPSA 
 To explore whether the MH shortage area further impacts access to care, we stratified the 
model by MH HPSA shortage. In adjusted DID models that examined the impact of ME on 
access to any MH utilization (OP, ED, and prescription), we did not observe any significant 
differences in any MH prescription, any MH ED, or any MH outpatient access. This was 
consistent across the full sample, the MH subsample, and shortage area status.  
Descriptively, we observed differences in DID estimates of utilization counts by shortage 
area. In the full sample, MH ED utilization counts are similar across both groups. However, for 
the MH sample, we observed lower utilization in MH ED utilization counts in the shortage 
sample group compared to the group with adequate provider supply (MH ED IRR: 0.606, p<0.10 
and 1.459, p<0.05, respectively) and this difference is statistically significant (z=-2.72, p<.05). 
Further, the DID estimate for MH OP utilization count was higher in shortage areas than non-
shortage areas for both the full and MH subsample; however, differences by shortage did not 
reach statistical significance (Table 3). Full regression results are reported in the appendix 
















   
MH HPSA Stratification. Difference-in-Difference Analysis of the Impact of Medicaid Expansion on MH 
Utilization and Self-Reported MH Outcomes Among Individuals at 138% FPL  
Standard DID (ME * Post) 
 HRSA MH Shortage Area (HPSA) 
 
Shortage No or Partial Shortage 
All levels of MH symptoms   
Any Utilization   
   Any MH Rx -0.005[-0.07,0.06] 0.020[-0.01,0.05] 
   Any MH related ED -0.009[-0.02,0.00] 0.002[-0.00,0.01] 
   Any MH outpatient 0.018[-0.03,0.07] 0.013[-0.02,0.04] 
Utilization count , IRR 
   Conditional on Any 
  
    Rx count 1.180*[0.97,1.43] 0.889[0.73,1.08] 
    ED count 1.693**[1.12,2.56] 1.683***[1.18,2.40] 
   MH outpatient count 2.120***[1.32,3.41] 1.152[0.77,1.72] 
Self-reported outcomes   
  Kessler 6 scale (continuous)   -0.316[-1.11,0.48] 0.304[-0.13,0.74] 
  Accomplished less due to MH    -0.034[-0.11,0.04] 0.015[-0.03,0.06] 
   
MH Subsample   
Any Utilization   
   Any MH Rx 0.017[-0.10,0.13] 0.021[-0.05,0.09] 
   Any MH related ED -0.022[-0.05,0.01] 0.000[-0.02,0.02] 
   Any MH outpatient 0.035[-0.06,0.14] 0.028[-0.04,0.10] 
Utilization count , IRR 
   Conditional on Any   
    Rx count 1.161[0.93,1.44] 0.878[0.70,1.10] 
    ED count 0.606*[0.37,1.00] 1.459**[1.01,2.11] 
   MH outpatient count 2.618***[1.49,4.60] 1.374[0.92,2.05] 
Self-reported outcomes   
  Kessler 6 scale (continuous)   0.496[-0.55,1.54] 0.541[-0.15,1.23] 
  Accomplished 
 less due to MH    
0.056[-0.03,0.15] 0.008[-0.05,0.07] 
Notes: Differences in ED counts between shortage and non-shortage areas are statistically significant. No other 
differences are statistically significant at the 0.05 level. Exponentiated coefficients for IRR estimates;  












 We used a two-way fixed effect (TWFE) DID quasi-experimental design in the 
sensitivity analysis to incorporate all years and states in the analysis. This analysis allowed us to 
incorporate the differential timing of the Medicaid expansion rollout by creating a single time-
varying DID estimator variable. We found that the results were not sensitive to the DID 
specification or early and late expander exclusion. The main analysis restricted the sample to 
states that expanded in 2014 and did not include 2014-2015. This sensitivity analysis used the 
variation across all states and years in a two-way fixed effects difference-in-difference 
regression. Magnitude, direction, and significance were very similar to the primary model, with 
two exceptions. In the 200% FPL group, any MH outpatient utilization reached significance 
(0.016, p<0.05). Second, the MH outpatient utilization outcome in the 100% FPL model reached 


















Difference-in-Difference Analysis of the Impact of Medicaid Expansion on MH Utilization and Self-Reported 
MH Outcomes Among Individuals at 138% FPL  
Two Way Fixed Effect Model, Medicaid expansion is time-varying  
100% FPL 138% FPL 200% FPL 
All levels of MH symptoms    
Any Utilization    
   Any MH Rx 0.006[-0.02,0.03] 0.006[-0.02,0.03] -0.002[-0.02,0.02] 
   Any MH related ED -0.006[-0.01,0.00]  -0.003[-0.01,0.00] -0.001[-0.00,0.00] 
   Any MH outpatient 0.013[-0.01,0.03] 0.009[-0.01,0.03] 0.016**[0.00,0.03] 
Utilization count , IRR 




    Rx count 0.936[0.81,1.07] 0.981[0.87,1.10] 1.025[0.93,1.13] 
    ED count 1.447***[1.17,1.79] 1.330***[1.12,1.57] 1.260***[1.08,1.47] 
   MH outpatient count 1.386*[1.06,1.81] 1.337**[1.02,1.75] 1.318**[1.04,1.66] 
Selfs-reported outcomes    
  Kessler 6 cale (continuous)   -0.041[-0.41,0.33] -0.012[-0.31,0.29] -0.028[-0.27,0.21] 
  Accomplished less due to MH    0.008[-0.02,0.04] 0.009[-0.02,0.03] -0.0004[-0.02,0.02] 
MH Subsample 
Any Utilization    
   Any MH related ED  -0.011[-0.03,0.01] -0.007[-0.02,0.01] -0.006[-0.02,0.00] 
   Any MH outpatient 0.012[-0.03,0.06] 0.012[-0.03,0.05] 0.023[-0.01,0.05] 
   Any MH Rx -0.008[-0.05,0.04] -0.002[-0.04,0.04] -0.004[-0.04,0.03] 
Utilization count , IRR 
   Conditional on Any    
    Rx count 0.899[0.78,1.04] 0.968[0.85,1.10] 1.001[0.89,1.12] 
    ED count 1.631***[1.25,2.12] 1.512***[1.24,1.85] 1.393***[1.16,1.67] 
   MH outpatient count 1.338**[1.05,1.70] 1.438***[1.14,1.81] 1.411***[1.13,1.75] 
Self-reported outcomes    
  Kessler 6 scale (continuous)   0.082[-0.39,0.56] 0.133[-0.27,0.54] 0.112[-0.23,0.46] 
  Accomplished less due to MH    0.011[-0.03,0.05] 0.013[-0.02,0.04] 0.004[-0.02,0.03] 






















Using nationally representative data, we conducted a quasi-experimental study to 
examine the impact of Medicaid expansion and MH workforce on MH utilization and self-
reported outcomes. We find evidence that the number of MH OP and MH ED visits increased to 
a greater extent in Medicaid expansion states. These findings are robust across three income 
groups and within the full and MH subsample. Further, findings are closely mirrored in 
sensitivity tests that include all years and states that expanded before and after 2014 expansions. 
The number of MH OP and ED visits after expansion is higher in Medicaid expansion states than 
non-expansion states. However, similar to other literature, we do not find evidence of greater 
increases in the share of individuals who access MH services.28 Further, we do not find evidence 
of improved self-reported MH outcomes in Medicaid expansion states in the post-expansion 
period relative to non-Medicaid expansion states.   
Mental health workforce shortages may help explain the slow growth in access to MH 
care, even in areas with high coverage rates. Estimates suggest that the current MH workforce 
can only meet 28% of MH needs and research shows that those seeking MH care have difficulty 
accessing services.12,59 In a study examining experiences securing an appointment for MH 
treatment, callers were unable to reach providers on the first call 77% of the time, and only 26% 
of inquiries were returned.59 Securing an appointment for MH treatment with a psychiatrist was 
particularly difficult in pediatric populations, and the difficulty was greatest for those insured by 
Medicaid.60  
To examine the influence of workforce shortages on access to BH services, we stratified 
our models by HPSA. We found little difference between counties with MH workforce shortage 





access in primary care and dental workforce shortage areas.56,61 However, we do find evidence 
that Medicaid expansion decreases MH ED in areas with a workforce shortage, but increases MH 
ED in areas without a workforce shortage. This finding may be explained by disparities in 
insurance acceptance between shortage and non-shortage areas, particularly if shortage areas 
contain providers that are more likely to accept Medicaid. Further, individuals who reside in MH 
shortage areas may have greater access to services intended to serve low-income populations, 
like Federally Qualified Health Centers. To the extent that this is true, it may be easier for 
Medicaid populations to obtain appointments in shortage areas, which may offset ED care 
seeking. We do observe descriptive differences between MH OP utilization counts in shortage 
areas and non-shortage areas, but these differences are not statistically significant.  
HRSA methodology, which generates MH workforce shortage area designations, may 
also explain null findings. HRSA methodology primarily uses the number of psychiatrists 
located in the geographic area as the provider supply indicator. It considers geographic areas 
with one psychiatrist per 30,000 residents adequate supply unless high needs are indicated, in 
which case adequate supply is defined as one psychiatrist to 20,000 residents.12 Given the nearly 
50 percent prevalence of BH disorders in Medicaid recipients, HRSA estimates may understate 
demand for this population.62 Further, the HRSA MH shortage designation requires that the 
supply of psychiatrists is incorporated to determine shortage designation, but reporting other MH 
provider types is optional.12,54 MH service delivery is not limited to psychiatrists, as many other 
provider types also provide MH treatment.67 For example, literature has demonstrated the 
positive impact of the psychiatric nurse practitioner (NP) workforce on access to behavioral 
health services.68 NPs are more likely to accept Medicaid patients, and literature has documented 





authority. These improvements are concentrated in areas with greater physician shortages.69–71 
Future research should incorporate psychiatric NP workforce supply and practice autonomy in 
studies that focus on the impact of Medicaid expansion on access to MH services. 
MH workforce shortages may be further exacerbated by low insurance acceptance among 
psychiatrists and narrow insurance networks for MH providers.63 The disparity is particularly 
acute for Medicaid, with only 43% of psychiatrists accepting new Medicaid patients, compared 
to 73% Medicaid acceptance among other physician types.35   Low insurance participation may 
be explained by federal parity violations, including differential reimbursement for psychiatric 
services compared to medical services, higher administrative burden, and delayed 
reimbursement.64–66 Recent literature shows Medicaid acceptance increased in behavioral health 
facilities in expansion states, but not for psychiatrists.36,37 Low insurance acceptance among MH 
providers disproportionately impacts Medicaid recipients, who cannot pay for services out-of-
pocket.  
Challenges navigating insurance to access care is another mechanism that may help 
explain why we did not find differences in mental health service utilization in expansion states. 
Most state Medicaid programs administer benefits to low-income members through private 
insurance companies, making it essential for Medicaid populations to understand health 
insurance terminology and how to use health insurance to access needed care and services.13,72 
Low understanding of health insurance terms is prevalent across all populations but more acute 
in low-income populations. Difficulty understanding insurance can lead to reduced access to MH 
services, particularly among newly insured, who have little experience using insurance to obtain 
needed care. Research demonstrates that confusion around out-of-pocket costs will result in 





populations are more likely to experience both MH conditions and low HIL, the role of HIL in 
accessing MH services may be particularly relevant for this population. Further, mistrust of the 
healthcare providers, fear of poor treatment by healthcare providers, and community or peer 
group stigma against care-seeking are additional factors that may deter care-seeking 
behaviors.14,74,75  
Limitations 
This study has several limitations. First, this study assumes Medicaid enrollment occurs 
among income-eligible individuals in Medicaid expansion states. However, enrollment gaps 
exist, as many Medicaid-eligible adults are not enrolled in Medicaid.76 Further, this study uses 
multiple cross-sections of nationally representative data but does not incorporate a within-subject 
longitudinal design. Future studies could use this design type to examine the impact of Medicaid 
expansion on MH access and outcomes after individuals gain access to Medicaid. In addition, 
prior experience with insurance or accessing care through a system leads to more referrals for 
healthcare, but we are unable to control for previous experiences with healthcare or health 
coverage directly. We do, however, control for the prevalence of chronic conditions in our 
regression models.  
In addition, there are limitations to the HRSA measure of MH workforce shortage. As 
discussed above, it only systematically accounts for the supply of psychiatrists.12 Other provider 
types, such as nurse practitioners, social workers, and psychologists are a part of the treatment 
landscape. Although they provide MH treatment services, their inclusion in the HRSA 
designation is optional and often not reported.54,55 Additionally, current supply measures do not 
account for the share of the MH workforce that accepts Medicaid insurance. Future studies may 





this analysis does not include factors, such as health insurance literacy and individual-level 
beliefs that may keep people from seeking MH care.  
Conclusions 
The ACA expanded health insurance coverage with MH benefits to millions of 
previously uninsured low-income individuals residing in Medicaid expansion states.78 Although 
nearly 50% of Medicaid enrollees live with a behavioral health disorder, the number of studies 
examining the impact of Medicaid expansion on access to MH services and outcomes is meager 
compared to the considerable research examining access to physical health services and health 
outcomes.62,79 Limited studies report mixed results on the impact of Medicaid expansion on 
access to behavioral health services. This impact may be more limited in areas where there are 
MH workforce shortages, and people have greater difficulty finding MH providers to treat 
them.25–27,29,78  
We find evidence that Medicaid expansion leads to an increase in MH outpatient and MH 
ED visits, but it does not increase the number of people who access care. Findings are similar 
when we examine outcomes by MH workforce supply. The lack of differences suggests other 
factors limit access to MH services in Medicaid expansion states, such as provider insurance 
acceptance, difficulty navigating insurance to obtain services, or individual beliefs or 
experiences that lead to reduced care-seeking behaviors. Research should examine barriers that 
suppress access to MH services in Medicaid populations. Future research could examine the 
following areas: (1) alternate workforce supply measures that account for the supply of 
psychiatric NP and other MH workforce providers, (2) insurer federal parity violations that make 
it difficult for providers to accept insurance, and (3) area-level indicators of Medicaid insurance 





MH treatment rates, patient reports of difficulty accessing MH treatment, rises in suicide rates, 
and steep increases in mental health distress during COVID highlight the critical need for 



























Chapter III: The Impact of CARA and Nurse Practitioner Scope-of-Practice Laws on 
Access to Medications for Opioid Use Disorders   
 Buprenorphine is a safe and effective medication that is commonly used to treat opioid 
use disorder (OUD).82–84 OUD is associated with a high risk of mortality, but medications, such 
as buprenorphine or methadone, reduce that risk.4,8 Despite the benefits of treatment, less than 
35% of adults with OUD receive any substance abuse treatment, and even fewer receive 
medications for OUD. 1,7 
Buprenorphine can be prescribed through physician offices and other outpatient clinics 
by any buprenorphine waivered prescriber. Waivers to prescribe buprenorphine must be obtained 
from the Substance Abuse Mental Health Services Administration (SAMHSA). High patient 
limit waivers (100 or 275 patients) have training requirements, whereas practitioners seeking 
lower limit waivers (30 patients) are no longer required to complete training.85  
Although the number of waivered providers has increased in recent years,86 there is still a 
significant shortage of providers authorized to prescribe buprenorphine. Over half of all rural 
counties do not have a single waivered prescriber,87 and a 2015 national needs assessment 
determined that 96% of states had opioid prescribing capacities below levels of need.88 The 
shortage is exacerbated by low prescribing patterns, as most waivered providers practice well 
under their patient limit, particularly 30 limit providers.89,90 This is important because the 
number of buprenorphine waivers is associated with buprenorphine prescribing, suggesting that 
increasing supply increases access to treatment.91 Low concentrations of buprenorphine waivered 
providers is related to more frequent opioid overdoses.92  
To address the shortage of buprenorphine waivered providers, lawmakers passed the 





prescribing privileges to nurse practitioners (NP) and physician assistants (PA) who obtain 
SAMHSA authorization. Over 325,000 NPs are licensed to practice in the U.S., with the majority 
(70%) delivering primary care services.71 Recent research suggests that NPs/PAs may be filling 
provider supply gaps for underserved areas and populations. For example, the extension of 
prescribing authority to NPs/PAs decreased the shortage of prescribers in many rural areas, and 
waivered NPs are more likely to treat Medicaid patients than waivered physicians.93–95  Further, 
national prescription data show that most increases in Medicaid buprenorphine prescribing in the 
year after CARA was attributable to NPs (see Figure 3 for a timeline of DATA waiver 
expansion).15  
      Figure 3. Timeline of Buprenoprhine Waiver Expansion to Mid-Level Practitioners 
 
 
While authorized NPs can prescribe buprenorphine in most states, they must operate in 
the confines of state scope-of-practice (SOP) laws that define the autonomy of their practice. 
SOP laws vary across states, from states where NPs are granted full SOP practice to states with 





physician oversight or collaboration 
whereas NPs who practice in states 
with restricted SOP must maintain a 
collaborative relationship or have 
direct oversight from a physician. 
Some states have moderate SOP laws 
that allow the NP to practice 
autonomously after a defined period 
of physician oversight or 
collaboration. To complicate matters 
further, NPs in some 
reduced/restricted SOP states cannot prescribe buprenorphine unless the physician providing 
their oversight or collaborative agreement also has a federal buprenorphine waiver.96 When 
CARA was enacted in 2016, 14 states were considered full SOP states, 27 states had restricted 
SOP, and 10 granted NP autonomy in practice after a period of oversight or collaboration with a 
physician.97  
States with broad SOP laws experienced more growth of NP buprenorphine waivers, and 
growth in mid-level prescribers was twice as large in rural areas of states with a broad SOP 
authority.94,98 Other factors that correlated with growth in waivered provider supply of 
physicians and NPs/PAs include high overdose death rates in preceding years, opioid treatment 
programs, and Medicaid expansion.37,99,100 Research in other areas of medicine, such as mental 
health, demonstrates improvements in mental health outcomes when nurse practitioners help fill 





 No known research has examined whether total buprenorphine dispensing increases after 
CARA in states with broad SOP laws. This study will examine (1) if CARA is associated with 
greater buprenorphine prescribing and (2) if buprenorphine prescribing increased following 
CARA to a greater extent in states with broad SOP, relative to states with narrow SOP.    









The conceptual framework, pictured in Figure 4 above, was adapted from the Donabedian 
structure, process, and outcome framework.41 Within the structure box is the CARA legislation, 
enacted in 2017 that authorized NPs to obtain waivers to prescribe buprenorphine. The 
conceptual framework shows that CARA, listed under structure, should lead to an increased 
supply of NP buprenorphine waivered prescribers, listed under process. The growth in the supply 
of NPs will vary depending on the NP state SOP laws. As a result, we expect the volume of 









Figure 4. Conceptual Framework: Nurse Practitioner Scope of Practice, Waivered Prescribers, 
and Access to OUD Treatment 
Process: 









population, with more 






Aims and Research Questions 
Aim #1. Determine the impact of CARA and SOP regulation on access to medication for opioid 
use disorder. 
H1: Grams of buprenorphine dispensed/100,000 increased in the post-CARA period, 
relative to the period before CARA was implemented.  
H2: Grams of buprenorphine dispensed/100,000 increased to a greater extent in the post-
CARA period in states with broad SOP, relative to states with narrow SOP. 
Study Data and Methods 
Summary of Analytic Approach 
We conducted a state-level quasi-experimental difference-in-difference (DID) analysis 
with state and year fixed effects to understand the impact of CARA on access to buprenorphine 
treatment in states with broad and narrow SOP. We linked multiple data sources to create the 
analytic file used to answer this question. The outcome, grams of buprenorphine 
dispensed/100,000, was extracted from the Drug Enforcement Agency’s (DEA) Automated 
Reports and Consolidated Ordering System (ARCOS).103 The DID estimator was constructed as 
an interaction of CARA legislation and a time-varying NP SOP variable, extracted from annual 
legislative updates.104–110 Covariates included supply, indicators of OUD prevalence, policy, and 
area-level variables. We controlled for the supply of buprenorphine waivered prescribers, 
obtained through a Freedom of Information Act (FOIA) request to the Substance Abuse and 
Mental Health Services Administration (SAMHSA). Policy variables included Medicaid 
expansion, 1115 substance use disorder waivers, mandatory prescription data monitoring 





conducted sensitivity tests and a falsification test using the number of prescriptions from a 
common blood pressure medication over the same period. 
Data Sources 
Automated Reports and Consolidated Ordering System (ARCOS). The outcome, 
grams of buprenorphine dispensed/100,000, was extracted from the Drug Enforcement Agency’s 
(DEA) Automated Reports and Consolidated Ordering System (ARCOS).103 The ARCOS drug 
summary reports, available from the Drug Enforcement Agency (DEA) website, summarize 
transactions of controlled substances dispensed by manufacturers and distributors. ARCOS data 
reports the aggregate grams of buprenorphine dispensed quarterly at a 3-digit zip code.103 
ARCOS is a comprehensive source of data that presents the total amount of buprenorphine 
dispensed at each time point, regardless of coverage, payer, or program, or dispensing location. 
The data is available online in PDF format; the current study utilizes 2014 to 2019. Using an 
online pdf-to-excel conversion tool, we converted the reports to excel format. Prescriber license 
type, the reason for prescription, and prescription dose are not available. 
Annual Legislative Updates. NP SOP categorization was derived from the Annual 
APRN Legislative Updates that categorizes state SOP laws into full, reduced, or restricted SOP 
classifications.104–110 This report, published at the beginning of each calendar year, also contains 
updates to NP SOP legislation and the number of Advanced Practice Registered Nurse (APRN) 
licenses for each year and state.  
Policy Variables Sources. We controlled for several state-level policies in this analysis. 
We obtained the Medicaid expansion variable data from the Kaiser Family Foundation 
website.111 Data for the Medicaid 1115 Substance Use Disorder (SUD) waivers variable was 





authorization for buprenorphine and state-level mandatory prescription monitoring policies were 
also incorporated in the analysis.113,114  
OUD Risks. We extracted opioid prescribing rates from the CDC injury center drug 
overdose webpage. The data are from INQVIA Xponent data, representing 92% of all retail 
prescriptions dispensed in the US, and are available at a year and state level for 2014-2018.115  
Buprenorphine Waivered Prescribers. To measure the supply of buprenorphine 
waivered prescribers, we obtained an extract of the controlled substances registrant file from the 
Substance Abuse and Mental Health Services Administration (SAMHSA) from 2002 to 2019 
through a Freedom of Information Act (FOIA) request. This file is a de-identified comprehensive 
list of all current waivered prescribers. Available information includes a unique identifier, 
provider license type (MD/DO, NP, PA), zip code, waiver patient limit, and the date that waiver 
was granted. Our study period spans the first quarter 2015 through the fourth quarter 2019. 
National Survey of Substance Abuse Treatment Services. The National Survey of 
Substance Abuse Treatment Services (N-SSATS) is an annual census of all substance abuse 
treatment facilities.116 We extracted the total number of Opioid Treatment Program facilities that 
prescribe methadone for 2014-2018. OTP counts are lagged by one year.  
State Health Facts. Kaiser Family Foundation state health facts is a publicly available 
data source that compiles data at a state and year level from various data sources, including the 
American Community Survey and the Behavioral Risk Factor Surveillance System (BRFSS). We 
obtained state-level demographic factors, poor mental health days, and indicators of health from 
Kaiser Family Foundation State Facts website.117  
Medicaid State Drug Utilization Data. Medicaid State Drug Utilization tracks and 





provided at a quarter, year, state level. We extracted the number of prescriptions for the common 
blood pressure medication, Metoprolol. To mirror the primary analysis, we used the years 2015-
2019.118 
Measures 
Appendix B, Table 1 summarizes study measures. 
Outcome 
Buprenorphine Prescription Access Outcome Measure. We population-adjusted total 
buprenorphine dispensing to create a rate of grams of buprenorphine per 100,000 population. To 
improve interpretability, we created a measure to estimate the number of 90-day buprenorphine 
prescriptions (1.4 grams of buprenorphine) per state and quarter. This estimate assumes a target 
maintenance dose of 16mg/day and continuous prescription adherence for the full quarter (90 
days).119 Similar to other studies, we conducted the analysis at state-level data because policies 
of interest, like NP SOP, are administered at a state level.98,120 ARCOS data was used to answer 
other research questions in this area of inquiry.91,121 We excluded three states from the analysis 
(OK, TN, and WY) because these states had specific NP buprenorphine prescribing restrictions 
at some point during the period of interest.96  
Independent Variables of Interest 
Comprehensive Addiction and Recovery Act (CARA) of 2016. CARA, passed in July 
of 2016, authorized NPs to obtain buprenorphine waivers and authorized them to prescribe 
buprenorphine in accordance with state laws.122 NP waivers started to appear in the 
buprenorphine waiver data in February 2017. A binary variable was constructed to identify 
quarters in the post-CARA period and were coded as 1 for all periods following quarter 1 2017. 





NP State Scope-of-Practice Categorization. NPs in full SOP states have full 
autonomous practice without physician supervision. NPs that practice in reduced SOP 
environments can reach autonomous practice with prescriptive authority after a period of 
supervision or collaboration with a physician (transition periods vary from 6 to 60 months). NPs 
in restricted SOP states are always required to practice with physician collaboration or oversight.  
 There is no consensus in the literature about the classification of NP SOP.98,123 Therefore, 
we explored various scope-of-practice specifications in sensitivity tests. Due to collinearity, the 
primary analysis uses a classification that groups states into broad or Narrow SOP states. States 
are grouped into a “broad SOP” categorization if (1) they are considered "full SOP" by the 
APRN legislative update or (2) they are considered reduced SOP by the APRN legislative update 
with a transition period to full SOP of 18 months or less. States were categorized as "Narrow 
SOP" if they (1) were classified as a restricted SOP state by the APRN legislative update or (2) 
they were a reduced SOP state with a transition period greater than 18 months.  
 I constructed three other specifications of the SOP term, including (1) a 3-category 
variable that uses the APRN legislative update categorizations of restricted, reduced, or full SOP, 
(2) a binary variable that grouped reduced and restricted SOPs together and compares it to the 
full SOP states, and (3) a variable that grouped full and reduced SOPs and compares it to 
restricted SOP. Appendix B (Table 7) details these variable groupings and the states contained 
within each grouping by year. Notably, all specifications produce similar results for DID variable 
of interest (Appendix B, Table 6). 
Control Variables 
Policy Variables. To control for the impact of Medicaid expansion on access to 





with Medicaid expansion were coded as 1; state years without expansion were coded as 0. To 
control for the role of Medicaid 1115 Substance Use Disorder (SUD) waivers on treatment 
access, we included a time-varying indicator to account for the state years with a waiver. This 
data was obtained from the Kaiser Family Foundation 1115 waiver policy tracker.124,125 We 
created time-varying variables to control for state-level laws restricting prior authorization for 
buprenorphine and state-level mandatory prescription monitoring policies.  
Opioid Overdose Deaths and Factors Related to the Opioid Epidemic. To control for 
differences in the opioid epidemic across states and years, we included the rate of opioid 
prescribing at the state level. It is important to control for the severity of the opioid epidemic, as 
the epidemic severity varies widely across years and states. Overdose deaths have been linked to 
inappropriate prescribing practices,124,125 and prescription opioids have been associated with the 
development of opioid use disorder.126 Given the high comorbidity between psychiatric 
conditions and opioid use disorder,127 we controlled for the share of individuals who reported 
that they spent 14 or more of the past 30 days in poor mental health, using data available from 
the KFF state facts. To control for the relationship between pain, chronic health conditions, and 
opioid prescribing, we controlled for the share of the population that report fair or poor health. 
We lag all OUD risk factors by one year. 
Demographic Characteristics. To control for time-varying differences in the health and 
demographic characteristics of the population that may be related to prescribing, we included 
state characteristics. When data were unavailable for the corresponding year, the closest year 
available was used. The following set of controls were derived as a percent of the total: race 





fair/poor health, and the share of the population at or below 100 percent of the federal poverty 
level. 
Supply Variables. To measure the supply of buprenorphine-waivered prescribers, we 
created a count of the total number of prescribers overall, a physician-specific count, and NP-
specific counts for each state and quarter year of interest for 2015 to 2019. We used population 
counts for each year to create a rate for each waiver group, adjusted for population size (per 
100,000 persons). In the regression analysis, we controlled for the rate of physician prescribers, 
but not the rate of NP waivers, which allows prescribing related to NP waivers to vary in the 
buprenorphine dispensing outcome of interest. To control for the supply of NP, we extracted the 
total number of NP for each state year from the APRN Annual Legislative Updates.104–110 We 
used yearly population counts to create a rate of APRN, adjusted for population size (per 
100,000 persons). 
We controlled for the supply of opioid treatment programs (OTP), which are programs 
authorized to dispense methadone—another medication for opioid use disorder. Although OTPs 
primarily dispense methadone, some also dispense buprenorphine. Practitioners who work at 
OTPs are not required to obtain a waiver to prescribe buprenorphine. We controlled for the 
supply of these facilities to account for OTP buprenorphine dispensing. We used population 
counts for each year to create a rate of OTPs, adjusted for population size (per 100,000 persons). 
The OTP rate was lagged by one year. 
Falsification Test, Metoprolol Prescriptions 
 To evaluate the validity of the key finding, we conduct a falsification test, substituting the 
number of Metoprolol prescriptions as the outcome (instead of buprenorphine dispensing rate). 





prescriptions at a quarter state level for the time period of interest (2014-2019). We summed the 
number of Metoprolol prescriptions to the state and year quarter level. We used population 
counts for each year to create a rate of Metoprolol prescriptions, adjusted for population size (per 
100,000 persons).  
Statistical Analysis 
 The primary outcome variable of interest, grams of buprenorphine per 100k, was over-
dispersed. To account for this overdispersion, we used negative binomial regressions. Negative 
binomial regressions are typically used for over-dispersed count data, but they are also used 
when the outcome is an over-dispersed rate.128,129 Further, we accounted for time-invariant 
effects using state and year fixed effects in all models. 
Preliminary Analyses 
 In preliminary analyses and as a check of data validity, we ran models to replicate 
previous literature findings to examine whether (1) NP waiver rates increase more in broad SOP 
states, relative to Narrow SOP states during the post-CARA period98 (2) there was a greater 
increase in overall waiver growth in broad SOP states after CARA implementation,94,98 and (3) 
an increase in buprenorphine waivers was associated with an increase in buprenorphine 
prescribing.91  
Primary Analysis 
 For the primary analysis, we estimated a difference-in-difference model with state and 
year fixed effects to estimate whether buprenorphine dispensing increases in broad SOP states 
relative to Narrow SOP states following CARA legislation. In addition to the primary outcomes 
of interest, grams of buprenorphine dispensed/100,000 persons, we transformed the outcome data 





models, we used cluster robust standard errors at the state level to account for unaccounted 
heteroskedasticity and autocorrelation. In sensitivity analyses, we explored various specifications 
of the SOP term and a falsification test.  
Model Specification 
 The study analysis sought to examine whether buprenorphine access, as measured by 
buprenorphine dispensing, increases following CARA to a greater extent in broad SOP states 
relative to narrow SOP states. We estimated the following negative binomial model using a 
difference in difference framework.   
 
Yist = β0 + β1CARAst + B2SOPst + B3(CARAst *  SOPst) +B4Xst + State + Year + εist (i) 
 
The dependent variable Y represents the individual observation (i), at quarter-year (t) and state (s).  
β1CARAst represents the post-CARA period and B2(SOPs) is a time-varying variable that 
represents the scope-of-practice in each state and year. Broad SOP state years were coded as 1. 
B3(CARAst *  SOPst) is the difference-in-difference term of interest that measures the relative 
increase of buprenorphine dispensing in broad SOP after CARA, relative to narrow SOP states. 
B4Xz represents a vector of controls including policy, OUD risks, demographic, and supply 
controls. State and  Year represent state and year fixed effects and εist the error term. All 
regressions used robust state-clustered standard errors. Analyses were conducted in STATA 14. 
Sensitivity Analyses 
Event Study and Parallel Trends. We conduct several sensitivity analyses. To 
examine how trends in prescribing vary throughout the period of interest, we used event study 
regressions to examine differences in buprenorphine prescribing in the quarters before and after 





separate parameter for each quarter of interest. The quarter of CARA implementation is coded as 
0 and used as the point of comparison for quarters before and after CARA. Quarters after CARA 
implementation are coded  +1 to +10 following the implementation quarter and -1 to -9 in the 
quarters before implementation. Predictive margins of the difference in difference estimate were 
produced and graphed. This analysis was also used as a measure of the parallel trends 
assumption, which is an assumption of the DID analysis. To meet this assumption, trend lines for 
both Broad and Narrow SOP states should move in synchrony in the pre-CARA period.     
Generate Estimates for a Hypothetical Scenario Where CARA Was Not Passed 
 We produced predictions of the difference-in-difference to estimate the grams of 
buprenorphine per 100,000 if CARA legislation had not been not passed. After running the 
model (i), we used margins to produce the predicted value for the DID term and stored estimates 
at the state year level. After changing CARA indicator from 1 to 0 for all estimates, we 
replicated this procedure, and we graphed the average estimates for broad SOP states with and 
without CARA legislation.  
Falsification Test 
We incorporated a falsification test using Metoprolol, a common blood pressure 
medication, to explore whether CARA impacts prescribing more generally and if this differs by 
SOP in the post CARA period. Using state quarter-level data downloaded from the Medicaid 
Utilization database, we fit the same regression model (i) described above, but changed the 
outcome variable to Metoprolol. Observations with fewer than 11 counts were suppressed from 
public view and unavailable for download. To assess data missingness, we use the Virginia 2019 
data and found 421 suppressed observations. Assuming the maximum of 10 prescriptions per 





buprenorphine, we examined changes by quarter using an event study and visualized the 
predicted values. Insignificant findings provided additional evidence that the key finding was not 
due to other changes in prescription policy that occured at the same time as CARA.    
SOP Specifications  
 To determine if the main findings were sensitive to the SOP specification, we ran 3 
additional specifications of the SOP term including (1) full, reduced, and restricted SOP states 
separately (Phillips, 2014-2020), (2) group reduced/restricted SOP together and full SOP 
separately, and (3) group full/reduced together and restricted separately. Next, to examine 
whether the time-varying SOP variable impacts findings, we limited the analyses to states that 
did not change SOP over the course of the study and ran the analyses only using states with static 
SOP across the study period.  
Study Results 
Descriptive Statistics 
The outcome of interest, the average logged grams of buprenorphine dispensed/100,000 
persons increased 7.9% in narrow SOP states and 3.6% in broad SOP states in the post-CARA 
period. These averages were not adjusted for state or year within trends. The share of states with 
Medicaid expansion remained fairly stable over the study period. We allowed SOP designation 
to vary over the study period, which explains the decrease in Medicaid expansion in broad SOP 
states post-CARA. We observed substantial increases in mandatory prescription monitoring 
databases, Medicaid 1115 waivers for SUD, and state laws with buprenorphine prior 
authorization prohibitions in the post-CARA period in both narrow and broad SOP states. 





waivers in the post-period, whereas there is more Medicaid expansion present in broad SOP state 
quarters.  
Demographic characteristics were relatively stable in both groups and time periods. In 
both SOP groups, we observed increases in the proportion of the population that was 65+ and 
decreases in the share of the population that was under 100% of the FPL. Both groups had a 
similar share of White population (between 66-69%) but varied in the share of Black/AA and 
Other race groups. Narrow SOP states had a larger share of Black/AA populations (about 13%), 
whereas broad SOP states had a larger share of Other race populations, such as Asian, Native 
American, and Pacific Islander (15-16%).  
Opioid prescribing rates decreased in both SOP groups in the post-CARA period, with 
opioid prescribing rates in the broad SOP states decreasing slightly more than narrow SOP states 
(-17.4% and -21.7% decrease, respectively). The share of the population that reported poor 
physical and mental health increased across both groups, with the greatest increases in poor 
mental health in narrow SOP states (12.9% and 8.6%, respectively).  
 The supply of APRN and waivered physicians increased to a greater extent in the narrow 












Table 5.  
 
Characteristics of Full and Narrow SOP States Before and After the Implementation of the Comprehensive Addiction and Recover 
Act (CARA)  (SD in parentheses) 
 Narrow SOP  Broad SOP  
 Before CARA After CARA Difference  Before CARA After CARA Difference 
No. of state-quarters 303 325 %  129 203 % 
Buprenorphine  
(per 100k residents) 
       
  Buprenorphine, grams 293.4 422.3 43.9  245.0 304.0 24.1 
  No. 90-day Rx 209.5 301.7 44.0  175.0 217.2 24.1 
  Log Buprenorphine, grams 5.42 5.85 7.9  5.29 5.48 3.6 
  Log No. 90-day Rx 5.08 5.49 8.1  4.95 5.15 4.0 
        
Policy (state-quarters), No.        
  Medicaid expansion  54.4 57.5 5.7  89.1 85.2 -4.4 
  Mandatory PDMP 29.4 69.8 137.4  11.6 33.9 192.2 
  1115 SUD/IMD waiver 1.9 33.8 1678.9  1.5 18.7 1146.7 
  State prior auth law .003 16.9 .  1.5 18.7 1146.7 
        
Population Characteristic        
   White 69.3 68.3 -1.4  66.1 66.2 0.2 
   Black 12.9 13.6 5.4  6.6 6.9 4.5 
   Hispanic 11.1 11.3 1.8  13.6 13.8 1.5 
   Other race 6.6 6.6 0.0  13.6 13.1 -3.7 
   Age: 0-18 24.1 23.6 -2.1  23.6 23.6 0.0 
   Age: 65+ 15.48 16.68 7.8  15.3 16.2 5.9 
   Under 100% FPL 14.14 13.26 -6.2  13.0 11.6 -10.8 
        
OUD risk factors        
  Opioid Rx Rate 79.7 65.8 -17.4  66.9 52.4 -21.7 
  Fair/poor health    17.7 18.9 6.8  15.3 15.9 3.9 
  Poor MH  11.6 13.1 12.9  10.5 11.4 8.6 
          
Supply  
(per 100k residents) 
       
   APRN/100k 111.8 131.8 17.9  130.5 143.8 10.2 
   Waivered MD 9.5 15.06 58.5  9.9 15.2 53.5 
   Waivered NP  0 2.6 .  0 3.7 . 











In preliminary analyses, we confirmed data validity by replicating findings in previous 
literature.91,94,98 Regression results showed that (1) After CARA, NP waiver rates increased more 
in broad SOP states, relative to narrow SOP states (Figure 5), (2) there was a greater increase in 
overall waiver growth in broad SOP states after CARA implementation  (Appendix B, Table 4), 
and (3) an increase in buprenorphine waivers was associated with increases in buprenorphine 







Increases in Buprenorphine Dispensing Post-CARA in Broad SOP States  
We conducted a DID analysis using a negative binomial regression model to determine if 
prescribing increased more following CARA in broad SOP states relative to narrow SOP states. 
We ran the models in two steps: (1) model 1 only adjusts for state and year fixed effects, and (2) 
model 2 is fully adjusted with policy, OUD risk variables, area-level demographics, and supply 
variables.  
For both fully adjusted outcomes, buprenorphine dispensing was significantly higher in 
the post-CARA period (16 grams of buprenorphine/100,000 persons and 11.48 more 90-day 
prescriptions/100,000 persons). These estimates were stable in all models (Table 2).   
I found a significant effect of the DID term in both models. Specifically, in the fully 
adjusted model, 22.01 more grams of buprenorphine/100,000 persons were dispensed in broad 
SOP states in the post-CARA period, relative to narrow SOP states (p<.05). Similarly, when the 
grams of buprenorphine were converted to the number of 90-day prescriptions, we found more 
90-day prescriptions/100,000 persons in the post-CARA period for broad SOP states, relative to 
narrow SOP states (p<.05). The DID estimates across all models were relatively stable in all 
models. 
Medicaid expansion, the supply of waivered physicians, and increases in younger aged 
populations were associated with greater buprenorphine dispensing rates. Factors associated with 
lower rates of buprenorphine prescribing rates included Medicaid 1115 waivers for SUD, 










Table 6. Buprenorphine Dispensing in Broad vs. Narrow SOP States Before and After CARA (DID) 
95% Confidence Interval in parentheses. Poor MH is defined as the number of people who report poor mental health 
for 14 or more days/last 30 days. APRN=Advanced Practice Registered Nurse. OTP=Opioid Treatment Program. 
PDMP= Prescription Data Monitoring Program. * p < 0.10, ** p < 0.05, *** p < 0.01. Appendix B, T2, full output. 
 Grams of buprenorphine dispensed/100k 
 




State and Year 
Fixed Effects  
Fully Adjusted State and Year 




2.843 5.147 2.234 4.219 
 [-30.84,36.53] [-22.41,32.70] [-21.23,25.70] [-14.88,23.32] 
Post-CARA 17.11*** 16.00*** 12.54*** 11.48*** 
 [9.03,25.19] [9.05,22.96] [6.92,18.15] [6.82,16.14] 
Broad SOP * CARA 23.52** 22.01** 15.83* 15.86** 
 [0.32,46.71] [3.82,40.20] [-1.11,32.78] [3.12,28.61] 
Policies     
   Medicaid expansion  16.79**  11.63** 
  [0.22,33.36]  [0.36,22.90] 
   Mandatory PDMP  -4.590  -2.166 
  [-18.24,9.06]  [-11.90,7.57] 
   SUD 1115 waiver  -20.27***  -14.08*** 
  [-33.30,-7.24]  [-23.07,-5.09] 
   State prior auth law  -0.994  -1.869 
  [-17.13,15.14]  [-12.91,9.17] 
OUD risk factors     
   Opioid Rx (1yr lag)  0.756  0.590* 
  [-0.24,1.75]  [-0.01,1.19] 
   Fair/Poor health(%)  -1.712  -0.936 
  [-6.34,2.91]  [-4.32,2.44] 
   Poor MH (1yr lag)  0.271  0.169 
  [-3.89,4.43]  [-2.80,3.13] 
Demographics     
   Black/AA(%)  -1.803  -1.940 
  [-18.66,15.06]  [-14.11,10.23] 
   Hispanic(%)  -26.73**  -18.29** 
  [-49.87,-3.58]  [-34.62,-1.97] 
   Other Race(%)  -6.455  -5.181 
  [-21.24,8.33]  [-15.52,5.16] 
   Age 0 to18(%)  15.20***  10.21*** 
  [4.64,25.76]  [2.92,17.50] 
   Age 65+(%)  -2.785  -2.055 
  [-12.18,6.61]  [-8.98,4.87] 
   Under FPL(%)  -5.417**  -3.941** 
  [-10.27,-0.57]  [-7.16,-0.72] 
Supply     
   APRN/100k  0.0817  0.0552 
  [-0.13,0.29]  [-0.08,0.19] 
   MD waiver/100k  1.442**  0.924** 
  [0.18,2.70]  [0.08,1.77] 
   OTP/100k  -18.86  -14.72 
  [-57.53,19.80]  [-41.62,12.19] 







 To further explore how trends in prescribing varies over the period of interest, we used an 
event study regression and graphed the predicted DID margins for broad and narrow SOP over 
that time. Figure 6 below shows an increasing trend in DID coefficient as quarters elapsed across 
the study period. In the regression analysis, we used the quarter before implementation as the 
comparator and found that most quarters reaching or approaching traditional significance in the 
post-CARA period (Appendix B, Table 5). Figure 6 shows a slight divergence of SOP difference 
in difference lines around quarter 3-4 preceding CARA implementation, which aligns with the 
time of CARA passage and enactment (Q3 2016). Changing the reference quarter to the quarter 4 
of 2016, when CARA passed the house and senate in quarter 3 2016 and was enacted, resulted in 




















Generate estimates for a hypothetical scenario where CARA was not passed. We 
produced predictions of the difference-in-difference to estimate the grams of buprenorphine per 
100,000 if CARA legislation had not been passed. After running the model (i), we used margins 
to produce the predicted value for the DID term and stored estimates at the state year level. After 
changing CARA indicator from 1 to 0 for all estimates, we replicated this procedure, and we 
graphed the average estimates for broad SOP states with and without CARA legislation. The 
dashed line represents the hypothetical scenario to examine what buprenorphine dispensing 




















 I conducted a falsification test using Metoprolol, a common blood pressure medication. 
There was no significant change in prescribing after CARA, suggesting that CARA legislation 
did not impact prescribing of the common drug, Metoprolol. Further, the DID estimate 
measuring the change in prescribing in broad SOP states post-CARA was also insignificant. 
Insignificant findings provide additional evidence that the key finding is not due to other changes 
in prescription policy that occurred at the same time as CARA (Table 7). Figure 8 shows trends 
in the predicted number of Metoprolol prescriptions across the study period. Broad and narrow 


















Table 7.  
Falsification Test: Prescriptions of Metoprolol (blood pressure) Dispensed in Broad vs. Narrow 
SOP States Before and After CARA (DID) 
 Prescriptions of Metoprolol /100k 
Marginal Effects 
  
Scope of Practice and CARA  
   Broad SOP (ref=Narrow SOP) 11.51 [-106.58,129.60] 
   Post-CARA (ref=pre-CARA) 17.39 [-10.08,44.86] 
   Broad SOP * CARA 4.242 [-70.40,78.88] 
  
Policies  
   Medicaid expansion 271.3*** [127.80,414.70] 
   Mandatory PDMP -35.78 [-87.71,16.16] 
   SUD 1115 waiver 39.75 [-17.28,96.79] 
   State prior auth law for BUP -34.31 [-82.21,13.59] 
  
OUD Risk Factors  
   Opioid Rx/100k(1yr lag) -1.417 [-5.24,2.41] 
   Fair/Poor Health(%) -6.880 [-24.03,10.27] 
   Poor MH (%, 1yr lag) 14.04 [-18.32,46.40] 
  
Supply  
   APRN/100k 0.952 [-0.29,2.19] 
   Waivered MD/100k -1.773 [-12.58,9.04] 
   OTP/100k 263.8** [62.77,464.88] 
  
Demographics  
  Black/AA (%) 2.903 [-47.99,53.79] 
  Hispanic (%) 62.75 [-104.73,230.22] 
  Other Race(%) 35.27 [-37.81,108.36] 
  Age 0 to 18 (%)  3.434 [-58.56,65.43] 
  Age 65/+(%) 11.58 [-24.09,47.25] 
  Under FPL(%) 6.161 [-15.26,27.58] 
Observations 960 
























Specification of the SOP Term 
To determine whether key results were sensitive to the specification of the SOP term, we 
ran 3 additional models with slight variations in the SOP term and concluded that the key 
findings were not sensitive to specification of the SOP term. Further, we ran a sensitivity 
analysis to determine the impact of using a time-varying SOP variable. We only included 
variables that did not switch SOP categories across the study time period, which dropped 6 states 
from the analysis. The key findings were nearly identical. Combined, these sensitivity analyses 
suggest that the key findings are not sensitive to SOP specification or the time-varying SOP 
variable (Appendix B, Table 4).  
Discussion 
To address the substantial shortage of buprenorphine waivered providers, CARA 
extended buprenorphine prescribing privileges to mid-level practitioners who obtained 
SAMHSA authorization. However, the CARA legislation stipulated mid-level practitioners must 
prescribe buprenorphine in accordance with state-level SOP laws. This study, using a quasi-
experimental difference-in-difference model, found evidence that buprenorphine dispensing 
increased more following CARA in broad SOP states, relative to narrow SOP states. Further, the 
post-CARA period was associated with increases in dispensing compared to pre-CARA. These 
key findings were not sensitive to SOP specification. Results from these sensitivity tests provide 
additional evidence that key findings are due to CARA, and unlikely related to something that 
impacts prescribing in general. 
Prior literature demonstrated the contributions of mid-level practitioners to the 
buprenorphine waivered workforce and treatment delivery, particularly for underserved 





CARA, with notable increases in underserved rural areas.94,98 Among waivered providers, nurse 
practitioners were more likely than physicians to prescribe to Medicaid patients, another 
underserved population.95  
While other studies demonstrated CARA increases the supply of buprenorphine waivered 
NPs and PAs, they do not provide measures of access to treatment, such as the amount of 
buprenorphine dispensed for all payers. This study shows that buprenorphine prescribing 
increases in the post CARA period. Further, it provides evidence that broad SOP combined with 
CARA improves access to buprenorphine treatment for individuals with OUD at a greater rate 
than what was observed in narrow SOP states. On average, the increase in 90-day buprenorphine 
prescriptions post-CARA in broad SOP states is equal to about 16 more 90-day buprenorphine 
prescriptions per 100,000 persons for each quarter year. Given the high mortality in individuals 
with OUD,130 and evidence that medication to treat OUD decreases mortality rates,131 it is 
important to assess and remove barriers to treatment. Recent changes to federal policy have 
reduced barriers to becoming waivered by removing training requirements for those who wish to 
prescribe under the 30-patient cap.85 The findings of this study provide evidence of increased 
buprenorphine prescribing in broad SOP states in the post-CARA period, suggesting that 
policymakers wishing to increase access to buprenorphine could consider SOP laws as a pathway 
to do so.   
Limitations 
The findings in this paper are subject to some limitations. ARCOS data provides an 
aggregate measure of buprenorphine dispensed across periods of interest, but it does not 
differentiate between NP and physician prescribing. Literature examining buprenorphine 





substantially among mid-level practitioners but stayed relatively stable for physicians over the 
same time period.15 Further, by incorporating the supply of waivered MDs in the analysis, we 
control for dispensing related to increases in MD waivers. Although we control for the number of 
MD waivers, we cannot determine which waivered providers are prescribing. We have not found 
evidence in the literature suggesting that prescriber engagement varies by state. State and year 
fixed effects are included in the model and will help control for dispensing that is particular to 
the state and year. 
A limitation of ARCOS is that it is not possible to differentiate between buprenorphine 
prescribed to treat OUD from buprenorphine prescribed for analgesic reasons. To explore the 
potential extent of this limitation, we conducted an informal analysis using state Medicaid 
utilization data and found that buprenorphine products that are typically prescribed for analgesic 
reasons (Belbuca, Buprenex, Butrans) accounted for 1% of all buprenorphine prescriptions in 
Virginia in 2019. This suggests that the vast majority of buprenorphine is prescribed for OUD 
treatment, rather than analgesic reasons. 
Full addresses were unavailable for prescribers, so it was not possible to exclude NPs that 
work at Veterans Affairs (VA) facilities that granted full scope-of-practice privileges. Further, 
we were unable to identify and remove prescribers who are no longer waivered. When we 
compared the FIOA prescriber file to another data source without inactive prescribers to for the 
third quarter of 2019, the number of prescribers was very similar, with less than a 2-percentage 
point discrepancy. Inactivity in physician-level providers may bias results downward if the rates 
of inactivity are varying over time and between states, as the increased number of physicians 
would absorb NP variation in the model outcome. However, we do not suspect variability of 





While visual inspection of the parallel trends in the pre-CARA period suggests similar 
dispensing in broad and narrow SOP states, some event study DID parameters show significance 
in pre-trends, suggesting some disturbance in the pre-CARA period. Hypothesizing that these 
pre-period differences could be due to the incident to billing (a physician NPI is used on billing 
claims, but mid-level providers provide service)132 following CARA passage, we set the 
reference point to the quarter when CARA was passed and observed an increase in significance 
in the post-CARA period and a decrease in the pre-CARA period.   
Further, we were unable to control for policy implementation in health systems or local 
governments. If buprenorphine distribution varies between years and states due to these policies, 
this could bias key findings upward if these policies are more common in broad SOP states. NPs 
prescribing higher doses of buprenorphine, relative to physicians, is another potential source of 
bias. Some evidence suggests that NPs and physicians have different opioid prescribing patterns, 
with NPs less likely to prescribe any opioids, but slightly more likely to prescribe higher doses of 
opioids.133 If this finding generalizes to NP buprenorphine prescribing, it could bias results 
upwards. However, it is possible that differences in opioid prescribing patterns could be due to 
relative differences in the medical complexity of the populations that NPs and physicians serve.  
Conclusion 
 This is one of the first studies to examine the intersection of federal and state policies and 
their combined impact to increase access to treatment for individuals with OUD. Even in the 
short time period after the CARA legislation was enacted, we observed that states with broad 
SOP laws prescribe substantially more buprenorphine, compared to the narrow SOP states. 
Future studies should extend this research by pairing DEA waiver data to national prescription 





address the opioid epidemic in their state should consider whether increasing NP SOP may lead 



























Chapter III: Does Health Insurance Literacy Predict Subsequent Access to Behavioral 
Health Services and Unmet Mental Health Needs? 
 
Introduction 
Behavioral health (BH) conditions are prevalent, with approximately 20% of U.S. adults 
living with a mental illness (AMI) and 7.4% with a substance use disorder (SUD).1 Untreated, 
symptoms can worsen, sometimes leading to more severe symptoms or diagnoses.2,3 Despite the 
high prevalence of BH disorders, relatively few receive treatment. Only 44.8% of those with an 
AMI received mental health (MH) services in the past year, and only 10.3% of individuals 12 
and older with a SUD received substance use treatment services.1   
Although there are gains in coverage of BH services through the Affordable Care Act and 
federal parity legislation, researchers have observed little overall change in reported access to 
BH services over the last decade. In 2019, 44.8% of those with an AMI reported any outpatient 
MH service in the previous year, compared to 40.9% in 2008. Trends in access to SUD treatment 
services are flat, with 10.4% accessing SUD treatment in 2015 and 10.3 percent in 2019.1 Slow 
gains in BH treatment rates suggest that other barriers remain. 
Health Insurance Literacy  
Health insurance literacy (HIL) is concerned with how people understand their health 
insurance plan and how that health insurance knowledge is used to obtain healthcare services.134 
Most adults have basic or low levels of HIL.135–138 In a study of commonly used health insurance 
terms, only 14% of adults could correctly answer four multiple-choice questions about general 
health insurance terminology.139  When asked about the basic attributes of their healthcare plans, 





research focused on factors associated with how individuals choose health plans. Literature 
indicates that individuals with low health insurance literacy have trouble choosing health plans 
that minimize their out-of-pocket costs.141,142 This is particularly true if the consumer is 
presented with too many choices, has a low level of plan comprehension, or has low 
numeracy.143–145  
Low HIL is associated with more emergency department visits, lack of adherence to 
prescription drug treatment, and poorer overall health.17,73 Insured individuals with low HIL are 
more likely to report putting off care due to perceived costs, even for fully covered services, such 
as preventive yearly check-ups.73 Factors correlated with low HIL include young age, low 
income, male sex, lower numeracy abilities, and low financial confidence.136,146–148 Some studies 
find that low HIL is more common in non-white groups, while other research finds no 
association between race and HIL.146,149 These findings suggest that low HIL may be a direct 
barrier to receiving needed care. Further, treatment barriers associated with low HIL may be 
more detrimental to groups with a higher prevalence of low HIL, like low-income populations.  
HIL, Behavioral Health, and Low-Income Populations 
Individuals must navigate complicated and evolving insurance requirements and the 
healthcare landscape to obtain needed services, medication, and supplies.150 Barriers to BH 
services may make these services particularly difficult to access. Widespread BH provider 
shortages, low insurance uptake among BH providers, slim provider networks, and insurer 
federal parity violations create barriers to BH services.12,35,37,64,151 Low HIL may amplify the 
detrimental impact of these barriers. Most state Medicaid programs administer benefits to low-






Further, BH conditions are more prevalent and associated with more co-occurring 
physical conditions in low-income populations than high-income.152,153 Similarly, low HIL is 
more common among low-income people.154 Because low-income populations are more likely to 
experience both BH conditions and low HIL, the role of HIL in accessing BH services may be 
particularly relevant for this population. Low HIL may influence undiagnosed or untreated BH 
diagnoses, potentially further exacerbating symptoms and unmet needs. 
Prior literature documents disparities in access to general healthcare services among 
those with low HIL.17,73 The prevalence of low HIL and BH conditions is higher among low-
income populations.154  Therefore, it is essential to understand how HIL may influence access to 
BH services in low-income people. Low-income populations often interact with private health 
insurance companies contracted with state Medicaid programs, potentially making HIL an 
essential component of care-seeking in low-income individuals.13 Despite the relevance, no 
evidence to date examines whether HIL influences access to BH services in low-income 
populations, suggesting a critical need for research in this area. This paper explores whether HIL, 
measured at study baseline, is associated with subsequent unmet needs for BH services due to 













Figure 9. Health Insurance Literacy and Mental Health Utilization: A Conceptual Framework 
 
This conceptual framework, adapted from Barnes143 and Andersen,155 depicts the 
relationship between HIL and other factors that lead to the utilization of BH services and met BH 
needs. On the left, the factors leading to HIL include locus of control, education, numeracy, 
experience with the health care system, and experience with health insurance. HIL leads to an 
ability to navigate the health care system to make and attend medical appointments within the 
constraints of the consumer’s health care plan. Mental health services utilization may be 
tempered by factors like beliefs about mental health treatment, level of mental health distress, 
and whether the individual has adequate supports that allow them to attend medical appointments 
(ie. transportation, childcare, flexible work schedule). Focusing on HIL, we can interpret the 
conceptual framework as follows: understanding basic health insurance terms will reduce 





their ability to navigate the healthcare system, ultimately leading to greater access to BH services 
and reduced unmet need for MH services. For example, in individuals with high HIL and MH 
needs, we expect to observe an increase in the utilization of BH services and a decrease in unmet 
need for MH services. 
Aims and Research Questions 
Aim#1 Does HIL affect access to and utilization of BH services in individuals with mental 
disorders?  
• H1: Individuals with high HIL are less likely to have unmet need for MH services due to 
cost.  
• H2: Individuals with high HIL are more likely to utilize BH services.  
Data and Methods 
Data Source  
Data for this study were collected as part of a larger randomized controlled trial that 
encouraged primary care visits through small cash incentives to a low-income population 
enrolled in a hospital safety-net coverage program called Virginia Coordinated Care (VCC).156 
This program, administered through Virginia Commonwealth University Health System 
(VCUHS), provided enrollees access to a community network of primary care providers. Primary 
care providers within the VCC network could refer patients to specialty care, including BH 
treatment services, within VCUHS. For the vast majority of patients enrolled in the trial (>99%), 
primary care and specialist visits, including BH services, were covered at 100% with no 
additional out-of-pocket costs to the patient, and prescriptions were provided with a $4 copay. 
Therefore, VCC enrollees experienced minimal financial barriers to BH treatment services. It is 





coverage program that offered access to primary care providers and specialists (including BH 
specialists) through VCUHS and the VCC’s network of local community primary care providers.   
Recruitment, which began in 2014, focused on enrolling individuals into the study 
immediately following enrollment into the VCC program. A large majority of study participants 
were new to the VCC program; however, about 8% were already enrolled in VCC but had no 
claims for the 9 months preceding study enrollment. During the recruitment period, all initially 
eligible individuals were sent a study recruitment letter. Study coordinators called potential 
participants to do a brief phone screening to ensure eligibility and to ascertain their interest in 
study participation. During this communication, study coordinators informed participants that 
they could access primary care and subsequent specialty services through a primary care referral. 
All screening and interviews were conducted over the telephone. Upon completion of the 
baseline survey, coordinators randomized participants to an incentive group ($0, $25, or $50) and 
informed those randomized to the $25 and $50 groups that they would receive the incentive 
following a primary care visit if that visit occurred within the next 6 months. A total of 1,226 
individuals were eligible and agreed to participate in this trial. Of those, 1,026 completed a 
follow-up assessment 12 months later, an 84% retention rate. With the exception of age (p<0.05), 
individuals who completed the follow-up survey were no different than non-completers. Younger 
participants were less likely to complete follow-up.   
Sample Inclusion Criteria 
The sample for the study is limited to people who responded to the HIL scale. The HIL 
scale was added after the start of the study. Early study participants were missing the HIL scale 
and were not included in the current analysis (n=367). Individuals who did not complete the HIL 





completed the HIL scale in terms of age, education, race, and income. An additional 3 
observations were dropped due to missing information on the HIL scale. Further, 32 participants 
completed abbreviated interviews at follow-up that did not include unmet need questions (n=32).  
 All analyses were conducted using two samples, the full sample and a MH subsample. 
The subsample was limited to individuals with higher-than-average levels of depression or 
anxiety. We measured depression and anxiety symptoms for all participants at baseline using the 
Patient Reported Outcomes Measurement Information System (PROMIS) scales. Participants 
responded to a 4-item questionnaire for anxiety and depression at baseline. Within each domain, 
responses were summed and converted to standardized t-scores, as specified by PROMIS scoring 
guidelines.157 A score of 50 represented the average level of depression for the U.S. general 
population, and one standard deviation is equal to 10 t-score points. A person with a score of 60 
is one standard deviation above the mean. 157,158 Participants whose score was above the 
standardized mean of 50 for depression (n=435) and/or anxiety (n=463) were considered to have 
higher than average levels of MH symptoms. Combined, the final MH subsample for the study 
was 513. The full sample size was 718.  
Survey data were collected at study baseline, shortly after enrollment into the VCC 
program, and again, 12 months later at follow-up. Administrative claims data were linked to 
survey data to obtain measures of health care utilization. IRB approval was obtained through 
Virginia Commonwealth University IRB and the University of Colorado.  
Outcomes 
Unmet Need for Mental Health Services. The primary outcome of interest was patient-
reported unmet MH care due to costs. Although participants had access to BH services at no cost 





altering care-seeking behaviors. At baseline and follow-up, patients were asked, “During the last 
12 months, was there any time you needed mental health care or counseling but couldn't afford 
it?” The source of this question was the National Health Interview Survey (NHIS), an annual 
survey that tracks the health of the non-institutionalized civilian population in the United States. 
The reference period for the follow-up question reflects the time period between the initial 
survey and follow-up. We conducted a power analysis based on the sample size of 481 patients 
and 11 covariates and found the sample size was sufficient to allow for the detection of a 5-
percentage point difference at p=0.05 in the probability of having an unmet need for MH care 
due to cost.  
Access to Behavioral Health Services. The secondary outcome of interest was 
outpatient BH services utilization and treatment setting type. BH services were identified 
through VCC administrative claims data. Outpatient use of BH treatment was defined as having 
an outpatient visit with an ICD-9 or ICD-10 code for a MH or SUD. The comorbidity between 
MH and SUD is very high, so we included both in the current analysis.1 The study period crossed 
the conversion period between ICD-9 or ICD-10, which required application of the relevant set 
of codes based on the date of visit (Appendix, C Table 10). Administrative claims notated 
whether the visit was considered a primary care or specialist visit.  
Using these designations, we created a three-level variable to categorize BH utilization 
into three groups: no treatment, BH treatment in the PCP setting, and BH treatment in a specialty 
setting. We considered specialty BH services a higher level of care and, accordingly, coded 
people who had both primary care and specialty BH visits as utilizing “specialty BH care.” 





“BH utilization in a primary care setting.” Individuals without BH utilization in either primary 
care setting or specialty setting were coded as “no treatment.”   
Independent Variables  
A summary of measures is located in the appendix (Appendix C, table 1).  
Health Insurance Literacy Scale. Our primary independent variable, health insurance 
literacy, is derived from a set of 6 questions that ask participants to identify their level of 
confidence with various health insurance terms, such as provider network or deductible (Figure 
10). Participants were asked to rate their level of understanding with these terms on a 4-point 
scale with responses that ranged from not at all confident to very confident. These questions were 
from the Health Reform Monitoring Survey, which is administered semiannually by the Urban 
Institute.159 Individual items were summed to create a total score with a range of 6 to 24. Higher 
scores indicate greater levels of confidence in health insurance terminology, or HIL. This scale 
has not been validated, so we conducted a Chronbach’s alpha test to measure the scale’s internal 
consistency. This scale had a Chronbach’s alpha of 0.84, suggesting relatively high internal 
consistency.160 After summing the health insurance literacy scale, we found the sample median. 
Scores above the median were coded as 1 and those below the median were coded as 0. In 
sensitivity analyses, we explore other specifications of the HIL term. 
 
Figure 10. Confidence in Health Insurance Terminology Scale 
I will read you a list of health insurance terms. For each term, please 
indicate how confident you are in how well you understand what 




Premiums Very confident 
Somewhat confident 
Not too confident 












 At baseline, data on the following demographics were collected: age, sex, race, marital 
status (married, unmarried), education (less than high school, high school, more than high 
school), monthly income (<$1500, ≥$1501), employment status (employed, not employed). The 
number of chronic conditions was also assessed via self-report, summed, and categorized into 
three groups (0 conditions, 1-2 conditions, 3+ conditions). We also assessed whether the 
participant had any prior health insurance coverage (private, public, or military) and was coded 
as (history of insurance, no history of insurance). As described above, study data were collected 
in the context of a clinical trial that sought to increase primary care utilization through cash 
incentives, so we controlled for randomization to the study treatment arm.156,161,162 demographic 
data was sparse but was replaced using multiple imputation methods (n=6). Regressions with and 
without multiple imputations reveal very similar estimates (Appendix C, Table 7-8).  
Analytic Approach 
 Differences between the characteristics of those with above and below median levels of 
health insurance literacy were analyzed using χ2 tests for categorical variables and t-tests for 
continuous variables. A logistic model was used to examine if health insurance literacy at 
baseline was related to unmet need for mental healthcare at the 12-month follow-up interview.  
 
• Yi= β0 + β1(HILi)  + XAi + εi   (1) 
The dependent variable, Y, represents the outcome, unmet need for mental healthcare, at an 
individual level (i). β1(HILi) represents the independent variable of interest, HIL at baseline. X is 
a matrix of covariates, A is a vector of parameters associated with those covariates, and ε notates 





A multinomial logistic regression was used to examine hypothesis 2, which measures the 
relationship between HIL at baseline and access to BH treatment in specialty and primary care 
locations in the 12-month period following baseline. 
• Yi = β0 + β1(HILi)  + Xi + εi   (2) 
The dependent variable, Y, represents the outcome, BH service utilization location, at an 
individual level (i). β1(HILi) represents the independent variable of interest, HIL at baseline. X is 
a matrix of covariates, A is a vector of parameters associated with those covariates, and ε notates 
the error term.  
Sensitivity Analyses 
We examined the relationship between BH diagnosis in the administrative claims data 
and anxiety and depression symptoms at baseline to establish whether anxiety and depression 
PROMIS scales are an appropriate tool to approximate the severity of MH symptoms. We 
explored other scoring specifications of the HIL measure, including (1) the continuous sum of all 
HIL questions and (2) splitting HIL responses into three parts, the bottom third of the 
distribution, the middle third, and those with the highest HIL were in the top third.  
 Using bivariate probit models, we explore whether the HIL term is endogenous. Factors 
that explain HIL may also explain treatment-seeking behaviors. The bivariate probit analysis 
uses maximum likelihood estimation to estimate two models simultaneously. The first model 
predicts the relationship for the full original regression, and the second estimates the relationship 
between the primary regressor and the remaining model covariates. The correlation between the 
standard errors of the joint models is estimated and a Wald test is used to determine whether the 
correlation coefficient is different from zero. A significant Wald tests suggests the presence of a 





estimated to examine potential endogeneity of the primary regressor (1) unmet need vs. no unmet 
need, (2) any BH treatment vs. no treatment, (3) any BH treatment in a primary care setting vs. 
no treatment, and (4) any specialist BH treatment vs. no specialist.  
Results 
Descriptives 
Table 8 reports descriptive measures for the full sample and the mental health subsample. 
Both samples were stratified by health insurance literacy. On average, the mental health sample 
was low-income (less than $1500 per month, 94%), non-White (72%), not married (89%), and 
not working (73%). The majority of individuals reported 2 or more chronic health conditions 
(71%), with only 10% reporting no chronic health conditions. About a third of the sample 
reported moderate or high levels of depression or anxiety, while those with symptoms above the 
standardized mean but below the moderate cutoff accounted for two-thirds of the sample.157   
Demographic and health characteristics were similar across HIL groups with a few 
exceptions. Comparing those who reported HIL above the median threshold with those who were 
below, we observed differences in education, prior health coverage experience, and chronic 
health conditions. Those with above-median HIL scores had higher educational attainment, had 











Table 8. Sample Characteristics by High and Low HIL 
 
  

















Unmet Needs        
  Unmet MH needs (n=481) 23.26 27.38 18.90***  29.31 34.65 23.35*** 
        
Mental Health Utilization        
   No MH treatment 71.73 73.02 70.37  67.64 69.89 65.16 
   Any MH PCP Tx 15.88 16.62 15.10  18.71 19.33 18.03 
   Any specialist Tx 12.40 10.35 14.53  13.65 10.78 16.80 
        
Demographics        
  Female 48.75 45.78 51.85*  51.66 47.96 55.74* 
  White race 27.72 25.07 30.48*  27.68 25.65 29.92 
  Married/partnered 12.12 11.17 13.11  11.11 10.41 11.89 
 Age group        
   21-35 22.42 24.25 20.51  22.80 25.28 21.72 
   36-50 38.02 36.24 39.89  40.39 38.29 40.57 
   51-64 39.55 39.51 39.60  36.81 36.43 37.70 
  Education        
  Less than high school 27.99 33.98 21.78***  29.24 35.69 22.13*** 
  High school 33.33 36.74 29.80  31.97 33.83 29.92 
  More than high school 38.68 29.28 48.42  37.82 29.00 47.54 
  missing 0.97 1.36 0.57  0.97 1.49 0.41 
Monthly income        
  <$1500 92.62 93.73 91.45  93.96 94.42 93.44 
  $1500+ 7.10 5.99 8.26  5.65 5.20 6.15 
  missing 0.28 0.27 0.28  0.39 0.37 0.41 
Employed 27.99 27.79 28.21  26.71 27.88 25.41 
History of insurance 76.18 72.21 80.34**  56.73 49.44 64.75*** 
        
Health risks        
Chronic conditions        
  0 13.65 15.26 11.97  10.33 12.27 8.20** 
  1 22.42 17.44 27.64  19.10 14.50 24.18 
  2 or more 63.93 67.30 60.40***  70.57 73.23 67.62 
BH at baseline        
  Mild MH symptoms 74.51 71.93 77.21  64.72 62.08 67.62 
  Moderate/High MH  25.49 28.07 22.79  35.28 37.92 32.38 
History of MH diagnosis 51.95 53.93 49.86  66.91 63.93 65.50 
History of SUD diagnosis 13.65 14.99 12.25  17.84 14.34 16.18 
        
Other        
  Incentive group 67.09 66.49 68.09  65.11 65.80 64.34 







Unmet MH Need Reported 12 Months After Study Enrollment 
 Table 9 reports the likelihood of unmet MH needs due to cost at 12 months in a series of 
three logistic regressions. We examined whether HIL was related to reported unmet MH need 12 
months later.  
In the full sample, the unadjusted regression shows a strong relationship between HIL 
and reports of unmet MH need, with those with higher HIL less likely to report unmet MH needs 
relative to those with low HIL (OR: 0.618, p<0.01). The direction of the influence of HIL on 
unmet MH need was similar in the fully adjusted model, but it did not reach full significance 
(OR: 0.71, p<0.10). Those with a high school education, relative to a lower education level, were 
less likely to report unmet needs. Further, moderate MH symptoms at baseline and history of 
MH diagnosis increased the probability of unmet MH needs.  
 In the MH sample, high HIL is related to lower unmet need in the unadjusted (OR: 0.57, 
p<0.01) and full adjusted regressions (OR: 0.64, p<0.05). Similar to the full sample, having a 
high school education, relative to those with less education, reduces the probability of unmet MH 
need, while MH baseline symptoms and history of a MH diagnosis increase the likelihood of 












Table 9. HIL and Unmet Mental Health Need Due to Cost 12 Months Later  
Logistic Regression, multiple imputation, odds ratio reported 
 Full Sample Subsample 










Unmet MH  
Fully adjust 
       
High HIL 0.618*** 0.615** 0.712* 0.575*** 0.578** 0.642** 
 (0.115) (0.118) (0.143) (0.118) (0.123) (0.141) 
Female  1.228 0.938  1.111 0.942 
  (0.238) (0.195)  (0.235) (0.211) 
White (ref=non-white)  1.000 0.755  1.018 0.820 
  (0.215) (0.170)  (0.245) (0.202) 
Married/Partnered  1.065 1.128  1.204 1.203 
  (0.316) (0.359)  (0.402) (0.413) 
Age group (ref=21-
35) 
      
36-50  1.269 1.206  1.186 1.182 
  (0.319) (0.328)  (0.320) (0.345) 
51-64  0.851 1.027  0.901 1.030 
  (0.222) (0.279)  (0.252) (0.311) 
Education       
High school  0.537*** 0.536**  0.535** 0.514** 
  (0.128) (0.142)  (0.139) (0.145) 
More than HS  0.723 0.705  0.742 0.703 
  (0.165) (0.168)  (0.190) (0.181) 
Income, 1500+ 
(ref=<$1500) 
 0.530 0.652  0.527 0.568 
  (0.251) (0.330)  (0.301) (0.347) 
Employed  0.746 0.864  0.659 0.825 
  (0.168) (0.211)  (0.169) (0.223) 
Insurance history  1.109 0.974  0.916 0.876 
  (0.251) (0.237)  (0.228) (0.230) 
Chronic conditions 
(ref=0) 
      
1   0.553*   0.501 
   (0.199)   (0.212) 
2+   0.629   0.547 
   (0.195)   (0.202) 
Incentive group   0.901   0.823 
   (0.189)   (0.188) 
Moderate MH 
symptom (ref=severe) 
  2.040***   1.750** 
   (0.448)   (0.393) 
Hx drug/alcohol   1.105   1.134 
   (0.304)   (0.320) 
Hx MH Dx   3.884***   2.705*** 
   (0.917)   (0.692) 
Constant 0.377*** 0.463** 0.295*** 0.530*** 0.782 0.631 
 (0.0454) (0.143) (0.121) (0.0700) (0.262) (0.283) 
       
Observations 675 675 675 481 481 481 





No BH treatment, primary care BH treatment, or Specialty BH treatment 
Table 10 reports the likelihood of a BH visit at a specialist or primary care location 
compared to no treatment in those with higher HIL for two samples—the full sample and the MH 
sample. A multinomial logit was used to produce estimates that are reported as relative risk 
ratios.  
In the full sample, individuals with high HIL are more likely to receive BH care at a 
specialist compared to no treatment (RRR=1.87, p<0.05). We observe no differences between 
HIL groups in the likelihood of a primary care visit compared to no treatment. A history of MH 
diagnosis and moderate/high levels of depression or anxiety at baseline were the strongest 
predictors of receipt of mental health care at a primary care or specialist compared to no 
treatment. Race was also a strong predictor, with White individuals more likely to receive mental 
health treatment at a primary care or specialist compared to no treatment, relative to non-White 
individuals.  
The findings for the MH sample were very similar. Individuals with high HIL were more 
likely to receive BH care at a specialist compared to no treatment (RRR=1.81, p<0.05). We 
observed no significant effect for the role of high HIL and a subsequent primary care visit 
compared to no treatment. A history of MH diagnosis and moderate/high levels of depression or 
anxiety at baseline were the strongest predictors of receipt of BH treatment at a primary care or 
specialist compared to no treatment. Race was also a strong predictor, with White individuals 
more likely to receive mental health treatment at specialist compared to no treatment, relative to 
non-White individuals. Married or partnered individuals, relative to unmarried, were less likely 
to receive specialty MH treatment than no treatment. Figure 11 shows the adjusted predicted 





Table 10. HIL and BH Service Utilization in the Subsequent 12 Months 
Multinomial Logistic Regression, multiple imputation, relative risk ratio reported 













High HIL  1.104 1.875**  1.134 1.817** 
  (0.254) (0.501)  (0.295) (0.525) 
Female  1.427 1.458  1.563* 1.423 
  (0.317) (0.397)  (0.390) (0.423) 
White (ref=non-white)  1.326 2.287***  1.053 1.949** 
  (0.345) (0.596)  (0.313) (0.559) 
Married/Partnered  0.693 0.444*  0.677 0.296** 
  (0.265) (0.206)  (0.297) (0.160) 
Age group (ref=21-35)       
36-50  0.921 0.559  0.894 0.753 
  (0.291) (0.198)  (0.311) (0.294) 
51-64  0.823 0.810  0.852 1.011 
  (0.280) (0.277)  (0.307) (0.398) 
Education       
High school  1.088 0.578  1.084 0.635 
  (0.322) (0.195)  (0.354) (0.237) 
More than HS  0.860 0.770  0.825 0.959 
  (0.250) (0.251)  (0.261) (0.341) 
Income, 1500+ 
(ref=<$1500) 
 1.030 0.892  0.621 0.928 
  (0.535) (0.582)  (0.421) (0.696) 
Employed  0.698 0.968  0.756 0.838 
  (0.198) (0.305)  (0.255) (0.305) 
Insurance history  1.241 0.499**  1.524 0.593 
  (0.373) (0.153)  (0.517) (0.202) 
Chronic conditions (ref=0)       
1  0.969 1.034  1.130 0.816 
  (0.419) (0.526)  (0.610) (0.476) 
2+  0.915 1.489  0.941 1.128 
  (0.349) (0.706)  (0.442) (0.606) 
Incentive group  1.139 0.802  0.959 0.797 
  (0.276) (0.210)  (0.257) (0.228) 
Moderate MH symptom 
(ref=severe) 
 1.937*** 2.150***  1.933** 2.243*** 
  (0.497) (0.615)  (0.524) (0.659) 
Hx drug/alcohol  1.339 1.446  1.583 1.423 
  (0.414) (0.484)  (0.524) (0.513) 
Hx MH Dx  5.331*** 4.786***  6.298*** 4.220*** 
  (1.585) (1.619)  (2.463) (1.665) 
Constant  0.0469*** 0.0609***  0.0369*** 0.0653*** 
  (0.0265) (0.0364)  (0.0244) (0.0441) 
       
Observations 718 718 718 513 513 513 






Figure 11. Adjusted Predicted Probability of Type of MH Utilization by High and Low HIL. 




We found that PROMIS anxiety and depression scores at baseline were predictive of BH 
diagnoses in administrative claims data in the subsequent 12 months (Appendix C, Table 3). 
Unmet needs results were not sensitive to the specification of the HIL term (Appendix C, Table 
4). However, we found evidence that the BH services utilization was sensitive to the HIL term 
specification (Appendix C, Table 5). Specifically, the HIL term was insignificant in the 
utilization models when the term was specified as continuous or split into a three-level variable. 
Further, analyses that used Poisson regressions to examine the influence of HIL on the number of 
visits for each treatment type suggested that HIL is unrelated to the number of primary care or 
specialist visits for BH reasons (Appendix C, Table 6).  
 Further, we examined the potential endogeneity of the HIL term using bivariate probit 





estimated models was interpreted as evidence of endogeneity in the primary regressor. We did 
not find evidence that the HIL term was endogenous in the model with the unmet MH needs 
versus no unmet MH needs outcome, the any treatment versus no treatment outcome, or the any 
MH primary care versus no MH primary care outcome. However, in the model that tests 
specialist visit vs. no specialist visit, we found suggestive evidence that the naïve association 
between HIL and specialist treatment may be overstated (Appendix C, Table 9). This approach is 
limited in that it relies only on the joint distribution of the error terms to identify possible 
unobserved variables involved in selection.  
Discussion 
This study examined the influence of HIL on subsequent unmet MH needs due to cost 
and BH utilization in low-income individuals enrolled in a community safety-net coverage 
program. Individuals with high HIL at baseline were less likely to report unmet MH needs due to 
cost 12-months later, compared to those with low HIL. These findings were not sensitive to 
specification of the HIL term. This is consistent with other literature that suggests that low HIL 
may be a barrier to care.73 Further, we found evidence that individuals with high HIL were more 
likely to receive BH care at a specialist compared to no treatment but not more likely to receive 
BH services in a primary care setting, compared to no treatment. The specialty utilization 
findings were sensitive to the specification of the HIL term and may be influenced by an 
unobserved variable, potentially biasing the findings.  
No known literature has examined the influence of HIL in BH utilization, and very little 
literature examines the impact of HIL on care-seeking patterns.73,163 However, qualitative work 
may provide clues to the mechanisms underlying the relationship between HIL and utilization 





individuals and found that participant’s perceived health insurance and the healthcare system as 
very complex. Study participants reported confusion around health insurance terms, cost-sharing 
concepts, where to access plan-covered care, and frustration around unexpected bills. Confusion 
about insurance and cost of care led to reports of individuals not seeking care when they needed 
it. Perhaps this helps to illustrate how confusion about HIL and how to use health insurance to 
access services can lead to increases in unmet need. Despite 100% coverage for services 
provided in the VCC network, study participants with low HIL were more likely to report unmet 
need for MH services due to cost in the current study, which may be explained by confusion 
around program coverage and costs.  
Although most study participants accessed PCP services during the primary RCT, 
participants with high HIL were more likely to navigate systems to access BH treatment in 
specialty settings.156 These findings suggest that high HIL helps people navigate healthcare 
systems to obtain care, even after connecting to primary care services. Notably, individuals with 
low HIL reported more severe MH symptoms (p=.105), suggesting a greater need for a higher 
level of behavioral health care. Yet, they were less likely to access BH services in a specialty 
setting. 
Limitations 
This study has limitations. Importantly, the data source for these findings utilize data that was 
collected as a part of a randomized controlled trial.156,161,162 At study enrollment, participants 
were exposed to a study coordinator who explained that participants have access to community 
primary care providers. When the participant had additional questions, study coordinators 
answered their question or directed them to relevant information. Further, the purpose of the 





doctor through a cash incentive. All participants were exposed to the experiment, and it is 
possible that the experiment, itself, increased health insurance literacy. To the extent that this is 
true, results would likely be biased downward, meaning that the magnitude of the influence of 
HIL on unmet need and utilization outcomes may be larger in other populations. We did include 
a control variable for incentive group assignment to control for the impact of incentive group 
assignment.  
Further, this study was conducted in a safety net health program, and it is possible that 
individuals enrolled in this program sought care outside of this health system. However, given 
that care received in the health system was free, it is likely that participants elected to obtain MH 
care within the health system.  
The population enrolled in the current study was a low-income population with complex 
health needs. These findings may not be generalizable to healthier populations with higher levels 
of income.154 However, low-income is associated with low HIL in prior literature, so limiting the 
sample to a low-income population limits bias associated with income level. 
We also must address issues of potential bias resulting from endogeneity. Prior research 
has found that locus of control and numeracy, unmeasured variables in the current study, are 
correlated with HIL.146,164 Locus of control or numeracy could be omitted variables that are 
associated with both outcomes of interest and HIL, making the measure of HIL endogenous. 
Further, we have a measure of prior experience with health insurance, but our measure does not 
allow us to account for the length of experience with health insurance and level of prior 
interaction with the health care system. It is possible that a continuous measure of insurance 
history would unveil that it is the intensity of prior interaction, rather than HIL, that predicts 





controlling for the number of chronic conditions and prior experience with private health 
insurance. Sensitivity analyses suggest the HIL variable in the model the specialty utilization 
may be endogenous and biasing estimates upward. Future research could explore this further by 
incorporating methods designed to address endogeneity, such as instrumental variables or two-
stage residual inclusion.165,166  
Conclusions 
 These findings provide evidence that HIL may help individuals gain access to needed 
care. Inversely, low HIL may be a barrier to the receipt of needed BH treatment. Particular 
attention should be paid to barriers that may be modifiable, such as HIL. Policy makers should 
consider ways to increase HIL or reduce the complexity of health insurance to aid consumer 
understanding. Interventions focused on increasing HIL in individuals reported mostly positive 
results, but at least one reported null findings.167–170 For example, Kneippi168 conducted an 
intervention to increase Medicaid knowledge and skills among women with chronic conditions. 
Those assigned to the intervention group increased in Medicaid knowledge and skills and were 
more likely to have a new MH visit. Another intervention, using targeted mailing materials to 
Medicare enrollees, observed utilization of mammography services.167 Further, many programs 
have utilized care coordinators or navigators through hospitals, outpatient clinics, or community 
health centers to help individuals navigate health systems, including health insurance 
landscapes.171 However, the efficacy of those individuals may be limited by the HIL of the 
navigator providing the service, as they may have low HIL, themselves.172   
Evidence suggests that access to BH treatment services can improve health outcomes and 
sometimes reduce the risk of mortality.8,161,173 Given the prevalence of MH conditions (20%) and 





suicide rates (35% increase from 1999 to 2018)1,5 researchers and policy makers should focus on 
reducing any barriers to BH services. Two potential paths to increasing HIL include (1) insurer-
level efforts to increase the clarity and accessibility of health insurance terms/processes and (2) 
interventions to increase health insurance literacy at the individual level. Addressing these 

























Chapter V: Conclusions 
Despite increased coverage of BH services through the Affordable Care Act,9 national 
trends show little overall change in reported access to BH services. Untreated BH symptoms can 
result in more severe symptoms, additional diagnoses, or increased mortality risk.2–5 Low 
treatment rates and slow growth in treatment trends suggest that other barriers remain. 
Workforce supply barriers may limit the full potential of reforms, like Medicaid 
expansion and CARA, to improve access to behavioral health services. State-level legislation 
limiting the practice authority of mid-level practitioners may exacerbate workforce shortage 
problems. Even when workforce supply is adequate and insurance provides behavioral health 
services coverage individual factors may mitigate demand. Limited understanding of insurance 
jargon can increase confusion about covered services and providers, resulting in limited-service 
utilization, particularly for those with little experience accessing healthcare services using 
insurance. This dissertation used data from three sources and quasi-experimental research 
methods to explore potential barriers to behavioral health services.  
Using nationally representative data, we conducted a quasi-experimental study to 
examine the impact of Medicaid expansion and MH workforce on MH utilization and self-
reported outcomes. We find evidence that the number of MH OP and MH ED visits (conditional 
on any visit) increase in Medicaid expansion states after expansion. However, similar to other 
literature, we do not find evidence of greater increases in the number of individuals who access 
MH services in Medicaid expansion states.28 Estimates suggest that the current MH workforce 
can only meet 28% of MH needs.12 To examine the influence of workforce shortage on access to 
BH services, we stratified our models by HPSA. We found little difference between counties 





be higher in areas with adequate supply. These findings may be limited by the HPSA measure, 
which relies heavily on psychiatry supply. Further, supply measures do not account for the share 
of providers that accept Medicaid patients. Researchers and policymakers should explore the 
mechanisms that may prevent increases in the number of individuals who access MH services in 
MH expansion states.  
The interaction between federal and state policies may impact access to care for those 
seeking medications for opioid use disorder. We used DEA buprenorphine dispensing data and 
buprenorphine waivered provider counts merged with multiple other national data sources to 
determine the impact of buprenorphine dispensing following CARA. Further, we examined 
whether buprenorphine dispensing increases more in states where NPs have more practice 
autonomy. We find evidence that buprenorphine dispensing increases after CARA, and that 
increase is greater in states where NPs are granted more practice autonomy. Policymakers 
working to address the opioid epidemic in their state should consider whether increasing NP 
practice autonomy may lead to increased access to medication for OUD, particularly among 
underserved populations.   
Finally, we used data from members enrolled in a safety-net coverage program to 
examine whether health insurance literacy at baseline hinders subsequent access to BH services 
and increases reports of unmet MH need 12 months later. We find evidence that low health 
insurance literacy is associated with an increased probability of reported unmet MH need 12 
months later in individuals with mental health symptoms. Further, individuals with low HIL at 
baseline are less likely to access specialist BH services, but additional testing suggests that the 





(1) insurer-level efforts to increase the clarity and accessibility of health insurance 
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Appendix A, Table 1. Summary of Measures, Chapter II 
Mental Health (MH) 
Outcomes (MEPS) 




Covariates and Other 
Measures 
Probability of a MH-related 
office visits 
 
# of MH-related office visits 
 
Probability of receiving any 
MH pharmacotherapy 
 
Accomplished Less due to 
emotional problems  
 
Level of Psychological 
Distress 
Above cut-off for 
moderate psychological 




































Appendix A. Figure 1. Parallel Trends Assumption, Any MH Outpatient 
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Appendix A. Figure 3. Parallel Trends Assumption, Any MH ED Visit 
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Appendix A. Figure 5. Parallel Trends Assumption, Number of MH Prescriptions 
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Appendix A.  Figure 7. Parallel Trends Assumption, Kessler-6 Scale (continuous) 
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Appendix A, Table 2. 2x2 DID estimates for Medicaid Expansion, Full Sample at 100% FPL 
 Any Utilization (LPM) Self-Reported Outcome (LPM) Number of Visits, Conditional on Any (Poisson, 
IRR) 




Any MH Rx Kessler 6 
Scale 
Accomplished 
ANY less due to 
MH 
    Rx count ED count MH Outpatient 
count 
Expansion      1.734** 0.612* 0.514** 
   Medicaid expansion 
State 
0.0147 0.00978 -0.0750* 0.450 0.0359 [1.13,2.66] [0.36,1.05] [0.30,0.89] 
 [-0.02,0.05] [-0.07,0.09] [-0.15,0.00] [-0.38,1.28] [-0.06,0.13] 0.991 0.788 0.874 
   Post-ME 0.00538 0.00776 0.0330* -1.134*** -0.159*** [0.85,1.16] [0.49,1.26] [0.64,1.20] 
 [-0.00,0.01] [-0.02,0.04] [-0.00,0.07] [-1.66,-0.61] [-0.20,-0.12] 0.898 1.838*** 1.594*** 
   Medicaid expansion 
State * Post ME 
-0.00562 0.00563 0.0113 0.230 0.00370 [0.75,1.08] [1.30,2.59] [1.16,2.20] 
 [-0.01,0.00] [-0.02,0.03] [-0.02,0.05] [-0.27,0.73] [-0.04,0.05]    
Age      1.142 0.826 1.137 
   25-35 0.000922 0.0204** 0.0596*** 0.988*** 0.0584*** [0.96,1.35] [0.61,1.11] [0.81,1.59] 
 [-0.00,0.01] [0.00,0.04] [0.04,0.08] [0.67,1.31] [0.03,0.09] 1.595*** 0.933 1.368* 
   36-50 0.00936*** 0.0528*** 0.105*** 1.558*** 0.113*** [1.33,1.91] [0.69,1.25] [0.99,1.90] 
 [0.00,0.02] [0.03,0.07] [0.08,0.13] [1.23,1.88] [0.08,0.14] 1.343*** 0.930 1.162 
   51-64 0.000515 0.000558 0.111*** 0.723*** 0.129*** [1.12,1.61] [0.63,1.38] [0.80,1.69] 
 [-0.01,0.01] [-0.02,0.03] [0.08,0.14] [0.33,1.11] [0.09,0.17]    
Gender      1.041 0.857 0.761*** 
   Female 0.00482** 0.0278*** 0.0527*** 0.396*** 0.0458*** [0.95,1.14] [0.71,1.04] [0.64,0.91] 
 [0.00,0.01] [0.01,0.04] [0.04,0.07] [0.16,0.63] [0.03,0.06]    
Education (ref=less than HS)     0.981 0.736** 1.174 
   High School -0.00298 0.0122 0.00403 -0.234 -0.0404*** [0.89,1.08] [0.58,0.94] [0.93,1.49] 
 [-0.01,0.00] [-0.01,0.03] [-0.02,0.03] [-0.56,0.09] [-0.06,-0.02] 0.982 0.802* 1.303** 
   More than HS -0.00279 0.0138 0.0233* -0.547*** -0.0454*** [0.87,1.10] [0.64,1.01] [1.01,1.67] 
 [-0.01,0.00] [-0.01,0.03] [-0.00,0.05] [-0.90,-0.20] [-0.07,-0.02] 0.997 1.428* 1.481 
   Other/unknown -0.00174 0.00987 -0.00803 -0.517* -0.0621** [0.85,1.17] [0.99,2.07] [0.88,2.48] 
 [-0.01,0.01] [-0.02,0.04] [-0.05,0.03] [-1.09,0.05] [-0.11,-0.01]    
Chronic Conditions      1.242*** 1.192 1.222 
   1-2 0.00508** 0.0778*** 0.131*** 1.777*** 0.164*** [1.09,1.42] [0.95,1.50] [0.96,1.56] 
 [0.00,0.01] [0.06,0.10] [0.11,0.15] [1.53,2.03] [0.14,0.19] 1.536*** 1.144 1.257 
   3+ 0.00893** 0.181*** 0.351*** 4.370*** 0.342*** [1.34,1.76] [0.91,1.44] [0.93,1.70] 
 [0.00,0.02] [0.15,0.21] [0.32,0.38] [3.93,4.81] [0.31,0.37]    





   Hispanic -0.00447* -0.0816*** -0.119*** -1.203*** -0.0393*** [0.67,0.88] [0.85,2.01] [0.54,0.88] 
 [-0.01,0.00] [-0.10,-0.06] [-0.14,-0.10] [-1.57,-0.83] [-0.07,-0.01] 0.713*** 0.825 1.166 
   Black/African 
American 
-0.00398* -0.100*** -0.143*** -1.133*** -0.0632*** [0.65,0.79] [0.63,1.09] [0.91,1.49] 
 [-0.01,0.00] [-0.12,-0.08] [-0.17,-0.12] [-1.43,-0.83] [-0.09,-0.04] 1 1 1 
   Alaskan/Native 
American 
0.00120 -0.00649 -0.0298 -0.129 -0.0577 [1.00,1.00] [1.00,1.00] [1.00,1.00] 
 [-0.01,0.02] [-0.06,0.05] [-0.09,0.03] [-1.51,1.26] [-0.16,0.04] 1.208 0.841 0.689** 
   Asian -0.00192 -0.0761*** -0.123*** -0.869*** -0.0329 [0.94,1.55] [0.39,1.83] [0.50,0.96] 
 [-0.01,0.01] [-0.11,-0.04] [-0.17,-0.07] [-1.50,-0.24] [-0.09,0.03] 0.552*** 1.892** 1.683 
   Multiple/Other 0.00818 0.0284 0.0251 0.993** 0.0759** [0.37,0.82] [1.09,3.28] [0.84,3.36] 
 [-0.01,0.03] [-0.02,0.08] [-0.03,0.08] [0.20,1.79] [0.01,0.14] 0.841 0.652*** 1.503** 
Married -0.0108*** -0.0700*** -0.0796*** -1.481*** -0.108*** [0.68,1.04] [0.48,0.89] [1.04,2.16] 
 [-0.01,-0.01] [-0.09,-0.05] [-0.10,-0.06] [-1.76,-1.20] [-0.13,-0.08] 0.799*** 0.772 0.759*** 
Percent of FPL 0.0000867 0.000447 0.000314 0.0176 0.00234** [0.72,0.88] [0.51,1.16] [0.63,0.92] 
 [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [-0.01,0.04] [0.00,0.00] 1.003 0.969*** 0.994 
Psychiatrists/100k -0.000179** 0.000485 0.000252 -0.00526 -0.000152 [1.00,1.01] [0.95,0.99] [0.97,1.02] 
 [-0.00,-0.00] [-0.00,0.00] [-0.00,0.00] [-0.01,0.00] [-0.00,0.00]    
Year      0.997 0.864 0.820 
   2011 0.00497 0.00418 -0.000451 -0.142 -0.00776 [0.90,1.11] [0.58,1.29] [0.64,1.05] 
 [-0.00,0.01] [-0.02,0.03] [-0.03,0.02] [-0.46,0.17] [-0.04,0.02] 0.929 1.547** 0.842 
   2012 0.00447 0.0169 0.0223 -0.119 -0.00572 [0.82,1.05] [1.04,2.30] [0.64,1.11] 
 [-0.00,0.01] [-0.01,0.04] [-0.00,0.05] [-0.48,0.24] [-0.04,0.03] 0.850** 1.073 1.077 
   2013 0.00263 0.00314 -0.00362 -0.439** -0.0214 [0.73,0.99] [0.81,1.42] [0.79,1.46] 
 [-0.00,0.01] [-0.02,0.03] [-0.03,0.02] [-0.84,-0.04] [-0.05,0.01] - - - 
   2014 0.00456 0.00157 -0.0288* 0.0192 0.101***    
 [-0.00,0.01] [-0.02,0.03] [-0.06,0.00] [-0.48,0.52] [0.06,0.14] 0.927 1.106 0.832 
   2015 -0.000538 -0.00614 -0.0477*** -0.399* -0.0108 [0.82,1.05] [0.77,1.58] [0.66,1.05] 
 [-0.01,0.01] [-0.03,0.02] [-0.07,-0.02] [-0.83,0.04] [-0.05,0.02] 1.028 0.915 1.155 
   2016 0 0 0 0 0 [0.92,1.15] [0.65,1.29] [0.80,1.67] 
 [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] 1.028 0.915 1.155 
   2017 0.00445 0.0768** 0.129*** 4.880*** 0.344*** [0.92,1.15] [0.65,1.29] [0.80,1.67] 
 [-0.01,0.02] [0.00,0.15] [0.06,0.20] [3.93,5.83] [0.25,0.43] 1 1 1 
   2018 0.00497 0.00418 -0.000451 -0.142 -0.00776 [1.00,1.00] [1.00,1.00] [1.00,1.00] 
 [-0.00,0.01] [-0.02,0.03] [-0.03,0.02] [-0.46,0.17] [-0.04,0.02] - - - 
Constant 0.00447 0.0169 0.0223 -0.119 -0.00572    
 [-0.00,0.01] [-0.01,0.04] [-0.00,0.05] [-0.48,0.24] [-0.04,0.03]    
Observations 304873 304873 304873 301761 302743 283117 157885 273626 





Appendix A. Table 3. 2x2 DID estimates for Medicaid Expansion, Full Sample at 138% FPL 
 Any Utilization (LPM) Self-Reported Outcome (LPM) Number of Visits, Conditional on Any (Poisson, 
IRR) 




Any MH Rx Kessler 6 
Scale 
Accomplished 
ANY less due 
to MH 
    Rx count ED count MH 
Outpatient 
count 
Expansion         
   Medicaid expansion State 0.00527 0.0298 -0.0231 0.774 0.0377 1.659*** 0.914 0.612*** 
 [-0.03,0.04] [-0.04,0.10] [-0.11,0.07] [-0.30,1.85] [-0.09,0.17] [1.19,2.30] [0.69,1.22] [0.44,0.85] 
   Post-ME 0.00174 0.0262** 0.0350*** -0.991*** -0.154*** 0.979 0.969 0.903 
 [-0.00,0.01] [0.00,0.05] [0.01,0.06] [-1.41,-0.58] [-0.19,-0.12] [0.85,1.13] [0.66,1.42] [0.68,1.19] 
   Medicaid expansion State * 
Post ME 
-0.00183 0.0102 0.00953 0.124 0.00412 0.947 1.552*** 1.410** 
 [-0.01,0.00] [-0.01,0.03] [-0.02,0.04] [-0.26,0.51] [-0.03,0.04] [0.81,1.11] [1.18,2.04] [1.04,1.92] 
Age         
   25-35 0.000513 0.0174** 0.0532*** 0.806*** 0.0544*** 1.188** 0.894 1.097 
 [-0.00,0.00] [0.00,0.03] [0.03,0.07] [0.55,1.07] [0.03,0.08] [1.02,1.38] [0.70,1.14] [0.82,1.46] 
   36-50 0.00707*** 0.0393*** 0.0908*** 1.184*** 0.100*** 1.532*** 0.985 1.296* 
 [0.00,0.01] [0.02,0.06] [0.07,0.11] [0.91,1.45] [0.08,0.12] [1.32,1.78] [0.75,1.30] [0.99,1.70] 
   51-64 0.0000555 -0.00641 0.0941*** 0.458*** 0.121*** 1.318*** 0.994 1.127 
 [-0.01,0.01] [-0.03,0.01] [0.07,0.12] [0.14,0.78] [0.09,0.15] [1.13,1.54] [0.68,1.46] [0.81,1.57] 
Gender         
   Female 0.00476*** 0.0296*** 0.0588*** 0.470*** 0.0544*** 1.033 0.852* 0.727*** 
 [0.00,0.01] [0.02,0.04] [0.05,0.07] [0.28,0.66] [0.04,0.07] [0.96,1.12] [0.71,1.02] [0.61,0.86] 
Education (ref=less than HS)         
   High School -0.00150 0.00708 -0.000531 -0.248* -0.0383*** 1.001 0.758** 1.087 
 [-0.01,0.00] [-0.01,0.02] [-0.02,0.02] [-0.53,0.03] [-0.06,-0.02] [0.91,1.10] [0.60,0.96] [0.87,1.36] 
   More than HS -0.00256 0.0131 0.0143 -0.559*** -0.0518*** 0.984 0.815* 1.169 
 [-0.01,0.00] [-0.01,0.03] [-0.01,0.04] [-0.86,-0.26] [-0.08,-0.03] [0.89,1.09] [0.66,1.01] [0.92,1.49] 
   Other/unknown -0.00116 0.0123 0.00921 -0.598*** -0.0577*** 0.986 1.180 1.263 
 [-0.01,0.01] [-0.02,0.04] [-0.02,0.04] [-1.05,-0.15] [-0.10,-0.02] [0.86,1.13] [0.83,1.68] [0.78,2.05] 
Chronic Conditions         
   1-2 0.00462** 0.0718*** 0.122*** 1.714*** 0.153*** 1.245*** 1.080 1.220* 
 [0.00,0.01] [0.06,0.09] [0.10,0.14] [1.51,1.91] [0.13,0.17] [1.11,1.40] [0.89,1.31] [0.98,1.53] 
   3+ 0.00942*** 0.180*** 0.349*** 4.460*** 0.347*** 1.561*** 1.050 1.309** 
 [0.00,0.02] [0.16,0.20] [0.32,0.37] [4.09,4.83] [0.32,0.37] [1.39,1.75] [0.87,1.27] [1.01,1.70] 
Race/Ethnicity         
   Hispanic -0.00231 -0.0701*** -0.118*** -1.126*** -0.0370*** 0.846*** 1.181 0.715*** 





   Black/African American -0.00331* -0.0967*** -0.140*** -1.146*** -0.0678*** 0.715*** 0.801** 1.180 
 [-0.01,0.00] [-0.11,-0.08] [-0.16,-0.12] [-1.40,-0.89] [-0.09,-0.05] [0.66,0.78] [0.66,0.97] [0.96,1.46] 
   Alaskan/Native American -0.0000406 -0.000441 -0.0300 -0.230 -0.0420 1.104 0.872 0.809 
 [-0.01,0.01] [-0.03,0.03] [-0.08,0.02] [-1.25,0.79] [-0.12,0.04] [0.88,1.39] [0.42,1.82] [0.57,1.14] 
   Asian -0.00263 -0.0759*** -0.126*** -0.915*** -0.0529** 0.566*** 1.759*** 1.541 
 [-0.01,0.00] [-0.10,-0.05] [-0.16,-0.09] [-1.45,-0.38] [-0.10,-0.01] [0.39,0.82] [1.15,2.69] [0.83,2.86] 
   Multiple/Other 0.00769 0.0209 0.0132 1.119*** 0.0973*** 0.907 0.686*** 1.458** 
 [-0.01,0.02] [-0.02,0.07] [-0.04,0.06] [0.36,1.88] [0.04,0.15] [0.75,1.09] [0.55,0.85] [1.03,2.07] 
Married 0 0 0 0 0 1 1 1 
 [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] [1.00,1.00] [1.00,1.00] [1.00,1.00] 
Percent FPL -0.00887*** -0.0672*** -0.0763*** -1.376*** -0.0951*** 0.782*** 0.706** 0.784*** 
 [-0.01,-0.01] [-0.08,-0.05] [-0.09,-0.06] [-1.61,-1.14] [-0.11,-0.08] [0.72,0.85] [0.52,0.96] [0.66,0.93] 
Psychiatry 100k -0.00000680 0.000184 0.0000238 0.0178 0.00174** 1.004 0.977*** 0.991 
 [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [-0.00,0.04] [0.00,0.00] [1.00,1.01] [0.96,0.99] [0.97,1.01] 
Year         
   2011 0.00444 0.0107 0.0126 -0.0528 0.00945 1.019 0.863 0.888 
 [-0.00,0.01] [-0.01,0.03] [-0.01,0.03] [-0.33,0.22] [-0.02,0.04] [0.92,1.13] [0.63,1.18] [0.70,1.13] 
   2012 0.00386 0.0227** 0.0279** 0.0778 0.00530 0.963 1.578*** 0.917 
 [-0.00,0.01] [0.00,0.04] [0.01,0.05] [-0.25,0.40] [-0.02,0.03] [0.87,1.07] [1.12,2.22] [0.70,1.20] 
   2013 0.00317 0.0102 0.00424 -0.278 -0.0153 0.932 1.072 1.121 
 [-0.00,0.01] [-0.01,0.03] [-0.02,0.03] [-0.62,0.06] [-0.04,0.01] [0.82,1.06] [0.86,1.34] [0.87,1.44] 
   2016 0.00542* -0.00639 -0.0190 0.0545 0.108*** 0.938 0.966 0.849 
 [-0.00,0.01] [-0.03,0.01] [-0.04,0.00] [-0.33,0.44] [0.07,0.14] [0.84,1.04] [0.72,1.29] [0.69,1.05] 
   2017 0.00275 -0.0130 -0.0276** -0.247 -0.00281 1.021 0.833 1.090 
 [-0.00,0.01] [-0.03,0.01] [-0.05,-0.01] [-0.59,0.10] [-0.03,0.03] [0.93,1.12] [0.63,1.10] [0.82,1.45] 
   2018 0 0 0 0 0 1 1 1 
 [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] [1.00,1.00] [1.00,1.00] [1.00,1.00] 
Constant 0.0131 0.0708** 0.117*** 4.387*** 0.325*** - - - 
 [-0.01,0.03] [0.01,0.13] [0.06,0.17] [3.45,5.32] [0.23,0.42]    
Observations 307704 307704 307704 303366 304153 278266 169916 271557 
95% confidence intervals in brackets 









Appendix Table 4. 2x2 DID estimates for Medicaid Expansion, Full Sample at 200% FPL 
 Any Utilization (LPM) Self-Reported Outcome (LPM) Number of Visits, Conditional on Any 
(Poisson, IRR) 




Any MH Rx Kessler 6 
Scale 
Accomplished 
ANY less due 
to MH 
    Rx count ED count MH Outpatient 
count 
Expansion         
   Medicaid expansion 
State 
0.00681 0.0269 -0.0221 0.795 0.0634 1.392* 0.924 0.607*** 
 [-0.02,0.04] [-0.03,0.09] [-0.10,0.06] [-0.31,1.90] [-0.02,0.15] [0.96,2.03] [0.71,1.21] [0.45,0.81] 
   Post-ME 0.000722 0.00833 0.0291** -1.031*** -0.149*** 0.985 0.914 0.880 
 [-0.00,0.01] [-0.01,0.03] [0.01,0.05] [-1.36,-0.70] [-0.18,-0.12] [0.85,1.13] [0.68,1.24] [0.69,1.13] 
   Medicaid expansion 
State * Post ME 
-0.00109 0.0133 -0.00469 0.0941 0.00138 0.979 1.599*** 1.470*** 
 [-0.01,0.00] [-0.01,0.03] [-0.03,0.02] [-0.23,0.42] [-0.03,0.03] [0.85,1.13] [1.27,2.01] [1.11,1.95] 
Age         
   25-35 0.00175 0.0212*** 0.0594*** 0.636*** 0.0450*** 1.233*** 0.936 1.160 
 [-0.00,0.01] [0.01,0.03] [0.04,0.08] [0.42,0.85] [0.02,0.07] [1.08,1.41] [0.76,1.14] [0.91,1.49] 
   36-50 0.00451** 0.0304*** 0.0902*** 0.798*** 0.0745*** 1.506*** 1.037 1.324** 
 [0.00,0.01] [0.02,0.04] [0.07,0.11] [0.57,1.03] [0.05,0.10] [1.31,1.73] [0.82,1.31] [1.04,1.68] 
   51-64 -0.00108 -0.00202 0.0913*** 0.250* 0.0948*** 1.333*** 1.014 1.169 
 [-0.01,0.00] [-0.02,0.01] [0.07,0.11] [-0.02,0.52] [0.07,0.12] [1.16,1.54] [0.75,1.38] [0.87,1.58] 
Female 0.00439*** 0.0340*** 0.0714*** 0.542*** 0.0636*** 1.004 0.868* 0.791*** 
 [0.00,0.01] [0.02,0.04] [0.06,0.08] [0.39,0.69] [0.05,0.08] [0.94,1.07] [0.74,1.01] [0.67,0.93] 
Education (ref=less 
than HS) 
        
   High School -0.00151 -0.000669 -0.00381 -0.258** -0.0428*** 1.012 0.740** 1.126 
 [-0.00,0.00] [-0.01,0.01] [-0.02,0.01] [-0.48,-0.03] [-0.06,-0.03] [0.93,1.10] [0.59,0.93] [0.91,1.39] 
   More than HS -0.00260 0.0112 0.00950 -0.608*** -0.0554*** 0.992 0.796** 1.213* 
 [-0.01,0.00] [-0.00,0.03] [-0.01,0.03] [-0.86,-0.35] [-0.08,-0.03] [0.91,1.08] [0.66,0.97] [0.98,1.50] 
   Other/unknown -0.000311 0.0139 0.00913 -0.619*** -0.0519*** 0.990 1.174 1.246 
 [-0.01,0.01] [-0.01,0.04] [-0.02,0.04] [-0.96,-0.28] [-0.08,-0.02] [0.88,1.12] [0.89,1.55] [0.84,1.86] 





   1-2 0.00482*** 0.0615*** 0.113*** 1.569*** 0.138*** 1.271*** 1.013 1.205* 
 [0.00,0.01] [0.05,0.07] [0.10,0.13] [1.42,1.72] [0.12,0.15] [1.16,1.39] [0.85,1.21] [0.99,1.46] 
   3+ 0.0101*** 0.166*** 0.334*** 4.409*** 0.339*** 1.625*** 1.065 1.383*** 
 [0.01,0.02] [0.15,0.19] [0.31,0.36] [4.12,4.70] [0.32,0.36] [1.47,1.79] [0.90,1.26] [1.10,1.74] 
Race/Ethnicity         
   Hispanic -0.000837 -0.0683*** -0.116*** -1.097*** -0.0433*** 0.866** 1.077 0.822* 
 [-0.00,0.00] [-0.08,-0.06] [-0.13,-0.10] [-1.33,-0.86] [-0.06,-0.02] [0.78,0.97] [0.78,1.49] [0.67,1.01] 
   Black/African 
American 
-0.00145 -0.0890*** -0.138*** -1.059*** -0.0672*** 0.740*** 0.869* 1.196* 
 [-0.00,0.00] [-0.10,-0.08] [-0.15,-0.12] [-1.27,-0.85] [-0.08,-0.05] [0.69,0.80] [0.75,1.00] [0.98,1.46] 
   Alaskan/Native 
American 
-0.00199 -0.00481 -0.0355* -0.164 -0.0242 1.151 0.904 0.900 
 [-0.01,0.01] [-0.04,0.03] [-0.07,0.00] [-0.92,0.59] [-0.09,0.04] [0.92,1.44] [0.47,1.76] [0.67,1.22] 
   Asian -0.00270 -0.0735*** -0.134*** -0.846*** -0.0399** 0.599*** 1.778** 1.456 
 [-0.01,0.00] [-0.09,-0.05] [-0.16,-0.11] [-1.25,-0.44] [-0.08,-0.00] [0.44,0.81] [1.08,2.92] [0.79,2.69] 
   Multiple/Other 0.00984 0.0215 0.00235 0.839*** 0.0667*** 0.989 0.757*** 1.385** 
 [-0.00,0.02] [-0.01,0.06] [-0.04,0.04] [0.27,1.41] [0.02,0.11] [0.84,1.16] [0.64,0.90] [1.05,1.83] 
Married -0.00717*** -0.0656*** -0.0668*** -1.188*** -0.0917*** 0.743*** 0.852 0.766*** 
 [-0.01,-0.00] [-0.08,-0.05] [-0.08,-0.05] [-1.39,-0.99] [-0.11,-0.08] [0.69,0.80] [0.68,1.07] [0.66,0.89] 
Percent FPL 0.0000379 0.000168 -0.000226 0.0194** 0.00173*** 1.007** 0.980*** 0.994 
 [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [0.00,0.04] [0.00,0.00] [1.00,1.01] [0.97,0.99] [0.98,1.01] 
Psychiatrists/100,000 -0.0000554 0.000437* 0.000142 0.00239 0.000478 1.000 0.998 1.008*** 
 [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [-0.00,0.01] [-0.00,0.00] [1.00,1.00] [0.99,1.01] [1.00,1.01] 
Year         
   2011 0.00126 -0.00411 0.0110 -0.0855 -0.00445 1.010 0.808 0.914 
 [-0.00,0.01] [-0.02,0.01] [-0.01,0.03] [-0.32,0.15] [-0.03,0.02] [0.93,1.10] [0.59,1.12] [0.74,1.12] 
   2012 0.00210 0.00507 0.00867 -0.102 -0.0118 0.970 1.283** 0.913 
 [-0.00,0.01] [-0.01,0.02] [-0.01,0.03] [-0.39,0.19] [-0.04,0.01] [0.88,1.07] [1.01,1.63] [0.73,1.15] 
   2013 0.00146 -0.00329 -0.00152 -0.364** -0.0302** 0.952 0.998 1.073 
 [-0.00,0.01] [-0.02,0.01] [-0.02,0.02] [-0.65,-0.08] [-0.06,-0.00] [0.85,1.07] [0.84,1.19] [0.86,1.34] 
   2016 0.00428* -0.00629 -0.0233** 0.0759 0.0859*** 0.945 0.928 0.885 





   2017 0.00360 -0.00829 -0.0225** -0.211 -0.00808 1.000 0.796* 1.086 
 [-0.00,0.01] [-0.02,0.01] [-0.04,-0.00] [-0.47,0.04] [-0.03,0.02] [0.92,1.09] [0.62,1.03] [0.86,1.36] 
   2018 0 0 0 0 0 1 1 1 
 [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] [1.00,1.00] [1.00,1.00] [1.00,1.00] 
Constant 0.00770 0.0823*** 0.110*** 3.860*** 0.297***    
 [-0.01,0.02] [0.03,0.14] [0.05,0.17] [2.99,4.73] [0.23,0.36]    
Observations 309142 309142 309142 303803 304876 271873 177492 263433 
95% confidence intervals in brackets 































Appendix A. Table 5. Mental Health Subsample, 2x2 DID estimates for Medicaid Expansion, Full Sample at 100% FPL 
 Any Utilization (LPM) Self-Reported Outcome (LPM) Number of Visits, Conditional on Any     
(Poisson, IRR) 




Any MH Rx Kessler 6 
Scale 
Accomplished 
ANY less due 
to MH 
    Rx count ED count MH 
Outpatient 
count 
Expansion         
   Medicaid expansion State 0.0263 0.0573 -0.00712 0.667 0.0370 1.710** 0.348** 0.577* 
 [-0.04,0.09] [-0.09,0.21] [-0.11,0.10] [-0.68,2.01] [-0.01,0.09] [1.13,2.59] [0.15,0.78] [0.31,1.06] 
   Post-ME 0.0213** 0.0397 0.0975*** -0.734** -0.104*** 1.061 0.874 0.855 
 [0.00,0.04] [-0.02,0.10] [0.04,0.16] [-1.38,-0.08] [-0.16,-0.05] [0.88,1.28] [0.52,1.47] [0.61,1.20] 
   Medicaid expansion State 
* Post ME 
-0.00721 0.0171 0.00632 0.583* 0.0195 0.888 2.139*** 1.667*** 
 [-0.03,0.02] [-0.04,0.08] [-0.06,0.07] [-0.09,1.26] [-0.04,0.08] [0.73,1.09] [1.31,3.50] [1.22,2.27] 
Age         
   25-35 -0.00661 0.00925 0.0827*** 1.088*** 0.0496** 1.056 0.819 1.121 
 [-0.02,0.01] [-0.04,0.06] [0.03,0.14] [0.61,1.56] [0.01,0.09] [0.83,1.34] [0.57,1.17] [0.80,1.57] 
   36-50 0.0117 0.0727*** 0.148*** 1.667*** 0.108*** 1.511*** 0.797 1.159 
 [-0.01,0.03] [0.03,0.12] [0.10,0.20] [1.22,2.12] [0.06,0.15] [1.21,1.89] [0.55,1.15] [0.83,1.61] 
   51-64 0.00107 -0.00763 0.179*** 1.207*** 0.150*** 1.349** 0.952 0.965 
 [-0.02,0.02] [-0.06,0.05] [0.13,0.23] [0.72,1.69] [0.10,0.20] [1.07,1.71] [0.62,1.47] [0.70,1.33] 
Female 0.00872* 0.0356** 0.0645*** 0.286 0.0516*** 1.031 0.920 0.803** 
 [-0.00,0.02] [0.01,0.07] [0.03,0.10] [-0.07,0.64] [0.03,0.08] [0.93,1.14] [0.78,1.09] [0.68,0.95] 
         
Education (ref=less than 
HS) 
        
   High School -0.00557 0.0457*** 0.0354* -0.174 -0.0193 0.994 0.662** 1.321*** 
 [-0.02,0.01] [0.01,0.08] [-0.00,0.07] [-0.51,0.16] [-0.05,0.01] [0.90,1.10] [0.44,0.99] [1.08,1.62] 
   More than HS -0.00162 0.0333 0.0580** -0.742*** -0.00666 1.038 0.691** 1.470*** 
 [-0.02,0.01] [-0.01,0.07] [0.01,0.10] [-1.17,-0.31] [-0.04,0.03] [0.89,1.20] [0.52,0.93] [1.16,1.86] 
   Other/unknown 0.00434 0.0422 0.00142 -0.681 -0.0309 1.068 1.554** 1.424* 
 [-0.02,0.03] [-0.03,0.11] [-0.07,0.07] [-1.50,0.14] [-0.10,0.03] [0.90,1.27] [1.08,2.23] [0.97,2.09] 
Chronic Conditions         
   1-2 -0.00118 0.106*** 0.171*** 0.846*** 0.0831*** 1.172 1.324 1.183 
 [-0.01,0.01] [0.07,0.15] [0.13,0.22] [0.47,1.22] [0.04,0.12] [0.97,1.42] [0.94,1.86] [0.94,1.49] 
   3+ -0.00238 0.187*** 0.335*** 2.097*** 0.145*** 1.413*** 1.143 1.362** 
 [-0.02,0.01] [0.14,0.23] [0.29,0.38] [1.61,2.58] [0.11,0.19] [1.18,1.69] [0.84,1.55] [1.05,1.77] 
Race/Ethnicity         







[-0.17,-0.08] [-1.19,-0.21] [-0.05,0.02] [0.70,0.94] [0.83,1.97] [0.57,0.97] 
   Black/African American -0.0112** -0.137*** -0.188*** -0.783*** -0.0518*** 0.731*** 0.805 1.205 
 [-0.02,-0.00] [-0.17,-
0.10] 
[-0.23,-0.15] [-1.18,-0.39] [-0.08,-0.02] [0.65,0.82] [0.57,1.14] [0.96,1.51] 
   Alaskan/Native American -0.00457 -0.0913 -0.0251 0.708 0.00148 1.309** 1.535 0.775 
 [-0.04,0.03] [-0.20,0.02] [-0.14,0.09] [-1.01,2.42] [-0.09,0.10] [1.03,1.66] [0.88,2.69] [0.49,1.23] 
   Asian -0.0246*** -0.120** -0.179*** -0.637 0.0133 0.429***  1.768** 
 [-0.03,-0.01] [-0.22,-
0.02] 
[-0.29,-0.07] [-1.73,0.46] [-0.09,0.12] [0.29,0.63]  [1.10,2.83] 
   Multiple/Other 0.00876 0.00803 0.0147 0.245 0.0366 0.812 0.633** 1.811*** 
 [-0.03,0.04] [-0.07,0.09] [-0.08,0.11] [-0.56,1.05] [-0.02,0.09] [0.63,1.05] [0.43,0.94] [1.35,2.43] 
Married -0.0159*** -0.0856*** -0.0710*** -0.931*** -0.0397** 0.858** 0.848 0.711*** 
 [-0.02,-0.01] [-0.12,-
0.05] 
[-0.11,-0.03] [-1.33,-0.53] [-0.07,-0.01] [0.76,0.97] [0.60,1.19] [0.59,0.86] 
Percent FPL -0.0000587 -0.000405 -0.00291* -0.00490 0.000752 1.001 0.960*** 0.990 
 [-0.00,0.00] [-0.00,0.00] [-0.01,0.00] [-0.03,0.02] [-0.00,0.00] [0.99,1.01] [0.94,0.98] [0.98,1.00] 
Psychiatrists/100,000 -0.000213 0.000685 -0.000173 -0.0145** -0.000625 0.999 1.008 1.007*** 
 [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [-0.03,-0.00] [-0.00,0.00] [1.00,1.00] [0.99,1.03] [1.00,1.01] 
Year         
   2011 0.0100 0.0154 0.0214 -0.0311 0.00117 1.037 0.966 0.789** 
 [-0.01,0.03] [-0.03,0.06] [-0.03,0.07] [-0.56,0.50] [-0.04,0.04] [0.92,1.17] [0.60,1.55] [0.62,1.00] 
   2012 0.0116 0.0406* 0.0580** 0.224 -0.0167 0.915 1.717** 0.867 
 [-0.00,0.03] [-0.01,0.09] [0.01,0.11] [-0.33,0.78] [-0.06,0.02] [0.80,1.05] [1.03,2.85] [0.65,1.16] 
   2013 0.00945 0.0222 0.0294 -0.154 0.00599 0.877 1.546** 1.160 
 [-0.01,0.03] [-0.03,0.08] [-0.02,0.08] [-0.68,0.37] [-0.03,0.04] [0.73,1.05] [1.07,2.23] [0.87,1.55] 
   2016 0.00108 -0.0132 -0.0770*** 0.117 0.0939*** 0.907 1.090 0.811 
 [-0.02,0.02] [-0.07,0.04] [-0.13,-0.02] [-0.55,0.79] [0.04,0.15] [0.78,1.06] [0.75,1.58] [0.61,1.07] 
   2017 -0.00661 -0.0129 -0.0800*** -0.180 -0.0193 0.986 0.841 1.058 
 [-0.03,0.02] [-0.07,0.04] [-0.13,-0.03] [-0.82,0.46] [-0.08,0.04] [0.87,1.12] [0.57,1.23] [0.77,1.45] 
   2018 0 0 0 0 0 1 1 1 
 [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] [1.00,1.00] [1.00,1.00] [1.00,1.00] 
Constant 0.0221 0.143*** 0.204*** 9.922*** 0.671*** - - - 
 [-0.01,0.06] [0.04,0.25] [0.09,0.32] [8.88,10.97] [0.59,0.75] - - - 
Observations 298392 298392 298392 298392 298324 287742 127156 272284 








Appendix A. Table 6. Mental Health Subsample, 2x2 DID estimates for Medicaid Expansion, Full Sample at 138% FPL 
 Any Utilization (LPM) Self-Reported Outcome (LPM) Number of Visits, Conditional on Any     
(Poisson, IRR) 




Any MH Rx Kessler 6 
Scale 
Accomplished 
ANY less due 
to MH 
    Rx count ED count MH 
Outpatient 
count 
Expansion         
   Medicaid expansion 
State 
0.0190 0.0592 0.0279 0.189 0.00716 1.472* 0.496** 0.633** 
 [-0.05,0.09] [-0.07,0.18] [-0.06,0.12] [-0.63,1.01] [-0.08,0.10] [1.00,2.18] [0.29,0.86] [0.41,0.98] 
   Post-ME 0.0146* 0.0550* 0.0829*** -0.762*** -0.121*** 1.029 1.086 0.861 
 [-0.00,0.03] [-0.00,0.11] [0.03,0.14] [-1.34,-0.19] [-0.17,-0.07] [0.86,1.23] [0.73,1.61] [0.64,1.16] 
   Medicaid expansion 
State * Post ME 
-0.00644 0.0225 0.0128 0.519* 0.0209 0.954 1.655*** 1.660*** 
 [-0.02,0.01] [-0.03,0.08] [-0.05,0.07] [-0.07,1.11] [-0.03,0.07] [0.80,1.14] [1.17,2.34] [1.23,2.24] 
Age         
   25-35 -0.00688 0.00954 0.0756*** 0.813*** 0.0566** 1.149 0.903 1.073 
 [-0.02,0.01] [-0.03,0.05] [0.03,0.12] [0.39,1.24] [0.01,0.10] [0.93,1.43] [0.65,1.26] [0.80,1.45] 
   36-50 0.00970 0.0637*** 0.131*** 1.331*** 0.105*** 1.582*** 0.895 1.067 
 [-0.01,0.02] [0.02,0.10] [0.09,0.18] [0.91,1.76] [0.06,0.15] [1.30,1.92] [0.61,1.30] [0.79,1.43] 
   51-64 0.000315 -0.00611 0.167*** 0.820*** 0.143*** 1.394*** 0.957 0.905 
 [-0.02,0.02] [-0.05,0.04] [0.12,0.21] [0.35,1.29] [0.10,0.19] [1.13,1.72] [0.59,1.55] [0.67,1.22] 
Female 0.00833** 0.0459*** 0.0771*** 0.228 0.0513*** 1.044 0.965 0.786*** 
 [0.00,0.02] [0.02,0.07] [0.05,0.10] [-0.10,0.55] [0.03,0.07] [0.96,1.14] [0.83,1.13] [0.67,0.92] 
         
Education (ref=less 
than HS) 
-0.00382 0.0400** 0.0264 -0.275* -0.0158 1.014 0.761* 1.133 
   High School [-0.01,0.01] [0.01,0.07] [-0.01,0.06] [-0.57,0.02] [-0.04,0.01] [0.92,1.12] [0.55,1.05] [0.93,1.38] 
 -0.00115 0.0380** 0.0475** -0.702*** -0.0114 1.040 0.760** 1.223* 
   More than HS [-0.01,0.01] [0.00,0.07] [0.01,0.09] [-1.12,-0.28] [-0.04,0.02] [0.92,1.18] [0.60,0.97] [0.98,1.53] 
 0.000502 0.0388 0.0188 -0.906*** -0.0166 1.074 1.391* 1.158 
   Other/unknown [-0.02,0.02] [-0.02,0.10] [-0.04,0.08] [-1.59,-0.23] [-0.07,0.04] [0.92,1.26] [0.97,2.00] [0.81,1.66] 
         
Chronic Conditions 0.00116 0.0941*** 0.161*** 0.845*** 0.0779*** 1.176* 1.297* 1.192 
   1-2 [-0.01,0.01] [0.06,0.13] [0.12,0.20] [0.54,1.15] [0.04,0.11] [0.99,1.40] [0.96,1.76] [0.96,1.48] 
 0.000976 0.178*** 0.341*** 2.326*** 0.153*** 1.409*** 1.162 1.422*** 
   3+ [-0.01,0.01] [0.14,0.21] [0.30,0.38] [1.93,2.72] [0.12,0.19] [1.19,1.67] [0.91,1.49] [1.10,1.84] 
         





   Hispanic [-0.01,0.01] [-0.13,-0.06] [-0.18,-0.11] [-1.01,-0.15] [-0.04,0.02] [0.76,1.03] [0.74,1.71] [0.61,0.96] 
 -0.00568 -0.135*** -0.196*** -0.726*** -0.0506*** 0.722*** 0.759** 1.195 
   Black/African 
American 
[-0.02,0.00] [-0.17,-0.11] [-0.23,-0.16] [-1.06,-0.40] [-0.08,-0.02] [0.65,0.80] [0.59,0.97] [0.96,1.49] 
 -0.00311 -0.0421 0.00182 0.799 0.00105 1.213 1.762** 1.003 
   Alaskan/Native 
American 
[-0.03,0.02] [-0.14,0.06] [-0.10,0.11] [-0.66,2.25] [-0.08,0.08] [0.96,1.53] [1.07,2.91] [0.56,1.80] 
 -0.0179*** -0.123*** -0.158*** -0.499 -0.0409 0.462*** 0.595*** 1.821** 
   Asian [-0.03,-0.01] [-0.21,-0.04] [-0.25,-0.06] [-1.48,0.48] [-0.13,0.05] [0.32,0.66] [0.43,0.82] [1.15,2.88] 
 0.00954 0.00900 0.0157 0.490 0.0569** 0.881 0.610*** 1.649*** 
   Multiple/Other [-0.02,0.04] [-0.07,0.09] [-0.06,0.10] [-0.23,1.21] [0.01,0.10] [0.71,1.09] [0.45,0.83] [1.22,2.24] 
 -0.0116*** -0.0775*** -0.0715*** -0.864*** -0.0304** 0.848*** 0.741** 0.786** 
Married [-0.02,-0.00] [-0.11,-0.05] [-0.10,-0.04] [-1.22,-0.51] [-0.05,-0.01] [0.76,0.94] [0.55,1.00] [0.65,0.94] 
 -0.000344 -0.000185 -0.00211 -0.000642 0.000506 1.002 0.972*** 0.992 
Percent FPL [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [-0.03,0.03] [-0.00,0.00] [1.00,1.01] [0.95,0.99] [0.98,1.01] 
 -0.000172 0.000703 -0.000123 -0.00905* -0.000404 0.999 1.007 1.008*** 
Psychiatrists/100,000 [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [-0.02,0.00] [-0.00,0.00] [1.00,1.00] [0.99,1.02] [1.00,1.01] 
         
Year 0.00686 0.00844 0.0359* -0.159 0.00449 1.035 0.921 0.803** 
   2011 [-0.01,0.02] [-0.03,0.05] [-0.00,0.08] [-0.61,0.29] [-0.03,0.04] [0.92,1.17] [0.61,1.38] [0.65,0.99] 
 0.00694 0.0317 0.0560*** 0.129 -0.0132 0.951 1.806*** 0.939 
   2012 [-0.01,0.02] [-0.01,0.07] [0.01,0.10] [-0.29,0.55] [-0.04,0.02] [0.84,1.07] [1.20,2.71] [0.72,1.22] 
 0.0107 0.0242 0.0390 -0.0349 0.000505 0.941 1.440*** 1.259* 
   2013 [-0.00,0.02] [-0.02,0.07] [-0.01,0.09] [-0.49,0.42] [-0.03,0.04] [0.81,1.09] [1.09,1.90] [0.98,1.61] 
 0.00207 -0.0255 -0.0517** 0.149 0.104*** 0.902 1.022 0.816 
   2016 [-0.01,0.02] [-0.08,0.03] [-0.10,-0.00] [-0.41,0.71] [0.05,0.15] [0.79,1.03] [0.76,1.37] [0.63,1.05] 
 -0.00167 -0.0248 -0.0364 -0.124 0.0107 0.997 0.780* 1.045 
   2017 [-0.02,0.02] [-0.07,0.02] [-0.09,0.01] [-0.64,0.39] [-0.04,0.06] [0.89,1.11] [0.58,1.05] [0.79,1.38] 
 0 0 0 0 0 1 1 1 
   2018 [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] [1.00,1.00] [1.00,1.00] [1.00,1.00] 
 [-0.07,-0.01] [-0.35,-0.03] [-0.03,0.16] [-2.84,-1.27] [-0.17,-0.03] [0.69,1.22]  [0.40,1.36] 
Constant 0.0312* 0.127** 0.184*** 10.12*** 0.665*** - - - 
 [-0.01,0.07] [0.03,0.23] [0.09,0.28] [9.18,11.07] [0.58,0.75] - - - 
Observations 298861 298861 298861 298861 298772 288303 142848 278597 
95% confidence intervals in brackets 







Appendix A. Table 7. Mental Health Subsample, 2x2 DID estimates for Medicaid Expansion, 200% FPL 
 Any Utilization (LPM) Self-Reported Outcome (LPM) Number of Visits, Conditional on Any     
(Poisson, IRR) 




Any MH Rx Kessler 6 
Scale 
Accomplished 
ANY less due 
to MH 
    Rx count ED count MH 
Outpatient 
count 
Expansion         
   Medicaid expansion 
State 
0.0210 0.0670 0.00411 0.571 0.0478 1.354 0.610** 0.664* 
 [-0.05,0.09] [-0.09,0.22] [-0.12,0.13] [-0.14,1.29] [-0.01,0.11] [0.92,1.99] [0.37,0.99] [0.44,1.00] 
   Post-ME 0.0119* 0.0373 0.0652** -0.652*** -0.113*** 1.074 0.925 0.828 
 [-0.00,0.03] [-0.01,0.09] [0.01,0.12] [-1.14,-0.16] [-0.16,-0.07] [0.91,1.27] [0.66,1.30] [0.64,1.07] 
   Medicaid expansion 
State * Post ME 
-0.00555 0.0270 0.00635 0.338 0.0131 0.953 1.656*** 1.676*** 
 [-0.02,0.01] [-0.02,0.08] [-0.05,0.06] [-0.14,0.82] [-0.03,0.05] [0.82,1.11] [1.25,2.19] [1.28,2.19] 
Age         
   25-35 -0.00356 0.0184 0.104*** 0.570*** 0.0450** 1.196** 0.911 1.090 
 [-0.01,0.01] [-0.02,0.06] [0.06,0.15] [0.22,0.92] [0.01,0.08] [1.00,1.42] [0.68,1.23] [0.84,1.41] 
   36-50 0.00553 0.0440** 0.144*** 0.979*** 0.0801*** 1.521*** 0.956 1.128 
 [-0.01,0.02] [0.01,0.08] [0.11,0.18] [0.62,1.34] [0.04,0.12] [1.29,1.80] [0.70,1.31] [0.89,1.43] 
   51-64 -0.00325 -0.00781 0.166*** 0.509** 0.116*** 1.367*** 1.014 1.000 
 [-0.02,0.01] [-0.05,0.03] [0.13,0.21] [0.07,0.95] [0.08,0.16] [1.14,1.64] [0.68,1.52] [0.77,1.29] 
Female 0.00950*** 0.0489*** 0.0927*** 0.238* 0.0562*** 1.021 0.942 0.864** 
 [0.00,0.02] [0.03,0.07] [0.07,0.12] [-0.02,0.50] [0.03,0.08] [0.94,1.10] [0.83,1.07] [0.75,0.99] 
Education (ref=less 
than HS) 
        
   High School -0.00238 0.0208 0.0176 -0.352** -0.0288** 1.019 0.754** 1.177* 
 [-0.01,0.01] [-0.01,0.05] [-0.01,0.05] [-0.63,-0.07] [-0.05,-0.01] [0.93,1.12] [0.57,1.00] [0.98,1.42] 
   More than HS -0.000310 0.0428*** 0.0390** -0.662*** -0.0113 1.051 0.750** 1.276** 
 [-0.01,0.01] [0.01,0.07] [0.00,0.08] [-1.02,-0.30] [-0.04,0.02] [0.95,1.17] [0.60,0.94] [1.04,1.56] 
   Other/unknown 0.00276 0.0372 0.0214 -0.883*** -0.0108 1.073 1.352* 1.220 
 [-0.01,0.02] [-0.02,0.09] [-0.03,0.07] [-1.43,-0.34] [-0.05,0.03] [0.94,1.23] [0.98,1.86] [0.89,1.67] 
Chronic Conditions         
   1-2 0.00576 0.0752*** 0.144*** 0.850*** 0.0757*** 1.225*** 1.157 1.197* 
 [-0.00,0.01] [0.05,0.11] [0.11,0.18] [0.58,1.12] [0.05,0.10] [1.07,1.40] [0.88,1.52] [0.98,1.46] 
   3+ 0.00668 0.166*** 0.327*** 2.460*** 0.152*** 1.484*** 1.118 1.418*** 





Race/Ethnicity         
   Hispanic 0.00411 -0.0905*** -0.147*** -0.468*** -0.0200 0.884* 1.018 0.868 
 [-0.01,0.01] [-0.12,-0.06] [-0.18,-0.11] [-0.80,-0.13] [-0.05,0.01] [0.78,1.01] [0.75,1.39] [0.69,1.09] 
   Black/African 
American 
-0.00200 -0.130*** -0.191*** -0.595*** -0.0586*** 0.738*** 0.854 1.211* 
 [-0.01,0.01] [-0.16,-0.10] [-0.22,-0.16] [-0.89,-0.30] [-0.08,-0.04] [0.67,0.81] [0.70,1.03] [0.98,1.50] 
   Alaskan/Native 
American 
-0.00544 -0.0191 -0.0117 0.772 -0.00222 1.275** 1.866*** 1.086 
 [-0.03,0.02] [-0.11,0.07] [-0.10,0.07] [-0.40,1.94] [-0.09,0.08] [1.02,1.59] [1.21,2.89] [0.71,1.66] 
   Asian -0.0167*** -0.133*** -0.175*** -0.397 -0.0188 0.485*** 0.554*** 1.789** 
 [-0.02,-0.01] [-0.20,-0.06] [-0.25,-0.10] [-1.16,0.36] [-0.09,0.06] [0.34,0.69] [0.43,0.71] [1.14,2.81] 
   Multiple/Other 0.0126 0.0242 0.0134 0.609* 0.0480* 0.956 0.642*** 1.468*** 
 [-0.01,0.04] [-0.05,0.09] [-0.06,0.09] [-0.10,1.32] [-0.00,0.10] [0.79,1.16] [0.48,0.86] [1.13,1.90] 
Married -0.00964*** -0.0922*** -0.0693*** -0.777*** -0.0467*** 0.803*** 0.923 0.818** 
 [-0.02,-0.00] [-0.12,-0.07] [-0.10,-0.04] [-1.06,-0.50] [-0.07,-0.02] [0.73,0.88] [0.73,1.17] [0.69,0.96] 
Percent FPL -0.000214 0.00000976 -0.00206* 0.00807 0.00134* 1.003 0.979** 0.991 
 [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [-0.01,0.03] [-0.00,0.00] [1.00,1.01] [0.96,1.00] [0.98,1.00] 
Psychiatrists/100,000 -0.0000346 0.000718 -0.0000872 -0.00908** -0.000420 1.000 1.000 1.008*** 
 [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [-0.02,-0.00] [-0.00,0.00] [1.00,1.00] [0.99,1.01] [1.00,1.01] 
Year         
   2011 0.000952 -0.0151 0.0310* -0.153 -0.0160 1.025 0.771 0.843* 
 [-0.01,0.01] [-0.05,0.02] [-0.01,0.07] [-0.48,0.18] [-0.05,0.01] [0.93,1.13] [0.50,1.19] [0.71,1.01] 
   2012 0.00428 0.0135 0.0339 0.0452 -0.0267* 0.972 1.296* 0.938 
 [-0.01,0.01] [-0.02,0.05] [-0.01,0.08] [-0.36,0.45] [-0.06,0.00] [0.87,1.08] [0.97,1.73] [0.77,1.14] 
   2013 0.00682 0.00481 0.0248 -0.138 -0.0242 0.974 1.138 1.215* 
 [-0.00,0.02] [-0.03,0.04] [-0.02,0.07] [-0.53,0.25] [-0.06,0.01] [0.86,1.11] [0.88,1.46] [0.99,1.49] 
   2016 0.00180 -0.0207 -0.0402 0.0347 0.0691*** 0.892* 0.991 0.893 
 [-0.01,0.02] [-0.07,0.03] [-0.09,0.01] [-0.42,0.48] [0.03,0.11] [0.79,1.01] [0.76,1.29] [0.71,1.12] 
   2017 -0.000166 -0.0215 -0.0177 -0.226 -0.00922 0.952 0.776* 1.092 
 [-0.02,0.02] [-0.06,0.02] [-0.06,0.03] [-0.64,0.19] [-0.06,0.04] [0.85,1.06] [0.60,1.01] [0.87,1.36] 
   2018 0 0 0 0 0 1 1 1 
 [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] [1.00,1.00] [1.00,1.00] [1.00,1.00] 
Constant 0.0220 0.159** 0.188*** 9.909*** 0.671*** - - - 
 [-0.01,0.05] [0.03,0.28] [0.07,0.30] [9.07,10.75] [0.61,0.74] - - - 
Observations 303269 303269 303269 303269 303141 290070 162111 285221 
95% confidence intervals in brackets 






Appendix A. Table 8. TWFE, DID Medicaid Expansion, 100% FPL, Full Sample 
 Any Utilization (LPM) Self-Reported Outcome 
(LPM) 
Number of Visits, Conditional on Any     
(Poisson, IRR) 




Any MH Rx Kessler 6 
Scale 
Accomplished 
ANY less due 
to MH 
    Rx count ED count MH 
Outpatient 
count 
Expansion -0.00648 0.0132 0.00617 -0.0415 0.00857 0.936 1.447*** 1.386* 
 [-0.01,0.00] [-0.01,0.03] [-0.02,0.03] [-0.41,0.33] [-0.02,0.04] [0.81,1.07] [1.17,1.79] [1.06,1.81] 
Age         
   25-35 -0.000755 0.0280*** 0.0479*** 0.868*** 0.0634*** 1.285*** 0.991 1.257 
 [-0.01,0.00] [0.01,0.04] [0.03,0.06] [0.62,1.12] [0.04,0.09] [1.12,1.47] [0.80,1.22] [1.00,1.58] 
   36-50 0.00637* 0.0576*** 0.0995*** 1.388*** 0.125*** 1.751*** 1.038 1.502*** 
 [0.00,0.01] [0.04,0.08] [0.08,0.12] [1.12,1.66] [0.10,0.15] [1.52,2.02] [0.86,1.25] [1.18,1.91] 
   51-64 -0.00158 0.0207 0.119*** 0.740*** 0.142*** 1.520*** 0.883 1.410* 
 [-0.01,0.01] [-0.00,0.04] [0.10,0.14] [0.41,1.07] [0.12,0.17] [1.33,1.74] [0.66,1.19] [1.04,1.91] 
Female 0.00343 0.0327*** 0.0625*** 0.465*** 0.0480*** 1.000 0.877 0.754*** 
 [-0.00,0.01] [0.02,0.04] [0.05,0.08] [0.29,0.64] [0.03,0.06] [0.93,1.07] [0.75,1.03] [0.66,0.86] 
Education (ref=less than HS)         
   High School -0.000505 0.00725 0.00970 -0.249* -0.0375*** 0.987 0.849 1.153 
 [-0.00,0.00] [-0.01,0.02] [-0.01,0.03] [-0.48,-0.02] [-0.06,-0.02] [0.90,1.08] [0.67,1.07] [0.96,1.39] 
   More than HS 0.00224 0.0167* 0.0236* -0.437** -0.0435*** 1.016 0.897 1.367*** 
 [-0.00,0.01] [0.00,0.03] [0.00,0.04] [-0.70,-0.18] [-0.06,-0.02] [0.92,1.12] [0.74,1.09] [1.16,1.61] 
   Other/unknown 0.00179 0.0144 0.0173 -0.418 -0.0609** 0.943 1.278 1.390 
 [-0.01,0.01] [-0.01,0.04] [-0.01,0.05] [-0.89,0.05] [-0.10,-0.02] [0.82,1.08] [0.85,1.92] [0.88,2.19] 
Chronic Conditions         
   1-2 0.00571** 0.0823*** 0.135*** 1.814*** 0.153*** 1.266*** 1.078 1.056 
 [0.00,0.01] [0.07,0.10] [0.12,0.15] [1.61,2.02] [0.13,0.17] [1.13,1.42] [0.96,1.21] [0.82,1.36] 
   3+ 0.00973** 0.179*** 0.350*** 4.454*** 0.336*** 1.480*** 1.109 1.077 
 [0.00,0.02] [0.16,0.20] [0.33,0.37] [4.10,4.81] [0.31,0.36] [1.34,1.64] [0.95,1.29] [0.83,1.39] 
Race/Ethnicity         
   Hispanic -0.00369 -0.0798*** -0.115*** -1.156*** -0.0500*** 0.798*** 1.076 0.796* 
 [-0.01,0.00] [-0.10,-
0.06] 
[-0.13,-0.10] [-1.42,-0.89] [-0.07,-0.03] [0.71,0.90] [0.78,1.49] [0.67,0.95] 
   Black/African American -0.00469* -0.0908*** -0.135*** -1.039*** -0.0640*** 0.707*** 0.834* 0.998 
 [-0.01,-0.00] [-0.11,-
0.07] 
[-0.15,-0.12] [-1.27,-0.81] [-0.08,-0.05] [0.65,0.77] [0.72,0.96] [0.82,1.21] 
   Alaskan/Native American -0.00777 -0.0668** -0.0647* -0.235 -0.0540 1.042 0.838 0.640*** 
 [-0.02,0.00] [-0.11,-
0.02] 





   Asian -0.00753* -0.0952*** -0.129*** -0.666** -0.0529** 0.535*** 1.276 1.417 
 [-0.01,-0.00] [-0.12,-
0.07] 
[-0.16,-0.10] [-1.11,-0.22] [-0.09,-0.01] [0.41,0.70] [0.81,2.00] [0.71,2.81] 
   Multiple/Other 0.0140 0.0198 -0.00691 0.687* 0.0763*** 0.916 0.826 1.406* 
 [-0.00,0.03] [-0.02,0.06] [-0.05,0.03] [0.12,1.25] [0.03,0.12] [0.79,1.06] [0.63,1.08] [1.06,1.86] 
Married -0.0104*** -0.0649*** -0.0618*** -1.457*** -0.0960*** 0.766*** 0.896 0.780** 
 [-0.01,-0.01] [-0.08,-
0.05] 
[-0.08,-0.05] [-1.68,-1.24] [-0.12,-0.08] [0.71,0.83] [0.72,1.12] [0.66,0.92] 
Percent FPL -0.000109 -0.0000281 0.0000932 0.0218* 0.00233** 1.002 0.982* 1.000 
 [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [0.00,0.04] [0.00,0.00] [1.00,1.01] [0.97,1.00] [0.98,1.02] 
Psychiatrists/100k -0.0000901 0.000432 0.000343 -0.00260 0.0000610 0.999 0.997 1.007** 
 [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [-0.01,0.01] [-0.00,0.00] [1.00,1.00] [0.99,1.01] [1.00,1.01] 
Year         
   2010 0 0 0 0 0 1 1 1 
 [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] [1.00,1.00] [1.00,1.00] [1.00,1.00] 
   2011 0.00383 0.00672 0.00571 -0.143 0.00175 0.984 1.006 0.794 
 [-0.00,0.01] [-0.01,0.03] [-0.02,0.03] [-0.44,0.15] [-0.03,0.03] [0.88,1.10] [0.73,1.39] [0.61,1.04] 
   2012 0.00295 0.0101 0.0147 -0.126 0.000985 0.908 1.516* 0.849 
 [-0.00,0.01] [-0.01,0.03] [-0.01,0.04] [-0.46,0.21] [-0.03,0.03] [0.80,1.03] [1.04,2.21] [0.68,1.06] 
   2013 0.00253 -0.000721 -0.00292 -0.489** -0.0223 0.869 1.108 0.920 
 [-0.00,0.01] [-0.02,0.02] [-0.03,0.02] [-0.82,-0.16] [-0.05,0.01] [0.75,1.00] [0.87,1.41] [0.69,1.23] 
   2014 0.00642 0.00856 0.00898 -0.761*** -0.0540** 1.052 0.965 0.927 
 [-0.00,0.01] [-0.01,0.03] [-0.02,0.04] [-1.17,-0.35] [-0.09,-0.02] [0.91,1.22] [0.72,1.30] [0.65,1.32] 
   2015 0.00740* 0.0169 0.0308* -0.835*** -0.0665*** 0.979 0.880 0.701* 
 [0.00,0.01] [-0.01,0.04] [0.00,0.06] [-1.22,-0.45] [-0.10,-0.03] [0.83,1.15] [0.66,1.18] [0.50,0.98] 
   2016 0.0111** 0.0119 0.0110 -0.798*** -0.0475* 0.937 0.975 0.790 
 [0.00,0.02] [-0.01,0.04] [-0.02,0.04] [-1.22,-0.37] [-0.08,-0.01] [0.80,1.09] [0.75,1.27] [0.57,1.09] 
   2017 0.00482 0.00117 -0.00996 -1.205*** -0.159*** 1.036 0.890 1.276 
 [-0.00,0.01] [-0.02,0.03] [-0.04,0.02] [-1.62,-0.79] [-0.20,-0.12] [0.88,1.22] [0.62,1.28] [0.92,1.77] 
   2018 0.00613 0.00678 0.0331* -0.958*** -0.158*** 0.995 1.045 0.982 
 [-0.00,0.01] [-0.02,0.03] [0.00,0.06] [-1.40,-0.51] [-0.20,-0.12] [0.86,1.15] [0.73,1.49] [0.72,1.34] 
Constant 0.00845 0.0624 0.119** 4.391*** 0.309*** - - - 
 [-0.01,0.02] [-0.01,0.14] [0.05,0.19] [3.44,5.34] [0.23,0.39] - - - 
Observations 311324 311324 311324 307895 308915 284926 204670 279819 
95% confidence intervals in brackets 








Appendix A. Table 9.  TWFE, DID Medicaid Expansion, 138% FPL, Full Sample 
 Any Utilization (LPM) Self-Reported Outcome (LPM) Number of Visits, Conditional on Any     
(Poisson, IRR) 




Any MH Rx Kessler 6 
Scale 
Accomplished 
ANY less due to 
MH 
    Rx count ED count MH 
Outpatient 
count 
Expansion -0.00293 0.00950 0.00584 -0.0121 0.00941 0.981 1.330*** 1.337** 
 [-0.01,0.00] [-0.01,0.03] [-0.02,0.03] [-0.31,0.29] [-0.02,0.03] [0.87,1.10] [1.12,1.57] [1.02,1.75] 
Age         
   25-35 -0.000783 0.0207*** 0.0489*** 0.693*** 0.0586*** 1.297*** 1.004 1.293** 
 [-0.00,0.00] [0.01,0.03] [0.03,0.06] [0.50,0.89] [0.04,0.08] [1.15,1.46] [0.86,1.17] [1.06,1.58] 
   36-50 0.00401* 0.0428*** 0.0886*** 1.085*** 0.110*** 1.700*** 1.048 1.478*** 
 [-0.00,0.01] [0.03,0.06] [0.07,0.10] [0.87,1.30] [0.09,0.13] [1.50,1.92] [0.88,1.25] [1.21,1.81] 
   51-64 -0.00245 0.00932 0.106*** 0.481*** 0.127*** 1.492*** 0.977 1.399** 
 [-0.01,0.00] [-0.01,0.03] [0.09,0.13] [0.22,0.74] [0.11,0.15] [1.33,1.68] [0.75,1.27] [1.06,1.84] 
Female 0.00356** 0.0315*** 0.0650*** 0.505*** 0.0523*** 1.006 0.861** 0.765*** 
 [0.00,0.01] [0.02,0.04] [0.05,0.08] [0.37,0.64] [0.04,0.06] [0.94,1.07] [0.75,0.99] [0.67,0.87] 
Education (ref=less 
than HS) 
        
   High School -0.000510 0.00122 0.00514 -0.210** -0.0337*** 0.993 0.902 1.118 
 [-0.00,0.00] [-0.01,0.01] [-0.01,0.02] [-0.42,-0.00] [-0.05,-0.02] [0.91,1.08] [0.74,1.10] [0.94,1.33] 
   More than HS 0.000162 0.0175** 0.0172** -0.455*** -0.0445*** 1.001 0.908 1.249*** 
 [-0.00,0.00] [0.00,0.03] [0.00,0.03] [-0.68,-0.23] [-0.06,-0.03] [0.92,1.09] [0.77,1.08] [1.07,1.46] 
   Other/unknown 0.000454 0.0127 0.0277** -0.461** -0.0535*** 0.940 1.230 1.235 
 [-0.00,0.01] [-0.01,0.03] [0.00,0.05] [-0.83,-0.09] [-0.08,-0.02] [0.83,1.07] [0.87,1.74] [0.81,1.87] 
Chronic Conditions         
   1-2 0.00574*** 0.0753*** 0.123*** 1.764*** 0.149*** 1.257*** 1.061 1.086 
 [0.00,0.01] [0.06,0.09] [0.11,0.14] [1.61,1.92] [0.13,0.16] [1.14,1.39] [0.94,1.20] [0.87,1.36] 
   3+ 0.0103*** 0.177*** 0.346*** 4.467*** 0.338*** 1.487*** 1.089 1.134 
 [0.01,0.02] [0.16,0.19] [0.33,0.37] [4.17,4.76] [0.32,0.36] [1.36,1.63] [0.96,1.23] [0.89,1.44] 
Race/Ethnicity         
   Hispanic -0.00161 -0.0721*** -0.117*** -1.140*** -0.0556*** 0.842*** 1.013 0.796*** 
 [-0.01,0.00] [-0.08,-0.06] [-0.13,-0.10] [-1.37,-0.92] [-0.07,-0.04] [0.76,0.93] [0.79,1.30] [0.68,0.93] 
   Black/African 
American 
-0.00355* -0.0898*** -0.134*** -1.102*** -0.0715*** 0.718*** 0.856** 1.054 
 [-0.01,0.00] [-0.10,-0.08] [-0.15,-0.12] [-1.30,-0.90] [-0.09,-0.05] [0.67,0.77] [0.76,0.96] [0.88,1.26] 
   Alaskan/Native 
American 
-0.00580 -0.0448** -0.0505** -0.107 -0.0242 0.954 1.000 0.696** 





   Asian -0.00571*** -0.0920*** -0.136*** -0.671*** -0.0699*** 0.564*** 1.209 1.347 
 [-0.01,-0.00] [-0.11,-0.07] [-0.16,-0.11] [-1.02,-0.32] [-0.10,-0.04] [0.44,0.72] [0.84,1.75] [0.76,2.38] 
Multiple/Other 0.0125* 0.0134 -0.00978 0.734*** 0.0767*** 0.938 0.878 1.409*** 
 [-0.00,0.03] [-0.02,0.04] [-0.04,0.02] [0.20,1.27] [0.04,0.12] [0.82,1.07] [0.72,1.08] [1.10,1.81] 
Married -0.00883*** -0.0627*** -0.0615*** -1.313*** -0.0861*** 0.771*** 0.886 0.795*** 
 [-0.01,-0.01] [-0.07,-0.05] [-0.07,-0.05] [-1.50,-1.13] [-0.10,-0.07] [0.72,0.83] [0.74,1.07] [0.69,0.92] 
Percent FPL -0.000135 -0.000112 0.0000924 0.0193** 0.00171*** 1.003 0.986** 0.996 
 [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [0.00,0.04] [0.00,0.00] [1.00,1.01] [0.97,1.00] [0.98,1.01] 
Psychiatrists/100k -0.0000971* 0.000340 0.000235 -0.00222 0.000235 0.999 0.997 1.008*** 
 [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [-0.01,0.01] [-0.00,0.00] [1.00,1.00] [0.99,1.01] [1.00,1.01] 
Year         
   2011 0.00363 0.00992 0.0163* -0.0762 0.0108 1.009 0.988 0.863 
 [-0.00,0.01] [-0.01,0.02] [-0.00,0.03] [-0.34,0.19] [-0.01,0.04] [0.91,1.11] [0.76,1.29] [0.67,1.11] 
   2012 0.00222 0.0135 0.0238** 0.0323 0.00950 0.956 1.366* 0.921 
 [-0.00,0.01] [-0.00,0.03] [0.00,0.04] [-0.26,0.32] [-0.02,0.04] [0.86,1.06] [0.99,1.89] [0.74,1.15] 
   2013 0.00261 0.00607 0.00847 -0.311** -0.0231* 0.951 1.030 0.994 
 [-0.00,0.01] [-0.01,0.02] [-0.01,0.03] [-0.60,-0.02] [-0.05,0.00] [0.85,1.07] [0.84,1.26] [0.78,1.26] 
   2014 0.00415 0.0169* 0.0204* -0.584*** -0.0412*** 1.043 0.885 0.910 
 [-0.00,0.01] [-0.00,0.04] [-0.00,0.04] [-0.93,-0.24] [-0.07,-0.01] [0.92,1.19] [0.70,1.13] [0.68,1.23] 
   2015 0.00646** 0.0206** 0.0302*** -0.689*** -0.0465*** 0.935 0.852 0.735** 
 [0.00,0.01] [0.00,0.04] [0.01,0.05] [-1.01,-0.37] [-0.07,-0.02] [0.82,1.07] [0.68,1.07] [0.55,0.99] 
   2016 0.00728** 0.0174* 0.0188 -0.792*** -0.0497*** 0.940 0.937 0.829 
 [0.00,0.01] [-0.00,0.04] [-0.00,0.04] [-1.15,-0.43] [-0.08,-0.02] [0.82,1.07] [0.73,1.20] [0.63,1.09] 
   2017 0.00414 0.0125 0.00502 -1.073*** -0.153*** 1.015 0.877 1.189 
 [-0.00,0.01] [-0.01,0.03] [-0.02,0.03] [-1.42,-0.73] [-0.18,-0.12] [0.88,1.17] [0.66,1.17] [0.88,1.61] 
   2018 0.00258 0.0221** 0.0349*** -0.915*** -0.160*** 0.984 1.134 0.949 
 [-0.00,0.01] [0.00,0.04] [0.01,0.06] [-1.28,-0.55] [-0.19,-0.13] [0.87,1.12] [0.84,1.53] [0.72,1.25] 
Constant [-0.04,-0.00] [-0.26,0.05] [-0.00,0.19] [-2.02,-0.18] [0.01,0.19] [0.80,2.05] - [0.48,1.80] 
 0.0150 0.0716* 0.103*** 4.198*** 0.315*** - - - 
Observations [-0.01,0.04] [-0.00,0.15] [0.04,0.16] [3.38,5.02] [0.24,0.39] - - - 
 311305 311305 311305 306295 307754 273221 210184 268124 
95% confidence intervals in brackets 










Appendix A. Table 10. TWFE, DID Medicaid Expansion, 200% FPL, Full Sample 
 Any Utilization (LPM) Self-Reported Outcome 
(LPM) 
Number of Visits, Conditional on Any     (Poisson, 
IRR) 




Any MH Rx Kessler 6 
Scale 
Accomplished 
ANY less due 
to MH 
    Rx count ED count MH Outpatient 
count 
Expansion -0.00127 0.0161** -0.00197 -0.0282 -0.000409 1.025 1.260*** 1.318** 
 [-0.00,0.00] [0.00,0.03] [-0.02,0.02] [-0.27,0.21] [-0.02,0.02] [0.93,1.13] [1.08,1.47] [1.04,1.66] 
Age         
   25-35 -0.000511 0.0202*** 0.0513*** 0.532*** 0.0468*** 1.327*** 0.992 1.234** 
 [-0.00,0.00] [0.01,0.03] [0.04,0.06] [0.36,0.70] [0.03,0.06] [1.19,1.48] [0.87,1.12] [1.04,1.46] 
   36-50 0.00158 0.0301*** 0.0829*** 0.725*** 0.0807*** 1.643*** 1.050 1.442*** 
 [-0.00,0.00] [0.02,0.04] [0.07,0.10] [0.54,0.91] [0.06,0.10] [1.47,1.83] [0.90,1.22] [1.21,1.72] 
   51-64 -0.00318 0.00467 0.0946*** 0.257** 0.0991*** 1.476*** 0.999 1.374** 
 [-0.01,0.00] [-0.01,0.02] [0.08,0.11] [0.04,0.47] [0.08,0.12] [1.32,1.64] [0.82,1.22] [1.07,1.76] 
Female 0.00346*** 0.0342*** 0.0723*** 0.568*** 0.0601*** 1.007 0.874** 0.838*** 
 [0.00,0.01] [0.03,0.04] [0.06,0.08] [0.45,0.68] [0.05,0.07] [0.95,1.06] [0.78,0.98] [0.74,0.94] 
Education 
(ref=less than HS) 
        
   High School -0.000171 -0.00422 0.000907 -0.213** -0.0384*** 1.003 0.876 1.135 
 [-0.00,0.00] [-0.01,0.01] [-0.01,0.01] [-0.38,-0.05] [-0.05,-0.02] [0.93,1.08] [0.75,1.03] [0.96,1.34] 
   More than HS -0.00137 0.0136** 0.0124* -0.516*** -0.0497*** 0.993 0.873* 1.239*** 
 [-0.00,0.00] [0.00,0.02] [-0.00,0.03] [-0.69,-0.34] [-0.06,-0.04] [0.92,1.07] [0.76,1.01] [1.06,1.45] 
   Other/unknown -0.000467 0.0145 0.0261** -0.437*** -0.0435*** 0.974 1.240 1.264 
 [-0.00,0.00] [-0.00,0.03] [0.01,0.05] [-0.70,-0.18] [-0.07,-0.02] [0.88,1.08] [0.93,1.65] [0.89,1.79] 
Chronic 
Conditions 
        
   1-2 0.00519*** 0.0649*** 0.113*** 1.616*** 0.138*** 1.254*** 1.012 1.062 
 [0.00,0.01] [0.06,0.07] [0.10,0.12] [1.50,1.73] [0.13,0.15] [1.16,1.36] [0.90,1.13] [0.88,1.29] 
   3+ 0.0102*** 0.164*** 0.336*** 4.355*** 0.333*** 1.520*** 1.083 1.157 
 [0.01,0.01] [0.15,0.18] [0.32,0.35] [4.13,4.58] [0.32,0.35] [1.40,1.65] [0.96,1.22] [0.93,1.44] 
Race/Ethnicity         
   Hispanic -0.00154 -0.0653*** -0.112*** -1.061*** -0.0538*** 0.845*** 1.060 0.823*** 
 [-0.00,0.00] [-0.08,-0.05] [-0.12,-0.10] [-1.24,-0.89] [-0.07,-0.04] [0.77,0.93] [0.88,1.28] [0.71,0.95] 
   Black/African 
American 





 [-0.01,0.00] [-0.09,-0.07] [-0.14,-0.12] [-1.19,-0.84] [-0.08,-0.05] [0.69,0.79] [0.81,0.99] [0.90,1.23] 
   Alaskan/Native 
American 
-0.00507* -0.0294** -0.0439** 0.0416 -0.0143 0.984 0.806 0.730** 
 [-0.01,0.00] [-0.06,-0.00] [-0.08,-0.01] [-0.74,0.82] [-0.07,0.04] [0.83,1.17] [0.52,1.25] [0.54,0.98] 
   Asian -0.00531*** -0.0840*** -0.135*** -0.583*** -0.0507*** 0.612*** 1.331 1.316 
 [-0.01,-0.00] [-0.10,-0.07] [-0.15,-0.12] [-0.87,-0.30] [-0.08,-0.03] [0.50,0.75] [0.89,1.98] [0.73,2.38] 
Multiple/Other 0.00933* 0.0126 -0.0145 0.529** 0.0475*** 0.998 0.841* 1.349*** 
 [-0.00,0.02] [-0.01,0.04] [-0.04,0.01] [0.12,0.94] [0.01,0.08] [0.89,1.12] [0.71,1.00] [1.09,1.67] 
Married -0.00720*** -0.0603*** -0.0607*** -1.159*** -0.0866*** 0.746*** 0.897* 0.771*** 
 [-0.01,-0.01] [-0.07,-0.05] [-0.07,-0.05] [-1.31,-1.00] [-0.10,-0.07] [0.70,0.79] [0.79,1.02] [0.68,0.87] 
Percent FPL -0.000133 -0.000144 -0.000248 0.0201*** 0.00167*** 1.005** 0.989** 0.999 
 [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [0.01,0.03] [0.00,0.00] [1.00,1.01] [0.98,1.00] [0.98,1.01] 
Psychiatrists/100k -0.0000309 0.000252 0.0000685 0.00103 0.000493 0.999 0.997 1.009*** 
 [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [-0.01,0.01] [-0.00,0.00] [1.00,1.00] [0.99,1.00] [1.01,1.01] 
Year         
   2011 0.00105 -0.00275 0.0125* -0.0191 -0.000475 1.020 0.935 0.879 
 [-0.00,0.00] [-0.01,0.01] [-0.00,0.03] [-0.23,0.19] [-0.02,0.02] [0.94,1.11] [0.74,1.18] [0.71,1.08] 
   2012 0.00125 0.00117 0.0102 -0.0239 -0.00428 0.990 1.205 0.912 
 [-0.00,0.00] [-0.01,0.02] [-0.01,0.03] [-0.27,0.22] [-0.03,0.02] [0.90,1.09] [0.94,1.54] [0.74,1.12] 
   2013 0.00162 -0.00378 0.00162 -0.311** -0.0351*** 0.990 0.989 0.992 
 [-0.00,0.01] [-0.02,0.01] [-0.02,0.02] [-0.56,-0.06] [-0.06,-0.01] [0.89,1.10] [0.85,1.16] [0.80,1.24] 
   2014 0.00333 0.00271 0.0121 -0.543*** -0.0461*** 1.032 0.910 0.903 
 [-0.00,0.01] [-0.01,0.02] [-0.01,0.03] [-0.83,-0.26] [-0.07,-0.02] [0.92,1.16] [0.76,1.09] [0.67,1.21] 
   2015 0.00424* 0.0123* 0.0268** -0.638*** -0.0493*** 0.954 0.864 0.802* 
 [-0.00,0.01] [-0.00,0.03] [0.01,0.05] [-0.93,-0.34] [-0.08,-0.02] [0.84,1.08] [0.70,1.06] [0.63,1.02] 
   2016 0.00418* 0.00414 0.00879 -0.746*** -0.0584*** 0.954 0.952 0.868 
 [-0.00,0.01] [-0.01,0.02] [-0.01,0.03] [-1.03,-0.46] [-0.08,-0.03] [0.85,1.07] [0.80,1.13] [0.67,1.12] 
   2017 0.00453** 0.00335 0.00466 -1.001*** -0.150*** 1.013 0.879 1.138 
 [0.00,0.01] [-0.01,0.02] [-0.02,0.02] [-1.27,-0.73] [-0.17,-0.13] [0.89,1.15] [0.73,1.07] [0.87,1.49] 
   2018 0.000750 0.00921 0.0275** -0.880*** -0.149*** 1.015 1.141 0.938 
 [-0.00,0.00] [-0.01,0.03] [0.01,0.05] [-1.17,-0.59] [-0.18,-0.12] [0.90,1.14] [0.90,1.45] [0.73,1.20] 
Constant 0.0117* 0.0810*** 0.103*** 3.737*** 0.295***    
 [-0.00,0.03] [0.02,0.14] [0.04,0.16] [2.99,4.49] [0.25,0.34]    
Observations 311252 311252 311252 303681 305694 254533 202948 248336 
95% confidence intervals in brackets 







Appendix A. Table 11. TWFE, DID Medicaid Expansion, 100% FPL, MH Sub-sample 
 Any Utilization (LPM) Self-Reported Outcome 
(LPM) 
Number of Visits, Conditional on Any     
(Poisson, IRR) 




Any MH Rx Kessler 6 
Scale 
Accomplished 
ANY less due 
to MH 
    Rx count ED count MH 
Outpatient 
count 
Expansion -0.0114 0.0121 -0.00818 0.0822 0.0107 0.899 1.631*** 1.338** 
 [-0.03,0.01] [-0.03,0.06] [-0.05,0.04] [-0.39,0.56] [-0.03,0.05] [0.78,1.04] [1.25,2.12] [1.05,1.70] 
Age         
   25-35 -0.00895 0.0348* 0.0786*** 0.976*** 0.0588*** 1.304*** 0.987 1.135 
 [-0.03,0.01] [-0.00,0.07] [0.04,0.12] [0.62,1.33] [0.02,0.10] [1.08,1.57] [0.77,1.26] [0.87,1.48] 
   36-50 0.00643 0.0790*** 0.147*** 1.364*** 0.126*** 1.762*** 1.003 1.248 
 [-0.01,0.02] [0.04,0.12] [0.11,0.19] [1.01,1.71] [0.09,0.16] [1.48,2.09] [0.78,1.29] [0.93,1.67] 
   51-64 -0.00550 0.0250 0.204*** 1.071*** 0.159*** 1.580*** 0.912 1.134 
 [-0.02,0.01] [-0.02,0.07] [0.16,0.25] [0.65,1.49] [0.12,0.20] [1.33,1.88] [0.66,1.26] [0.81,1.60] 
Female 0.00572 0.0441*** 0.0757*** 0.223* 0.0457*** 0.993 0.833** 0.809*** 
 [-0.00,0.01] [0.02,0.07] [0.05,0.10] [-0.03,0.48] [0.03,0.07] [0.92,1.07] [0.71,0.98] [0.70,0.93] 
Education 
(ref=less than HS) 
        
   High School -0.000346 0.0384*** 0.0352** -0.128 -0.0171 1.024 0.806 1.344*** 
 [-0.01,0.01] [0.01,0.07] [0.01,0.06] [-0.38,0.13] [-0.04,0.01] [0.93,1.13] [0.59,1.10] [1.15,1.58] 
   More than HS 0.00819 0.0423** 0.0601*** -0.643*** -0.0127 1.068 0.800** 1.528*** 
 [-0.00,0.02] [0.01,0.08] [0.03,0.09] [-0.94,-0.34] [-0.04,0.01] [0.95,1.20] [0.65,0.99] [1.28,1.82] 
   Other/unknown 0.0115 0.0444 0.0387 -0.488 -0.0446 0.996 1.307 1.505** 
 [-0.01,0.03] [-0.01,0.10] [-0.02,0.10] [-1.15,0.17] [-0.10,0.01] [0.86,1.15] [0.91,1.87] [1.07,2.11] 
Chronic 
Conditions 
        
   1-2 0.00567 0.118*** 0.175*** 0.952*** 0.0630*** 1.206** 1.118 1.012 
 [-0.00,0.02] [0.09,0.15] [0.14,0.21] [0.66,1.24] [0.03,0.09] [1.03,1.41] [0.93,1.35] [0.76,1.34] 
   3+ 0.00233 0.187*** 0.323*** 2.226*** 0.128*** 1.371*** 1.120 1.059 
 [-0.01,0.01] [0.15,0.22] [0.29,0.36] [1.85,2.60] [0.10,0.16] [1.19,1.58] [0.94,1.34] [0.79,1.43] 
Race/Ethnicity         
   Hispanic -0.00336 -0.0912*** -0.113*** -0.421** -0.0310** 0.839*** 1.055 0.784** 
 [-0.01,0.01] [-0.12,-0.06] [-0.15,-0.08] [-0.78,-0.06] [-0.06,-0.00] [0.74,0.95] [0.74,1.51] [0.64,0.95] 
   Black/African 
American 
-0.00831* -0.115*** -0.165*** -0.560*** -0.0540*** 0.714*** 0.833* 1.005 
 [-0.02,0.00] [-0.14,-0.09] [-0.20,-0.13] [-0.86,-0.26] [-0.08,-0.03] [0.65,0.78] [0.68,1.02] [0.83,1.22] 






 [-0.03,0.00] [-0.23,-0.06] [-0.22,-0.02] [-0.93,1.62] [-0.05,0.10] [0.92,1.54] [1.07,2.11] [0.53,1.03] 
   Asian -0.0230*** -0.168*** -0.203*** -0.696** -0.0373 0.489***  1.530 
 [-0.03,-0.02] [-0.22,-0.12] [-0.26,-0.14] [-1.30,-0.09] [-0.10,0.02] [0.36,0.67]  [0.92,2.56] 
   Multiple/Other 0.0244 -0.0200 -0.0504 -0.0275 0.0337 0.898 0.917 1.515*** 
 [-0.01,0.06] [-0.08,0.04] [-0.12,0.01] [-0.67,0.61] [-0.01,0.08] [0.75,1.07] [0.72,1.18] [1.16,1.97] 
Married -0.0163*** -0.0725*** -0.0370** -0.837*** -0.0256** 0.815*** 0.836 0.772*** 
 [-0.02,-0.01] [-0.10,-0.04] [-0.07,-0.01] [-1.13,-0.54] [-0.05,-0.00] [0.74,0.89] [0.66,1.06] [0.66,0.91] 
Percent FPL -0.000343 -0.000223 -0.00189 0.00746 0.00171* 0.999 0.980** 0.997 
 [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [-0.01,0.03] [-0.00,0.00] [0.99,1.01] [0.96,1.00] [0.98,1.01] 
Psychiatrists/100k -0.0000949 0.000647 -0.000441 -0.0105* 0.0000943 0.999 1.000 1.008*** 
 [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [-0.02,0.00] [-0.00,0.00] [1.00,1.00] [0.99,1.01] [1.00,1.01] 
Year         
   2011 0.00718 0.00978 0.0193 -0.163 0.00318 1.041 1.089 0.865 
 [-0.01,0.02] [-0.03,0.05] [-0.02,0.06] [-0.62,0.29] [-0.03,0.04] [0.92,1.18] [0.74,1.61] [0.67,1.11] 
   2012 0.00534 0.0167 0.0248 0.143 -0.0174 0.908 1.738** 0.893 
 [-0.01,0.02] [-0.02,0.06] [-0.02,0.07] [-0.34,0.62] [-0.05,0.02] [0.80,1.04] [1.10,2.75] [0.73,1.10] 
   2013 0.00680 0.00219 0.0101 -0.232 0.00186 0.887 1.242 1.095 
 [-0.01,0.02] [-0.04,0.05] [-0.04,0.06] [-0.69,0.23] [-0.03,0.04] [0.75,1.05] [0.90,1.71] [0.83,1.44] 
   2014 0.0127 0.0418* 0.0488* -0.339 -0.00653 1.092 1.035 1.039 
 [-0.00,0.03] [-0.01,0.09] [-0.01,0.10] [-0.94,0.27] [-0.05,0.04] [0.93,1.28] [0.72,1.49] [0.76,1.41] 
   2015 0.0211** 0.0585** 0.0818*** -0.380 -0.0647*** 1.096 0.852 0.785 
 [0.00,0.04] [0.01,0.11] [0.03,0.13] [-0.92,0.16] [-0.11,-0.02] [0.92,1.31] [0.58,1.25] [0.57,1.08] 
   2016 0.0232** 0.0397 0.0342 -0.247 -0.0107 0.997 1.055 0.827 
 [0.00,0.04] [-0.01,0.09] [-0.02,0.09] [-0.86,0.36] [-0.05,0.03] [0.83,1.20] [0.74,1.50] [0.60,1.15] 
   2017 0.0113 0.0362 0.0357 -0.487 -0.122*** 1.074 0.838 1.221 
 [-0.01,0.03] [-0.02,0.09] [-0.02,0.09] [-1.08,0.11] [-0.17,-0.07] [0.89,1.29] [0.55,1.27] [0.87,1.72] 
   2018 0.0195* 0.0317 0.0821*** -0.456 -0.110*** 1.079 1.148 1.012 
 [-0.00,0.04] [-0.02,0.09] [0.03,0.14] [-1.04,0.13] [-0.16,-0.06] [0.91,1.28] [0.74,1.79] [0.74,1.38] 
Constant 0.0238 0.118** 0.171*** 9.665*** 0.651*** - - - 
 [-0.01,0.06] [0.01,0.23] [0.07,0.27] [8.79,10.54] [0.59,0.72] - - - 
Observations 310928 310928 310928 310928 310799 301770 179558 295465 
95% confidence intervals in brackets 









Appendix A. Table 11. TWFE, DID Medicaid Expansion, 138% FPL, MH Sub-sample 
 Any Utilization (LPM) Self-Reported Outcome (LPM) Number of Visits, Conditional on Any     
(Poisson, IRR) 




Any MH Rx Kessler 6 
Scale 
Accomplished 
ANY less due 
to MH 
    Rx count ED count MH 
Outpatient 
count 
Expansion -0.00773 0.0119 -0.00201 0.133 0.0129 0.968 1.512*** 1.438*** 
 [-0.02,0.01] [-0.03,0.05] [-0.04,0.04] [-0.27,0.54] [-0.02,0.04] [0.85,1.10] [1.24,1.85] [1.14,1.81] 
Age         
   25-35 -0.00568 0.0242 0.0834*** 0.714*** 0.0625*** 1.358*** 1.011 1.242 
 [-0.02,0.01] [-0.01,0.06] [0.05,0.12] [0.39,1.03] [0.03,0.10] [1.15,1.60] [0.82,1.25] [0.95,1.62] 
   36-50 0.00687 0.0660*** 0.139*** 1.161*** 0.123*** 1.790*** 0.997 1.299* 
 [-0.01,0.02] [0.03,0.10] [0.10,0.17] [0.87,1.46] [0.09,0.16] [1.53,2.09] [0.79,1.26] [0.96,1.75] 
   51-64 -0.00451 0.0179 0.199*** 0.761*** 0.149*** 1.581*** 0.935 1.166 
 [-0.02,0.01] [-0.02,0.05] [0.16,0.24] [0.41,1.12] [0.11,0.18] [1.35,1.85] [0.69,1.27] [0.82,1.65] 
Female 0.00513 0.0426*** 0.0785*** 0.154 0.0397*** 1.012 0.869** 0.839*** 
 [-0.00,0.01] [0.02,0.06] [0.06,0.10] [-0.07,0.38] [0.02,0.06] [0.94,1.09] [0.76,1.00] [0.74,0.96] 




        
   High School 0.000422 0.0267** 0.0255* -0.190* -0.0104 1.022 0.879 1.235** 
 [-0.01,0.01] [0.00,0.05] [-0.00,0.05] [-0.41,0.04] [-0.03,0.01] [0.93,1.12] [0.69,1.12] [1.05,1.46] 
   More than HS 0.00599 0.0495*** 0.0530*** -0.599*** -0.00709 1.048 0.842* 1.332*** 
 [-0.00,0.01] [0.02,0.08] [0.02,0.08] [-0.88,-0.32] [-0.03,0.02] [0.95,1.15] [0.70,1.01] [1.13,1.58] 
   Other/unknown 0.00611 0.0335 0.0488* -0.671** -0.0222 0.996 1.321* 1.267 
 [-0.01,0.02] [-0.02,0.08] [-0.00,0.10] [-1.23,-0.12] [-0.06,0.02] [0.86,1.16] [0.95,1.83] [0.93,1.73] 
Chronic 
Conditions 
        
   1-2 0.00753* 0.107*** 0.163*** 1.012*** 0.0667*** 1.189** 1.122 1.057 
 [-0.00,0.02] [0.08,0.13] [0.14,0.19] [0.78,1.24] [0.04,0.09] [1.03,1.37] [0.94,1.34] [0.81,1.37] 
   3+ 0.00541 0.182*** 0.325*** 2.390*** 0.137*** 1.359*** 1.145* 1.144 
 [-0.00,0.01] [0.15,0.21] [0.30,0.35] [2.09,2.69] [0.11,0.16] [1.19,1.55] [0.99,1.32] [0.86,1.52] 
Race/Ethnicity         
   Hispanic 0.00142 -0.0921*** -0.138*** -0.377** -0.0302** 0.888** 0.993 0.798** 
 [-0.01,0.01] [-0.12,-0.07] [-0.17,-0.11] [-0.69,-0.06] [-0.05,-0.01] [0.79,1.00] [0.74,1.33] [0.67,0.96] 






 [-0.01,0.00] [-0.14,-0.09] [-0.20,-0.14] [-0.77,-0.27] [-0.07,-0.03] [0.66,0.78] [0.70,0.96] [0.85,1.23] 
   Alaskan/Native 
American 
-0.0117 -0.0869* -0.0819 0.395 0.0342 1.033 1.489 0.769 
 [-0.03,0.00] [-0.19,0.02] [-0.19,0.02] [-0.80,1.59] [-0.03,0.09] [0.82,1.30] [0.80,2.77] [0.49,1.21] 
   Asian -0.0159*** -0.168*** -0.208*** -0.547** -0.0574** 0.526*** 0.717 1.483 
 [-0.02,-0.01] [-0.21,-0.12] [-0.26,-0.16] [-1.05,-0.05] [-0.11,-0.01] [0.40,0.69] [0.36,1.44] [0.89,2.46] 
   Multiple/Other 0.0197 -0.0123 -0.0305 0.179 0.0410** 0.922 0.914 1.466*** 
 [-0.01,0.05] [-0.07,0.04] [-0.09,0.03] [-0.45,0.81] [0.00,0.08] [0.79,1.07] [0.74,1.13] [1.14,1.88] 
Married -0.0125*** -0.0690*** -0.0416*** -0.728*** -0.0179* 0.824*** 0.855* 0.803*** 
 [-0.02,-0.01] [-0.09,-0.04] [-0.07,-0.02] [-0.99,-0.47] [-0.04,0.00] [0.76,0.89] [0.71,1.03] [0.69,0.93] 
Percent FPL -0.000451 -0.000245 -0.00129 0.00663 0.00123 0.999 0.984** 0.998 
 [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [-0.01,0.03] [-0.00,0.00] [0.99,1.01] [0.97,1.00] [0.98,1.02] 
Psychiatrist/100k -0.000105 0.000405 -0.000535 -0.0115** 0.0000365 0.999 0.999 1.009*** 
 [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [-0.02,-0.00] [-0.00,0.00] [1.00,1.00] [0.99,1.01] [1.01,1.01] 
Year         
   2011 0.00545 0.00304 0.0332* -0.199 0.00300 1.046 1.025 0.851 
 [-0.01,0.02] [-0.03,0.04] [-0.00,0.07] [-0.58,0.18] [-0.03,0.03] [0.93,1.17] [0.73,1.45] [0.69,1.05] 
   2012 0.00236 0.00919 0.0382** 0.0315 -0.0133 0.951 1.584** 0.951 
 [-0.01,0.01] [-0.03,0.04] [0.00,0.08] [-0.35,0.41] [-0.04,0.02] [0.85,1.07] [1.07,2.35] [0.78,1.16] 
   2013 0.00851 0.0125 0.0314 -0.0993 -0.00908 0.956 1.153 1.138 
 [-0.00,0.02] [-0.03,0.05] [-0.01,0.07] [-0.48,0.28] [-0.04,0.02] [0.83,1.10] [0.89,1.49] [0.90,1.43] 
   2014 0.00691 0.0395* 0.0512** -0.333 -0.00271 1.087 1.012 0.967 
 [-0.01,0.02] [-0.00,0.08] [0.01,0.10] [-0.84,0.17] [-0.04,0.03] [0.94,1.26] [0.74,1.39] [0.74,1.25] 
   2015 0.0167** 0.0518** 0.0874*** -0.412* -0.0507** 1.008 0.820 0.766** 
 [0.00,0.03] [0.01,0.09] [0.04,0.13] [-0.87,0.05] [-0.09,-0.01] [0.86,1.19] [0.60,1.12] [0.59,1.00] 
   2016 0.0158* 0.0328 0.0443* -0.377 -0.0284 0.972 1.043 0.827 
 [-0.00,0.03] [-0.01,0.08] [-0.00,0.09] [-0.91,0.15] [-0.07,0.01] [0.82,1.15] [0.76,1.43] [0.62,1.10] 
   2017 0.00929 0.0391* 0.0554** -0.496* -0.108*** 1.047 0.790 1.133 
 [-0.01,0.02] [-0.01,0.08] [0.00,0.11] [-1.04,0.05] [-0.15,-0.06] [0.89,1.24] [0.58,1.08] [0.83,1.55] 
   2018 0.0140* 0.0453* 0.0763*** -0.580** -0.136*** 1.049 1.174 0.942 
 [-0.00,0.03] [-0.01,0.10] [0.03,0.13] [-1.09,-0.07] [-0.18,-0.09] [0.90,1.23] [0.83,1.66] [0.72,1.24] 
Constant 0.0260 0.131** 0.144*** 9.814*** 0.651*** - - - 
 [-0.01,0.06] [0.01,0.25] [0.04,0.24] [9.05,10.58] [0.58,0.72] - - - 
Observations 310925 310925 310925 310925 310761 300202 197300 295297 
95% confidence intervals in brackets 






Appendix A. Table 12 TWFE, DID Medicaid Expansion, 200% FPL, MH Sub-sample 
 Any Utilization (LPM) Self-Reported Outcome (LPM) Number of Visits, Conditional on Any     
(Poisson, IRR) 




Any MH Rx Kessler 6 
Scale 
Accomplished 
ANY less due to 
MH 
    Rx count ED count MH 
Outpatient 
count 
Expansion -0.00562 0.0226 -0.00424 0.112 0.00428 1.001 1.393*** 1.411*** 
 [-0.02,0.00] [-0.01,0.05] [-0.04,0.03] [-0.23,0.46] [-0.02,0.03] [0.89,1.12] [1.16,1.67] [1.13,1.75] 
Age         
   25-35 -0.00497 0.0233* 0.0936*** 0.519*** 0.0485*** 1.371*** 0.972 1.158 
 [-0.02,0.01] [-0.00,0.05] [0.06,0.13] [0.25,0.79] [0.02,0.08] [1.19,1.57] [0.81,1.17] [0.95,1.42] 
   36-50 0.00145 0.0414*** 0.132*** 0.853*** 0.0903*** 1.703*** 1.018 1.271** 
 [-0.01,0.01] [0.01,0.07] [0.10,0.16] [0.59,1.12] [0.06,0.12] [1.49,1.95] [0.83,1.25] [1.01,1.60] 
   51-64 -0.00696 0.000978 0.173*** 0.472*** 0.118*** 1.536*** 0.934 1.174 
 [-0.02,0.00] [-0.03,0.03] [0.14,0.21] [0.14,0.80] [0.09,0.15] [1.33,1.77] [0.73,1.19] [0.88,1.57] 
Female 0.00657** 0.0461*** 0.0895*** 0.197** 0.0414*** 1.010 0.885** 0.904* 
 [0.00,0.01] [0.03,0.06] [0.07,0.11] [0.01,0.38] [0.03,0.06] [0.94,1.08] [0.79,0.99] [0.80,1.02] 
Education (ref=less 
than HS) 
        
   High School 0.00245 0.0109 0.0188 -0.205* -0.0200** 1.029 0.857 1.279*** 
 [-0.00,0.01] [-0.01,0.03] [-0.01,0.04] [-0.41,0.00] [-0.04,-0.00] [0.95,1.12] [0.70,1.05] [1.10,1.48] 
   More than HS 0.00336 0.0439*** 0.0430*** -0.619*** -0.0118 1.037 0.805*** 1.371*** 
 [-0.00,0.01] [0.02,0.07] [0.01,0.07] [-0.87,-0.37] [-0.03,0.01] [0.95,1.13] [0.69,0.94] [1.19,1.58] 
   Other/unknown 0.00461 0.0378* 0.0510** -0.634*** -0.00613 1.060 1.333* 1.378** 
 [-0.01,0.02] [-0.01,0.08] [0.01,0.09] [-1.05,-0.21] [-0.04,0.03] [0.94,1.20] [0.98,1.81] [1.07,1.78] 
Chronic Conditions         
   1-2 0.00831*** 0.0859*** 0.146*** 0.994*** 0.0689*** 1.211*** 1.026 1.081 
 [0.00,0.01] [0.06,0.11] [0.12,0.17] [0.80,1.19] [0.05,0.09] [1.08,1.36] [0.86,1.22] [0.87,1.35] 
   3+ 0.00849** 0.170*** 0.322*** 2.463*** 0.144*** 1.411*** 1.117 1.173 
 [0.00,0.02] [0.14,0.20] [0.29,0.35] [2.21,2.72] [0.12,0.17] [1.26,1.58] [0.95,1.31] [0.91,1.52] 
Race/Ethnicity         
   Hispanic 0.00404 -0.0940*** -0.142*** -0.398*** -0.0419*** 0.880** 1.014 0.841** 
 [-0.00,0.01] [-0.12,-0.07] [-0.17,-0.12] [-0.67,-0.13] [-0.06,-0.02] [0.79,0.98] [0.83,1.24] [0.71,0.99] 
   Black/African 
American 
-0.00173 -0.114*** -0.175*** -0.493*** -0.0614*** 0.740*** 0.872** 1.047 
 [-0.01,0.01] [-0.14,-0.09] [-0.20,-0.15] [-0.72,-0.27] [-0.08,-0.04] [0.68,0.80] [0.76,1.00] [0.88,1.24] 
   Alaskan/Native 
American 





 [-0.02,0.00] [-0.15,0.03] [-0.16,0.01] [-0.44,1.47] [-0.06,0.08] [0.87,1.32] [0.44,1.26] [0.54,1.11] 
   Asian -0.0137*** -0.169*** -0.216*** -0.537** -0.0545** 0.570*** 0.697 1.454 
 [-0.02,-0.01] [-0.21,-0.13] [-0.26,-0.17] [-0.97,-0.10] [-0.10,-0.01] [0.44,0.74] [0.36,1.36] [0.85,2.49] 
   Multiple/Other 0.0150 -0.00551 -0.0345 0.190 0.0313 0.997 0.843 1.403*** 
 [-0.01,0.04] [-0.06,0.04] [-0.08,0.02] [-0.35,0.73] [-0.01,0.07] [0.86,1.15] [0.67,1.06] [1.13,1.75] 
Married -0.0108*** -0.0802*** -0.0526*** -0.650*** -0.0316*** 0.803*** 0.897 0.821*** 
 [-0.02,-0.01] [-0.10,-0.06] [-0.07,-0.03] [-0.86,-0.44] [-0.05,-0.02] [0.75,0.86] [0.77,1.04] [0.72,0.93] 
Percent FPL -0.000468* -0.000284 -0.00155 0.0122 0.00144** 1.001 0.987* 0.998 
 [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [-0.01,0.03] [0.00,0.00] [1.00,1.01] [0.97,1.00] [0.98,1.01] 
Psychiatrists 100k -0.00000130 0.000400 -0.000561 -0.0102** -0.00000244 1.000 0.999 1.009*** 
 [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [-0.02,-0.00] [-0.00,0.00] [1.00,1.00] [0.99,1.01] [1.01,1.01] 
Year         
   2011 0.00180 -0.0133 0.0250 -0.0659 -0.0169 1.052 0.892 0.847* 
 [-0.01,0.01] [-0.04,0.01] [-0.01,0.06] [-0.37,0.24] [-0.04,0.01] [0.95,1.16] [0.66,1.21] [0.71,1.01] 
   2012 0.00238 -0.00403 0.0186 -0.00553 -0.0305** 0.989 1.270 0.927 
 [-0.01,0.01] [-0.03,0.03] [-0.02,0.05] [-0.36,0.34] [-0.06,-0.00] [0.89,1.10] [0.94,1.72] [0.77,1.11] 
   2013 0.00677 0.00265 0.0195 -0.0840 -0.0308** 0.999 1.041 1.115 
 [-0.00,0.02] [-0.03,0.04] [-0.02,0.06] [-0.43,0.26] [-0.06,-0.00] [0.88,1.13] [0.86,1.26] [0.91,1.36] 
   2014 0.00725 0.0211 0.0499** -0.203 -0.0253 1.083 0.991 0.953 
 [-0.00,0.02] [-0.02,0.06] [0.01,0.09] [-0.65,0.25] [-0.06,0.01] [0.95,1.24] [0.78,1.26] [0.74,1.23] 
   2015 0.0151** 0.0461*** 0.0788*** -0.271 -0.0555*** 1.024 0.790 0.778** 
 [0.00,0.03] [0.01,0.08] [0.04,0.12] [-0.72,0.18] [-0.09,-0.02] [0.88,1.19] [0.60,1.05] [0.62,0.98] 
   2016 0.0116* 0.0258 0.0344 -0.450** -0.0527*** 0.974 0.972 0.859 
 [-0.00,0.02] [-0.01,0.06] [-0.01,0.08] [-0.90,-0.00] [-0.09,-0.02] [0.84,1.14] [0.76,1.24] [0.65,1.13] 
   2017 0.00931 0.0260 0.0490** -0.509** -0.125*** 1.041 0.776* 1.105 
 [-0.00,0.02] [-0.01,0.06] [0.01,0.09] [-0.98,-0.04] [-0.16,-0.09] [0.90,1.20] [0.60,1.00] [0.84,1.45] 
   2018 0.0106* 0.0398* 0.0629*** -0.522** -0.125*** 1.092 1.121 0.911 
 [-0.00,0.02] [-0.00,0.08] [0.02,0.11] [-0.96,-0.08] [-0.17,-0.08] [0.95,1.26] [0.84,1.49] [0.71,1.16] 
Constant 0.0231* 0.163** 0.173*** 9.584*** 0.680*** - - - 
 [-0.00,0.05] [0.03,0.30] [0.06,0.29] [8.82,10.35] [0.62,0.74] - - - 
Observations 311341 311341 311341 311341 311112 298574 214101 294036 
95% confidence intervals in brackets 










Appendix A. Table 13. Medicaid Expansion by MH HPSA Shortage Area, Full Sample at 138% FPL 
     
 Any Utilization (LPM) Self-Reported Outcome 
(LPM) 
Any Utilization (LPM) Self-Reported Outcome (LPM) 




Any MH Rx Kessler 6 
Scale 
Accomplish
ed ANY less 





Any MH Rx Kessler 6 
Scale 
Accomplished 
ANY less due 
to MH 
 Shortage No or Partial Shortage 
Expansion           
   Medicaid 
expansion State 
-0.0350** 0.0304 0.0672 2.158*** 0.224*** 0.0264** 0.0353 -0.0689** -0.0619 -0.0669 
 [-0.06,-0.01] [-0.07,0.13] [-0.02,0.15] [0.68,3.64] [0.16,0.29] [0.00,0.05] [-0.02,0.09] [-0.13,-
0.01] 
[-1.36,1.24] [-0.18,0.04] 
   Post-ME 0.000357 0.0325 0.0330 -0.520 -0.129*** 0.000956 0.0119 0.0325** -1.196*** -0.165*** 
 [-0.01,0.01] [-0.01,0.07] [-0.02,0.08] [-1.32,0.28] [-0.19,-0.06] [-0.01,0.01] [-0.02,0.04] [0.00,0.06] [-1.69,-0.70] [-0.21,-0.12] 
   Medicaid 
expansion State 
* Post ME 
-0.00992 0.0182 -0.00524 -0.316 -0.0340 0.00219 0.0135 0.0205 0.304 0.0150 
 [-0.02,0.00] [-0.03,0.07] [-0.07,0.06] [-1.11,0.48] [-0.11,0.04] [-0.00,0.01] [-0.02,0.04] [-0.01,0.05] [-0.13,0.74] [-0.03,0.06] 
Age           
   25-35 0.00648 0.0229 0.0759*** 0.931*** 0.0791*** -0.00208 0.0164 0.0446*** 0.768*** 0.0425*** 
 [-0.00,0.02] [-0.01,0.05] [0.04,0.11] [0.49,1.38] [0.04,0.12] [-0.01,0.00] [-0.00,0.04] [0.02,0.07] [0.47,1.06] [0.01,0.07] 
   36-50 0.00751** 0.0314** 0.102*** 1.330*** 0.130*** 0.00692** 0.0460*** 0.0889*** 1.137*** 0.0870*** 
 [0.00,0.01] [0.00,0.06] [0.07,0.14] [0.82,1.84] [0.09,0.17] [0.00,0.01] [0.02,0.07] [0.06,0.11] [0.82,1.45] [0.06,0.12] 
   51-64 0.00591 -0.0209 0.0912*** 0.534 0.145*** -0.00259 0.00333 0.0988*** 0.421** 0.107*** 
 [-0.01,0.02] [-0.06,0.01] [0.05,0.13] [-0.13,1.20] [0.10,0.19] [-0.01,0.00] [-0.02,0.03] [0.07,0.13] [0.07,0.77] [0.07,0.14] 
Female 0.00648 0.0229 0.0759*** 0.931*** 0.0791*** -0.00208 0.0164 0.0446*** 0.768*** 0.0425*** 




          
   High School -0.00287 0.00458 0.00692 -0.151 -0.0457** -0.000719 0.00936 -0.00335 -0.306* -0.0348*** 
 [-0.01,0.01] [-0.02,0.03] [-0.03,0.04] [-0.62,0.32] [-0.08,-0.01] [-0.01,0.00] [-0.01,0.03] [-0.03,0.02] [-0.63,0.02] [-0.06,-0.01] 
   More than HS -0.000801 0.00566 0.0151 -0.542* -0.0485** -0.00334 0.0201** 0.0175 -0.586*** -0.0548*** 
 [-0.01,0.01] [-0.03,0.04] [-0.03,0.06] [-1.11,0.03] [-0.09,-0.00] [-0.01,0.00] [0.00,0.04] [-0.01,0.04] [-0.91,-0.26] [-0.08,-0.03] 
   
Other/unknown 
-0.00285 -0.0303 -0.00959 -0.765* -0.0503 -
0.000000336 
0.0331* 0.0187 -0.510* -0.0606** 







          
   1-2 0.000455 0.0566*** 0.104*** 1.545*** 0.133*** 0.00653*** 0.0790*** 0.129*** 1.789*** 0.161*** 
 [-0.01,0.01] [0.03,0.08] [0.07,0.13] [1.19,1.90] [0.10,0.17] [0.00,0.01] [0.06,0.10] [0.11,0.15] [1.54,2.04] [0.14,0.18] 
   3+ 0.00398 0.185*** 0.366*** 4.685*** 0.348*** 0.0119*** 0.177*** 0.336*** 4.336*** 0.346*** 
 [-0.01,0.02] [0.14,0.23] [0.32,0.41] [4.05,5.32] [0.31,0.39] [0.00,0.02] [0.15,0.20] [0.31,0.37] [3.91,4.76] [0.31,0.38] 
Race/Ethnicity           
   Hispanic -0.00268 -0.0707*** -0.128*** -0.996*** -0.0199 -0.00267 -0.0676*** -0.110*** -1.167*** -0.0448*** 




[-0.06,0.02] [-0.01,0.00] [-0.09,-0.05] [-0.13,-
0.09] 
[-1.54,-0.79] [-0.07,-0.02] 
   Black/African 
American 
-0.00913** -0.102*** -0.161*** -0.809*** -0.0470** -0.000687 -0.0866*** -0.124*** -1.236*** -0.0765*** 




[-0.09,-0.01] [-0.01,0.00] [-0.10,-0.07] [-0.14,-
0.10] 
[-1.52,-0.95] [-0.10,-0.05] 
   
Alaskan/Native 
American 
-0.00517 0.0405 -0.0398 -1.370 -0.127* 0.00105 -0.0216 -0.0255 0.389 0.00815 
 [-0.02,0.01] [-0.04,0.12] [-0.14,0.06] [-3.36,0.62] [-0.26,0.01] [-0.01,0.01] [-0.07,0.03] [-0.08,0.03] [-0.56,1.33] [-0.07,0.09] 
   Asian 0.00528 -0.0566** -0.0862* -1.091** -0.0850* -0.00400 -0.0778*** -0.128*** -0.899*** -0.0477* 
 [-0.03,0.04] [-0.11,-0.00] [-0.17,0.00] [-2.13,-
0.05] 
[-0.18,0.01] [-0.01,0.00] [-0.11,-0.05] [-0.17,-
0.09] 
[-1.53,-0.27] [-0.10,0.01] 
   
Multiple/Other 
-0.00297 -0.0345 -0.0342 2.135*** 0.161*** 0.0113 0.0435* 0.0330 0.762* 0.0724** 
 [-0.02,0.02] [-0.10,0.03] [-0.15,0.08] [0.90,3.36] [0.08,0.25] [-0.01,0.03] [-0.01,0.09] [-0.02,0.08] [-0.03,1.55] [0.01,0.14] 
Married -0.0139*** -0.0455*** -0.0555*** -1.138*** -0.0744*** -0.00622*** -0.0801*** -0.0890*** -1.479*** -0.105*** 




[-0.10,-0.05] [-0.01,-0.00] [-0.10,-0.06] [-0.11,-
0.07] 
[-1.78,-1.18] [-0.13,-0.08] 
Percent of FPL 0.000419 0.00129* -0.000675 0.00927 0.00167 -0.000368* -0.00106 -0.000528 0.0225 0.00221* 
 [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [-0.02,0.04] [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [-0.00,0.00] [-0.01,0.06] [-0.00,0.00] 
Year           
   2011 0.00507 0.0238* -0.000827 -0.205 0.00552 0.00362 0.00339 0.0207 0.0587 0.0128 
 [-0.00,0.01] [-0.00,0.05] [-0.03,0.03] [-0.64,0.23] [-0.04,0.05] [-0.00,0.01] [-0.02,0.03] [-0.01,0.05] [-0.29,0.41] [-0.02,0.05] 
   2012 0.00194 0.0292* 0.0138 0.166 0.0202 0.00459 0.0195 0.0379*** 0.0543 -0.00109 
 [-0.01,0.01] [-0.00,0.06] [-0.02,0.05] [-0.35,0.68] [-0.03,0.07] [-0.00,0.01] [-0.00,0.04] [0.01,0.07] [-0.36,0.47] [-0.04,0.04] 
   2013 -0.000688 0.0423* 0.0359 -0.0661 -0.00477 0.00599 -0.00665 -0.00664 -0.361 -0.0193 
 [-0.01,0.01] [-0.00,0.09] [-0.01,0.08] [-0.68,0.55] [-0.05,0.04] [-0.00,0.01] [-0.03,0.02] [-0.03,0.02] [-0.82,0.10] [-0.06,0.02] 
   2016 0.0119* 0.0125 0.0166 -0.169 0.0855** 0.00508 -0.0100 -0.0321** 0.175 0.119*** 
 [-0.00,0.03] [-0.03,0.05] [-0.03,0.07] [-0.99,0.65] [0.02,0.16] [-0.00,0.01] [-0.04,0.02] [-0.06,-
0.01] 
[-0.26,0.61] [0.08,0.16] 
   2017 0.00821 -0.00406 0.000665 -0.521 -0.0294 0.00225 -0.0126 -0.0355*** -0.122 0.00811 






   2018 0 0 0 0 0 0 0 0 0 0 
 [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] 
Constant 0.0182 0.0506 0.106** 3.415*** 0.236*** - - - - - 
 [-0.01,0.05] [-0.05,0.15] [0.02,0.19] [2.10,4.73] [0.15,0.32] - - - - - 
Observations 284004 284004 284004 278804 280286 306262 306262 306262 302144 302721 
95% confidence intervals in brackets 






















Appendix A. Table 14. Medicaid Expansion by MH HRSA Shortage Area, Full Sample at 138% FPL 
 Number of Visits, Conditional on Any     (Poisson, IRR) Number of Visits, Conditional on Any     (Poisson, IRR) 
     Rx count ED count MH Outpatient count     Rx count ED count MH Outpatient count 
 Shortage No/Partial Shortage 
Expansion   
   Medicaid expansion State 1.451** 1.033 0.367*** 1.931*** 0.562** 0.784 
 [1.07,1.98] [0.49,2.17] [0.21,0.65] [1.23,3.04] [0.34,0.93] [0.53,1.16] 
   Post-ME 0.925 0.578** 1.209 1.035 1.034 0.941 
 [0.74,1.15] [0.35,0.95] [0.77,1.91] [0.86,1.25] [0.62,1.71] [0.67,1.33] 
   Medicaid expansion State * Post 
ME 
1.180* 1.693** 2.120*** 0.889 1.683*** 1.152 
 [0.97,1.43] [1.12,2.56] [1.32,3.41] [0.73,1.08] [1.18,2.40] [0.77,1.72] 
Age       
   25-35 1.095 0.671** 0.883 1.233** 0.849 1.254 
 [0.87,1.37] [0.49,0.93] [0.62,1.26] [1.01,1.50] [0.64,1.13] [0.88,1.78] 
   36-50 1.317*** 0.950 1.156 1.657*** 0.922 1.462** 
 [1.08,1.61] [0.66,1.37] [0.84,1.60] [1.37,2.01] [0.64,1.33] [1.05,2.04] 
   51-64 1.145 0.661** 0.949 1.397*** 1.046 1.330 
 [0.93,1.41] [0.48,0.91] [0.63,1.42] [1.15,1.69] [0.67,1.63] [0.88,2.01] 
Female 1.185*** 0.962 0.820 0.950 0.874 0.690*** 
 [1.05,1.34] [0.75,1.23] [0.63,1.06] [0.86,1.05] [0.70,1.09] [0.56,0.86] 
Education (ref=less than HS)       
   High School 1.018 0.809* 1.250* 1.003 0.588*** 1.026 
 [0.89,1.17] [0.63,1.03] [1.00,1.57] [0.88,1.14] [0.41,0.83] [0.76,1.39] 
   More than HS 1.124 1.225 1.331** 0.928 0.645*** 1.111 
 [0.96,1.31] [0.96,1.57] [1.01,1.76] [0.82,1.04] [0.48,0.86] [0.81,1.53] 
     Other/unknown 1.244* 1.313 1.425 0.853** 1.113 1.210 
 [0.98,1.58] [0.82,2.10] [0.90,2.24] [0.73,1.00] [0.61,2.03] [0.67,2.19] 
Chronic Conditions       
   1-2 1.232** 0.998 1.380* 1.265*** 1.225 1.196 
 [1.04,1.46] [0.73,1.37] [0.98,1.94] [1.10,1.46] [0.90,1.67] [0.91,1.57] 
   3+ 1.675*** 1.252 1.191 1.501*** 1.127 1.278 
 [1.37,2.05] [0.91,1.72] [0.81,1.75] [1.33,1.70] [0.89,1.43] [0.92,1.77] 
Race/Ethnicity       
   Hispanic 0.921 0.855 1.118 0.821*** 1.076 0.638*** 
 [0.68,1.25] [0.61,1.19] [0.71,1.77] [0.72,0.94] [0.79,1.47] [0.49,0.83] 
   Black/African American 0.674*** 0.762** 1.365* 0.739*** 0.811* 1.187 
 [0.59,0.77] [0.60,0.96] [0.97,1.92] [0.66,0.83] [0.65,1.02] [0.91,1.56] 





Exponentiated coefficients; 95% confidence intervals in brackets 






 [0.67,1.38] [1.53,5.22] [0.50,1.99] [0.93,1.66] [0.33,2.12] [0.58,1.20] 
   Asian 0.728 1.415 1.391 0.525*** 1.994 1.741 
 [0.39,1.34] [0.80,2.51] [0.55,3.53] [0.34,0.81] [0.85,4.68] [0.83,3.64] 
   Multiple/Other 0.798 0.500** 1.231 0.953 0.787 1.478** 
 [0.61,1.05] [0.28,0.90] [0.74,2.04] [0.75,1.21] [0.58,1.06] [1.01,2.16] 
Married 0.802*** 0.855 0.694*** 0.768*** 0.693** 0.823* 
 [0.70,0.92] [0.66,1.10] [0.53,0.90] [0.69,0.86] [0.49,0.97] [0.65,1.04] 
Percent FPL 0.992* 1.010 0.988 1.009** 0.961*** 0.996 
 [0.98,1.00] [0.99,1.03] [0.96,1.01] [1.00,1.02] [0.94,0.98] [0.96,1.03] 
Year       
   2011 0.975 1.127 0.854 1.054 0.809 0.937 
 [0.83,1.15] [0.80,1.58] [0.59,1.24] [0.92,1.21] [0.46,1.41] [0.70,1.25] 
   2012 0.966 1.932*** 1.120 0.974 1.663** 0.883 
 [0.81,1.15] [1.34,2.79] [0.69,1.81] [0.84,1.13] [1.11,2.48] [0.63,1.24] 
   2013 1.011 1.270 1.508* 0.932 1.267 1.031 
 [0.84,1.21] [0.92,1.76] [0.98,2.31] [0.78,1.11] [0.92,1.75] [0.75,1.42] 
   2016 0.856* 2.435*** 0.737* 0.973 0.934 0.838 
 [0.72,1.02] [1.70,3.49] [0.52,1.05] [0.85,1.11] [0.67,1.30] [0.65,1.09] 
   2017 0.969 1.515* 0.798 1.043 0.684** 1.140 
 [0.82,1.15] [0.95,2.41] [0.53,1.19] [0.92,1.18] [0.50,0.94] [0.82,1.59] 
   2018 1 1 1 1 1 1 
 [1.00,1.00] [1.00,1.00] [1.00,1.00] [1.00,1.00] [1.00,1.00] [1.00,1.00] 





Appendix A. Table 15. Medicaid Expansion by MH HRSA Shortage Area, MH Subsample at 138% FPL 
 Any Utilization (LPM) Self-Reported Outcome 
(LPM) 
Any Utilization (LPM) Self-Reported Outcome 
(LPM) 




















ANY less due 
to MH 
 Shortage No or Partial Shortage 
Expansion   
   Medicaid expansion 
State 
-0.0569*** -0.0304 0.0596 0.302 0.0580 0.0651** 0.112* -0.0135 0.235 -0.0389 
 [-0.08,-
0.03] 
[-0.18,0.12] [-0.10,0.22] [-0.99,1.60] [-0.02,0.14] [0.01,0.12] [-0.01,0.24] [-0.12,0.09] [-0.53,1.00] [-0.12,0.04] 
   Post-ME 0.00970 0.0308 0.0393 -0.701 -0.138*** 0.0108 0.0391 0.0900*** -0.772** -0.105*** 
 [-0.01,0.03] [-0.05,0.11] [-0.06,0.14] [-1.72,0.32] [-0.23,-0.05] [-0.01,0.03] [-0.03,0.11] [0.02,0.16] [-1.45,-0.09] [-0.17,-0.04] 
   Medicaid expansion 
State * Post ME 
-0.0221 0.0354 0.0174 0.496 0.0569 0.0000939 0.0281 0.0211 0.541 0.00827 
 [-0.05,0.01] [-0.06,0.14] [-0.10,0.13] [-0.55,1.54] [-0.03,0.15] [-0.02,0.02] [-0.04,0.10] [-0.05,0.09] [-0.15,1.23] [-0.05,0.07] 
Age           
   25-35 0.00274 0.00138 0.0662 0.398 0.0492 -0.0141* 0.0193 0.0876*** 1.058*** 0.0548** 
 [-0.02,0.03] [-0.07,0.08] [-0.01,0.15] [-0.26,1.06] [-0.03,0.13] [-0.03,0.00] [-0.03,0.07] [0.03,0.14] [0.52,1.60] [0.00,0.11] 
   36-50 0.00455 0.0355 0.128*** 1.168*** 0.138*** 0.0105 0.0853*** 0.143*** 1.405*** 0.0846*** 
 [-0.01,0.02] [-0.04,0.11] [0.05,0.21] [0.50,1.84] [0.08,0.20] [-0.01,0.03] [0.04,0.13] [0.09,0.20] [0.83,1.98] [0.03,0.14] 
   51-64 0.00645 -0.0400 0.137*** 0.308 0.138*** -0.00411 0.0188 0.192*** 1.083*** 0.139*** 
 [-0.02,0.03] [-0.12,0.04] [0.06,0.22] [-0.58,1.19] [0.07,0.20] [-0.03,0.02] [-0.04,0.07] [0.14,0.25] [0.50,1.66] [0.08,0.20] 
Female 0.00715 0.0727*** 0.0942*** 0.333 0.0788*** 0.00849 0.0275* 0.0657*** 0.217 0.0348** 
 [-0.00,0.02] [0.03,0.11] [0.05,0.14] [-0.22,0.88] [0.04,0.11] [-0.00,0.02] [-0.00,0.06] [0.03,0.10] [-0.16,0.59] [0.01,0.06] 
           
Education (ref=less 
than HS) 
          
   High School -0.00983 0.0485* 0.0594** -0.118 -0.0119 0.00103 0.0396** 0.0105 -0.349* -0.0167 
 [-0.03,0.01] [-0.00,0.10] [0.01,0.11] [-0.58,0.34] [-0.06,0.03] [-0.01,0.01] [0.00,0.08] [-0.03,0.05] [-0.73,0.03] [-0.05,0.02] 
   More than HS 0.00457 0.0322 0.0504 -0.530 0.0271 -0.00381 0.0510** 0.0519** -0.774*** -0.0351* 
 [-0.02,0.03] [-0.03,0.10] [-0.02,0.12] [-1.24,0.18] [-0.02,0.07] [-0.02,0.01] [0.01,0.09] [0.00,0.10] [-1.28,-0.26] [-0.07,0.00] 
   Other/unknown 0.00335 -0.0252 0.00962 -1.229** 0.0136 0.0000357 0.0775* 0.0275 -0.686 -0.0279 
 [-0.04,0.04] [-0.11,0.06] [-0.07,0.09] [-2.33,-
0.13] 
[-0.07,0.09] [-0.02,0.02] [-0.00,0.16] [-0.05,0.10] [-1.51,0.14] [-0.10,0.04] 
Chronic Conditions           
   1-2 -0.0168* 0.0691** 0.102*** 0.796*** 0.0478* 0.00867 0.106*** 0.186*** 0.855*** 0.0904*** 





   3+ -0.0150 0.197*** 0.343*** 2.710*** 0.146*** 0.00687 0.166*** 0.327*** 2.110*** 0.150*** 
 [-0.04,0.01] [0.13,0.26] [0.28,0.40] [2.06,3.36] [0.10,0.19] [-0.01,0.02] [0.12,0.21] [0.28,0.38] [1.59,2.63] [0.10,0.20] 
Race/Ethnicity           
   Hispanic -0.00628 -0.105*** -0.126*** -1.133*** -0.0341 -0.00305 -0.0876*** -0.148*** -0.421* -0.00721 









   Black/African 
American 
-0.0147* -0.175*** -0.229*** -0.730** -0.0516** -0.000731 -0.106*** -0.179*** -0.700*** -0.0506*** 









   Alaskan/Native 
American 
-0.0135** 0.0714 0.0609 -0.213 0.0185 0.00116 -0.0928 -0.0363 1.513** 0.00559 
 [-0.03,-
0.00] 
[-0.08,0.23] [-0.14,0.26] [-2.87,2.44] [-0.10,0.14] [-0.04,0.04] [-0.21,0.03] [-0.15,0.08] [0.12,2.91] [-0.11,0.12] 
   Asian -0.0321*** -0.0604 -0.123 -0.687 -0.121 -0.0133** -0.130*** -0.168*** -0.500 -0.0254 
 [-0.05,-
0.01] 







   Multiple/Other -0.00841 -0.111** -0.0961 0.378 0.0928** 0.0141 0.0759 0.0735* 0.600 0.0242 
 [-0.04,0.03] [-0.22,-0.00] [-0.26,0.06] [-1.16,1.92] [0.01,0.17] [-0.02,0.05] [-0.02,0.17] [-0.00,0.15] [-0.32,1.52] [-0.04,0.09] 










Percent FLP 0.000800 0.000792 -0.00267 -0.0287 -0.000778 -0.00133** -0.00133 -0.00142 0.00346 0.000999 
 [-0.00,0.00] [-0.00,0.00] [-0.01,0.00] [-0.07,0.02] [-0.00,0.00] [-0.00,-
0.00] 
[-0.00,0.00] [-0.01,0.00] [-0.04,0.04] [-0.00,0.00] 
Year           
   2011 0.00713 0.0588* 0.0368 -0.400 0.00267 0.00449 -0.0202 0.0311 0.00346 0.00244 
 [-0.01,0.03] [-0.01,0.12] [-0.03,0.10] [-0.99,0.20] [-0.04,0.05] [-0.01,0.02] [-0.07,0.03] [-0.02,0.08] [-0.61,0.62] [-0.04,0.05] 
   2012 0.000793 0.0479 0.0564* 0.611* 0.00690 0.00863 0.0220 0.0543* -0.181 -0.0241 
 [-0.02,0.02] [-0.02,0.12] [-0.00,0.11] [-0.04,1.26] [-0.05,0.06] [-0.01,0.02] [-0.02,0.07] [-0.00,0.11] [-0.69,0.33] [-0.07,0.02] 
   2013 0.00503 0.0996** 0.0874** -0.00502 0.00863 0.0154 -0.0122 0.0160 0.0326 0.00638 
 [-0.02,0.03] [0.02,0.18] [0.00,0.17] [-0.81,0.80] [-0.05,0.07] [-0.00,0.03] [-0.06,0.04] [-0.04,0.07] [-0.49,0.55] [-0.04,0.05] 
   2016 0.0279* 0.0347 0.0125 -0.121 0.0864* -0.00488 -0.0401 -0.0784** 0.321 0.109*** 
 [-0.01,0.06] [-0.04,0.11] [-0.08,0.10] [-1.06,0.82] [-0.00,0.17] [-0.02,0.01] [-0.10,0.02] [-0.14,-
0.02] 
[-0.37,1.01] [0.05,0.17] 
   2017 0.0148 0.0173 0.0279 0.0428 0.0273 -0.00391 -0.0310 -0.0552* -0.186 0.00494 
 [-0.02,0.05] [-0.06,0.09] [-0.06,0.12] [-0.81,0.90] [-0.07,0.12] [-0.03,0.02] [-0.09,0.02] [-0.11,0.00] [-0.79,0.42] [-0.06,0.07] 
   2018 0 0 0 0 0 0 0 0 0 0 





Constant 0.0412* 0.124 0.178* 10.24*** 0.673*** 0.0309 0.129*** 0.187*** 10.18*** 0.673*** 
 [-0.00,0.09] [-0.04,0.29] [-0.01,0.37] [8.58,11.90] [0.54,0.81] [-0.01,0.08] [0.04,0.22] [0.08,0.30] [9.16,11.20] [0.57,0.77] 
Observations 251509 251509 251509 251509 251487 293578 293578 293578 293578 293511 
95% confidence intervals in brackets 




































Appendix A. Table 16. Medicaid Expansion by MH HRSA Shortage Area, MH Sub Sample at 138% FPL 
 Number of Visits, Conditional on Any     (Poisson, 
IRR) 
Number of Visits, Conditional on Any     (Poisson, IRR) 
     Rx count ED count MH Outpatient 
count 
    Rx count ED count MH Outpatient 
count 
 Shortage No/Partial Shortage 
Expansion       
   Medicaid expansion 
State 
1.056 1.441* 0.285*** 2.074*** 0.262*** 0.825 
 [0.82,1.36] [0.98,2.12] [0.12,0.69] [1.47,2.92] [0.15,0.46] [0.59,1.15] 
   Post-ME 0.911 0.663 1.146 1.178 0.708 0.877 
 [0.71,1.17] [0.35,1.26] [0.67,1.95] [0.94,1.48] [0.45,1.12] [0.60,1.29] 
   Medicaid expansion 
State * Post ME 
1.161 0.606* 2.618*** 0.878 1.459** 1.374 
 [0.93,1.44] [0.37,1.00] [1.49,4.60] [0.70,1.10] [1.01,2.11] [0.92,2.05] 
Age       
   25-35 1.162 1.075 0.866 1.174 0.654** 1.291 
 [0.81,1.67] [0.72,1.60] [0.58,1.30] [0.91,1.51] [0.44,0.97] [0.90,1.85] 
   36-50 1.420** 1.865*** 1.019 1.692*** 0.569*** 1.202 
 [1.07,1.89] [1.22,2.84] [0.73,1.43] [1.35,2.12] [0.38,0.85] [0.86,1.68] 
   51-64 1.250 1.111 0.852 1.481*** 0.870 1.027 
 [0.92,1.71] [0.62,1.99] [0.57,1.28] [1.16,1.89] [0.56,1.35] [0.72,1.46] 
Female 1.224** 0.662** 0.836 0.953 0.876 0.747*** 
 [1.04,1.44] [0.45,0.97] [0.63,1.10] [0.86,1.06] [0.66,1.16] [0.60,0.92] 
Education (ref=less 
than HS) 
      
   High School 1.066 0.994 1.354* 1.004 0.623*** 1.039 
 [0.91,1.24] [0.67,1.47] [1.00,1.84] [0.88,1.15] [0.47,0.82] [0.81,1.33] 
   More than HS 1.235** 0.968 1.266 0.960 0.533*** 1.158 
 [1.03,1.48] [0.62,1.51] [0.91,1.77] [0.82,1.12] [0.40,0.72] [0.87,1.54] 
     Other/unknown 1.284* 0.155*** 1.262 0.957 2.179*** 1.167 
 [0.98,1.68] [0.05,0.52] [0.69,2.29] [0.78,1.17] [1.25,3.80] [0.76,1.79] 
Chronic Conditions       
   1-2 1.334** 0.404*** 1.269 1.121 2.025*** 1.220 
 [1.06,1.67] [0.28,0.58] [0.83,1.94] [0.91,1.38] [1.34,3.06] [0.95,1.57] 
   3+ 1.671*** 0.735 1.117 1.276*** 1.739*** 1.569*** 
 [1.28,2.18] [0.50,1.08] [0.73,1.70] [1.06,1.53] [1.20,2.51] [1.15,2.14] 





   Hispanic 0.893 0.347*** 1.297 0.871* 1.135 0.660*** 
 [0.64,1.24] [0.19,0.65] [0.81,2.08] [0.74,1.03] [0.83,1.55] [0.52,0.84] 
   Black/African 
American 
0.678*** 0.513** 1.427* 0.746*** 0.836 1.183 
 [0.56,0.81] [0.29,0.90] [1.00,2.04] [0.65,0.85] [0.63,1.12] [0.90,1.55] 
   Alaskan/Native 
American 
0.979  1.060 1.470*** 4.228*** 1.218 
 [0.65,1.47]  [0.34,3.27] [1.12,1.93] [1.86,9.62] [0.84,1.77] 
   Asian 0.429**  1.291 0.472*** 0.429*** 2.195*** 
 [0.19,0.97]  [0.55,3.01] [0.31,0.71] [0.27,0.67] [1.25,3.84] 
   Multiple/Other 0.810 1.195 1.018 0.918 0.786 1.697*** 
 [0.59,1.11] [0.21,6.88] [0.57,1.83] [0.71,1.18] [0.54,1.16] [1.21,2.38] 
Married 0.927 0.428** 0.698** 0.785*** 0.878 0.822* 
 [0.77,1.11] [0.22,0.84] [0.51,0.95] [0.69,0.89] [0.68,1.13] [0.65,1.04] 
Percent FPL 0.985** 1.040** 0.989 1.010* 0.945*** 0.989 
 [0.97,1.00] [1.01,1.08] [0.96,1.02] [1.00,1.02] [0.92,0.97] [0.97,1.01] 
Year       
   2011 0.976 1.022 0.813 1.085 0.476** 0.863 
 [0.79,1.21] [0.56,1.87] [0.52,1.27] [0.93,1.26] [0.25,0.91] [0.69,1.08] 
   2012 0.978 1.339 1.224 0.952 1.303 0.866 
 [0.79,1.20] [0.60,2.99] [0.68,2.21] [0.81,1.11] [0.86,1.98] [0.67,1.12] 
   2013 1.031 0.891 1.624** 0.973 1.459* 1.179 
 [0.82,1.29] [0.46,1.74] [1.03,2.57] [0.79,1.20] [0.99,2.16] [0.89,1.56] 
   2016 0.869 1.433* 0.716* 0.898 1.559** 0.812 
 [0.73,1.03] [0.96,2.13] [0.49,1.04] [0.75,1.07] [1.06,2.30] [0.60,1.09] 
   2017 1.093 1.128 1.050 0.949 1.017 0.991 
 [0.92,1.30] [0.76,1.68] [0.67,1.64] [0.83,1.09] [0.60,1.74] [0.72,1.37] 
   2018 1 1 1 1 1 1 
 [1.00,1.00] [1.00,1.00] [1.00,1.00] [1.00,1.00] [1.00,1.00] [1.00,1.00] 
Observations 207602 49709 171014 272920 107741 257656 
Exponentiated coefficients; 95% confidence intervals in brackets 







Appendix B. Table 1. Summary of Data and Measures 
 Variable Data Source Years 
Primary analysis    
   Outcome 
 
Grams of buprenorphine/100,000 
persons 
Automated Reports and Consolidated 
Ordering System (ARCOS)  
2014-2019 
   Primary IV 
Nurse Practitioner SOP  Suzanne Phillips Annual Legislative 
Updates  
2014-2019 
CARA Q2 2017 - 
   Policy  
 
Medicaid Expansion Kaiser Family Foundation Policy Tracker 2014-2019 
1115 SUD Waiver Kaiser Family Foundation Policy Tracker 2014-2019 
Mandatory Prescription Data 
Monitoring 
 
Lee, Byungkyu (2021) Supplement table 
Legislation limiting the Use of 
Prior Authorization for 
Buprenorphine 
Legal Action Center Report published 
online 
2014-2019 
  Demographics 
*Race/Ethnicity  
*Age 
*Federal Poverty Level (100%) 
*Population in fair/poor health 
*Poor MH 14 of last 30 days, lag 
Kaiser Family Foundation State Health 
Facts 
2014-2019 
*Opioid prescribing rate, lagged CDC opioid prescribing rates available 
online  
2013-2018 
*Rate of APRN/100,000 Suzanne Phillips Annual Legislative 
Updates  
2014-2019 
*Rate of MD waivers/100,000 FOIA requested DEA list of 
buprenorphine waivered providers  
2014-2019 
*Opioid Treatment Programs National Survey of Substance Abuse 
Treatment Services (N-SSATS) 
2013-2018 
Falsification Test *State and year fixed effects  
  Outcome Prescriptions of 
Metoprolol/100,000 persons 
(Covariates, same as above) 
Medicaid State Utilization data 
downloaded for each year from here 
(Extracted prescriptions for Metoprolol 






OUD vs analgesic 
buprenorphine 
Share of Analgesic vs OUD.  
• Analgesic: (Belbuca, 
Buprenex, Butrans) 
• OUD: (Suboxone, Zubsolv, 
Bunavail, Subutex, 
Sublocade, Cassipa) 
Medicaid State Utilization data 
downloaded from here 
 






Appendix B. Table 2. Buprenorphine Dispensing in Broad vs. Narrow SOP States Before and After CARA 
(DID), Marginal Effects 
 
Grams of buprenorphine 
dispensed/100k 
 
Number of 90-day buprenorphine 
prescriptions (16mg/day)/100k 
 State and Year 
Fixed Effects and 
Population 
Fully Adjusted  State and Year 
Fixed Effects and 
Population 
Fully Adjusted 
SOP and CARA      
   Broad SOP 2.843 5.147  2.234 4.219 
  (Ref=Narrow SOP) [-30.84,36.53] [-22.41,32.70]  [-21.23,25.70] [-14.88,23.32] 
  Post-CARA 17.11*** 16.00***  12.54*** 11.48*** 
  (Ref= Narrow SOP) [9.03,25.19] [9.05,22.96]  [6.92,18.15] [6.82,16.14] 
DID term      
 Broad SOP x CARA=1 23.52** 22.01**  15.83* 15.86** 
 [0.32,46.71] [3.82,40.20]  [-1.11,32.78] [3.12,28.61] 
Policies      
  Medicaid Expansion  16.79**   11.63** 
  [0.22,33.36]   [0.36,22.90] 
  Mandatory PDMP  -4.590   -2.166 
  [-18.24,9.06]   [-11.90,7.57] 
  1115 SUD Waiver  -20.27***   -14.08*** 
  [-33.30,-7.24]   [-23.07,-5.09] 
  State prior auth law for    
  Bup 
 -0.994   -1.869 
  [-17.13,15.14]   [-12.91,9.17] 
OUD risk factors      
   Opioid Rx/100k(L)  0.756   0.590* 
  [-0.24,1.75]   [-0.01,1.19] 
   Fair/Poor Health  -1.712   -0.936 
  [-6.34,2.91]   [-4.32,2.44] 
   Poor MH  0.271   0.169 
  [-3.89,4.43]   [-2.80,3.13] 
Demographics      
   Black/African    
   American 
 -1.803   -1.940 
  [-18.66,15.06]   [-14.11,10.23] 
   Hispanic  -26.73**   -18.29** 
  [-49.87,-3.58]   [-34.62,-1.97] 
   Other Race  -6.455   -5.181 
  [-21.24,8.33]   [-15.52,5.16] 
   Age: 0to18  15.20***   10.21*** 
  [4.64,25.76]   [2.92,17.50] 
   Age: 65+  -2.785   -2.055 
  [-12.18,6.61]   [-8.98,4.87] 
   Under 100%  FPL  -5.417**   -3.941** 
  [-10.27,-0.57]   [-7.16,-0.72] 
Supply      
   APRN/100k   0.0817   0.0552 
  [-0.13,0.29]   [-0.08,0.19] 
   MD Waivers/100k  1.442**   0.924** 
  [0.18,2.70]   [0.08,1.77] 





  [-57.53,19.80]   [-41.62,12.19] 
States      
AK 0 0  0 0 
 [0.00,0.00] [0.00,0.00]  [0.00,0.00] [0.00,0.00] 
AL 249.2*** 88.19  177.8*** 61.05 
 [211.42,286.94] [-321.29,497.68]  [152.00,203.65] [-229.06,351.16] 
AR -90.43*** -109.5  -64.20*** -89.09 
 [-116.72,-64.14] [-382.10,163.20]  [-82.18,-46.21] [-284.50,106.33] 
AZ -169.6*** 551.2  -120.8*** 330.4 
 [-179.79,-159.32] [-
980.18,2082.54] 
 [-127.82,-113.86] [-670.64,1331.47] 




 [-162.43,-131.96] [-1424.16,2930.90] 
CO -169.9*** 35.14  -121.2*** 0.692 
 [-182.37,-157.41] [-424.88,495.15]  [-129.62,-112.69] [-322.96,324.34] 
CT 135.4*** 501.8*  96.27*** 334.8* 
 [101.52,169.24] [-59.69,1063.27]  [73.13,119.41] [-58.41,727.97] 
DC 43.23*** 299.7  31.98*** 245.2 
 [40.44,46.02] [-
581.49,1180.93] 
 [29.99,33.97] [-456.25,946.58] 
DE 67.98*** 136.7  48.68*** 94.23 
 [36.32,99.63] [-148.86,422.22]  [27.03,70.33] [-112.25,300.71] 
FL -71.33*** 809.8  -51.15*** 519.8 
 [-98.19,-44.48] [-
552.33,2171.96] 
 [-69.50,-32.80] [-395.57,1435.11] 
GA -147.3*** -112.6  -105.2*** -84.55 
 [-171.53,-122.97] [-374.27,148.99]  [-121.84,-88.65] [-272.42,103.32] 
HI -170.3*** 191.7  -121.6*** 166.4 
 [-180.50,-160.01] [-
720.19,1103.58] 
 [-128.60,-114.60] [-545.60,878.47] 
IA -253.7*** -252.5*  -181.0*** -190.9* 
 [-268.97,-238.43] [-516.61,11.68]  [-191.43,-170.58] [-382.88,1.16] 
ID -98.73*** -78.52  -70.27*** -73.05 
 [-104.71,-92.75] [-412.16,255.12]  [-74.35,-66.20] [-315.50,169.39] 
IL -191.5*** -49.75  -136.6*** -49.07 
 [-214.31,-168.70] [-325.79,226.29]  [-152.19,-121.01] [-252.00,153.86] 
IN 19.90 -45.33  14.88 -44.27 
 [-10.18,49.98] [-330.91,240.24]  [-5.73,35.48] [-249.73,161.19] 
KS -215.2*** -186.6  -153.6*** -145.4 
 [-237.14,-193.18] [-451.10,77.88]  [-168.65,-138.62] [-339.47,48.65] 
KY 548.8*** 209.8  391.1*** 134.2 
 [501.03,596.64] [-181.24,600.90]  [358.40,423.72] [-138.55,406.97] 
LA 114.3*** 36.58  81.73*** 27.55 
 [81.11,147.54] [-369.11,442.27]  [59.01,104.45] [-267.00,322.10] 
MA 328.4*** 547.4**  233.4*** 376.1** 
 [288.04,368.72] [118.03,976.69]  [205.87,260.95] [72.96,679.32] 
MD 124.9*** 244.6  89.28*** 188.3 
 [122.17,127.56] [-207.31,696.46]  [87.29,91.27] [-157.04,533.56] 
ME 461.4*** 130.4  330.6*** 79.35 
 [416.29,506.58] [-340.27,600.97]  [299.63,361.58] [-253.27,411.97] 
MI -18.46 -76.69  -13.40 -64.04 
 [-47.12,10.19] [-347.47,194.09]  [-32.98,6.18] [-256.89,128.81] 





 [-186.59,-156.86] [-451.54,58.00]  [-132.40,-112.19] [-335.23,34.94] 
MO -119.3*** -168.3  -84.60*** -129.6 
 [-144.65,-93.98] [-436.46,99.83]  [-101.94,-67.26] [-322.64,63.35] 
MS 48.28*** -65.04  33.94*** -45.93 
 [17.39,79.17] [-451.08,321.01]  [12.84,55.04] [-326.59,234.73] 
MT -74.90*** -134.2  -52.52*** -106.7 
 [-79.70,-70.11] [-414.00,145.70]  [-55.75,-49.29] [-309.46,96.09] 
NC 45.86*** 106.0  33.73*** 71.72 
 [14.85,76.87] [-172.82,384.80]  [12.46,54.99] [-128.11,271.56] 
ND -175.4*** -210.6  -124.9*** -160.4* 
 [-186.02,-164.80] [-469.13,47.94]  [-132.12,-117.67] [-348.19,27.44] 
NE -240.0*** -221.0  -171.2*** -169.3* 
 [-256.66,-223.30] [-485.87,43.88]  [-182.57,-159.83] [-362.77,24.23] 
NH 290.0*** 61.88  206.9*** 28.58 
 [272.44,307.57] [-337.48,461.24]  [194.92,218.91] [-254.02,311.19] 
NJ 2.807 569.6  1.469 381.6 
 [-26.54,32.15] [-
183.36,1322.48] 
 [-18.57,21.51] [-132.79,895.89] 






NV -193.2*** 347.0  -137.9*** 206.3 
 [-210.81,-175.55] [-
602.16,1296.09] 
 [-149.85,-125.94] [-422.59,835.10] 
NY -14.06 533.0  -9.995 361.8 
 [-42.90,14.78] [-
104.42,1170.32] 
 [-29.71,9.73] [-77.12,800.66] 
OH 160.1*** -5.793  113.7*** -13.25 
 [125.37,194.75] [-293.44,281.85]  [90.02,137.40] [-216.93,190.44] 
OR -53.98*** 66.25  -38.02*** 26.64 
 [-57.35,-50.60] [-295.20,427.70]  [-40.31,-35.73] [-235.26,288.55] 
PA 224.9*** 195.8  160.6*** 128.0 
 [187.94,261.85] [-110.09,501.70]  [135.35,185.91] [-91.33,347.39] 
RI 415.7*** 1034.9*  295.8*** 693.1* 
 [390.38,441.06] [-77.85,2147.68]  [278.53,313.16] [-66.79,1453.03] 
SC -70.33*** -90.80  -50.00*** -70.34 
 [-97.28,-43.39] [-382.90,201.30]  [-68.43,-31.56] [-277.21,136.53] 
SD -248.4*** -250.6*  -177.1*** -188.7** 
 [-266.41,-230.43] [-503.28,2.17]  [-189.43,-164.84] [-372.71,-4.76] 




 [-165.09,-134.83] [-1071.25,1997.47] 
UT 15.04 7.002  10.14 -11.32 
 [-14.72,44.79] [-340.88,354.88]  [-10.18,30.46] [-265.24,242.59] 
VA -48.40*** 7.901  -34.78*** -0.495 
 [-76.03,-20.77] [-207.04,222.84]  [-53.66,-15.89] [-155.67,154.68] 
VT 743.6*** 309.5  530.6*** 210.7 
 [689.09,798.13] [-314.41,933.44]  [493.36,567.89] [-231.12,652.52] 
WA -34.48*** 103.0  -23.90*** 60.52 
 [-36.81,-32.14] [-139.69,345.76]  [-25.48,-22.32] [-119.42,240.46] 
WI -112.2*** -123.7  -80.12*** -100.3 
 [-137.72,-86.74] [-397.79,150.33]  [-97.55,-62.70] [-299.16,98.63] 





 [558.43,658.02] [-296.21,726.87]  [399.26,467.28] [-220.78,487.81] 
Year      
   2015 0 0  0 0 
 [0.00,0.00] [0.00,0.00]  [0.00,0.00] [0.00,0.00] 
   2016 24.26*** 28.90***  17.36*** 20.71*** 
 [20.80,27.73] [21.25,36.55]  [14.77,19.94] [15.40,26.03] 
   2017 45.26*** 60.46***  32.42*** 43.26*** 
 [39.09,51.43] [43.60,77.33]  [28.00,36.85] [31.78,54.74] 
   2018 80.54*** 115.7***  57.10*** 83.00*** 
 [71.03,90.05] [85.56,145.86]  [50.30,63.90] [62.28,103.72] 
   2019 139.0*** 186.7***  98.13*** 133.5*** 
 [123.27,154.77] [134.93,238.52]  [87.01,109.25] [97.95,169.09] 
Observations 960 960  960 960 
95% confidence intervals in brackets 






































Appendix B. Table 3.  
Association between NP SOP on NP Waivers/100,000 after CARA legislation 
 
 All Waivers/100k, NP prescribers 
Incident Rate Ratio 
Broad SOP (ref=Narrow SOP) 1.091 
 [0.40,3.01] 
Interaction: Quarters after CARA x SOP  
(ref=implementation) 
 
   +1 x Broad SOP  1.050 
 [0.87,1.26] 
   +2 x Broad SOP 1.167 
 [0.93,1.47] 
   +3 x Broad SOP 1.209 
 [0.96,1.52] 
   +4 x Broad SOP 1.237* 
 [0.98,1.57] 
   +5 x Broad SOP 1.278* 
 [0.99,1.65] 
   +6 x Broad SOP 1.344** 
 [1.03,1.75] 
   +7 x Broad SOP 1.372** 
 [1.07,1.76] 
   +8 x Broad SOP 1.377** 
 [1.06,1.79] 
   +9 x Broad SOP 1.350** 
 [1.05,1.74] 
   +10 x Broad SOP 1.339** 
 [1.03,1.75] 
Quarters after CARA 
(ref implementation) 
 
   +1 2.175*** 
 [2.01,2.35] 
   +2 3.347*** 
 [3.11,3.60] 
   +3 4.353*** 
 [3.76,5.04] 
   +4 5.341*** 
 [4.54,6.28] 
   +5 6.288*** 
 [5.28,7.48] 
   +6 7.207*** 
 [5.98,8.69] 
   +7 8.386*** 
 [6.43,10.94] 
   +8 9.961*** 
 [7.59,13.07] 
   +9 11.30*** 
 [8.63,14.81] 
   +10 12.74*** 
 [9.66,16.79] 
Policies  






   PDMP 1.093* 
 [0.99,1.21] 
   1115 SUD Waiver 0.998 
 [0.92,1.09] 
   State prior auth law 1.017 
 [0.89,1.17] 
OUD Risk Factors  
   Opioid Rx/100k 0.997 
 [0.98,1.01] 
   Fair/Poor Health (%) 0.997 
 [0.96,1.04] 
   Poor MH (1 yr lag) 1.024 
 [0.99,1.07] 
Demographics  
   Black/AA (%) 0.934 
 [0.84,1.04] 
   Age: 0 to 18 (%) 0.971 
 [0.78,1.20] 
   Age: 65+ (%) 0.970 
 [0.84,1.12] 
   Under FPL(%) 0.970 
 [0.89,1.05] 
Supply  
   OTP/100k 1.163 
 [0.82,1.64] 











































































































95% confidence intervals in brackets 




































Appendix B. Table 4.  
(1) Increase in total Buprenorphine waivers in Broad SOP states relative to Narrow SOP 
after CARA 
(2) Association of Buprenorphine Waivers/100k and Grams of Buprenorphine 
Dispensed/100k 
 (1) (2) 









Grams of Buprenorphine/100k 
Broad SOP (ref=Narrow 
SOP) 
0.927  
 [0.81,1.07]  
Post-CARA (ref=Pre-Cara) 1.093***  
 [1.04,1.14]  
Broad SOP x CARA 1.239***  
 [1.12,1.37]  
All Waivers/100k, All 
prescribers 
 1.003*** 
  [1.00,1.01] 
Policies   
   Medicaid Expansion 0.951 1.044 
 [0.88,1.03] [0.98,1.11] 
   Mandatory PDMP 0.980 0.978 
 [0.92,1.05] [0.94,1.02] 
   1115 SUD Waiver 0.963 0.928*** 
 [0.91,1.01] [0.89,0.97] 
   State Prior Auth Law  
   for Buprenorphine 
0.991 1.004 
 [0.92,1.07] [0.95,1.06] 
OUD Risk   
   Opioid Rx/100k 0.997 1.003 
 [0.99,1.00] [1.00,1.01] 
   Fair/Poor Health(%) 0.994 0.994 
 [0.97,1.02] [0.98,1.01] 
   Poor MH (%) 1.007 1.004 
 [0.99,1.02] [0.99,1.02] 
Demographics   
   Black/AA(%) 0.971 1.006 
 [0.91,1.03] [0.95,1.06] 
   Hispanic (%) 0.931 0.934* 
 [0.84,1.03] [0.87,1.00] 
   Other Race (%) 0.984 0.991 
 [0.92,1.05] [0.95,1.03] 
   Age 0to18 (%) 0.978 1.053*** 
 [0.93,1.02] [1.02,1.09] 
   Age 65+ 1.031 0.987 
 [0.99,1.08] [0.96,1.01] 
   Under FPL(%) 1.017 0.985* 
 [0.99,1.04] [0.97,1.00] 





   OTP/100k 0.997 0.938 
 [0.82,1.21] [0.83,1.05] 
State   
AK 1 1 
 [1.00,1.00] [1.00,1.00] 
AL 0.348 1.278 
 [0.05,2.27] [0.40,4.05] 
AR 0.172** 0.651 
 [0.03,0.87] [0.25,1.67] 
AZ 1.408 2.652 
 [0.08,24.69] [0.35,20.19] 
CA 3.202 3.649 
 [0.11,96.18] [0.33,40.49] 
CO 0.793 1.183 
 [0.09,7.26] [0.27,5.19] 
CT 1.170 2.846* 
 [0.21,6.43] [0.97,8.35] 
DC 1.877 1.598 
 [0.23,15.17] [0.33,7.71] 
DE 0.616 1.487 
 [0.14,2.68] [0.63,3.52] 
FL 0.931 3.369 
 [0.09,9.92] [0.71,15.93] 
GA 0.486 0.509 
 [0.09,2.50] [0.18,1.48] 
HI 0.608 1.150 
 [0.05,7.32] [0.25,5.35] 
IA 0.0725*** 0.171*** 
 [0.01,0.47] [0.05,0.54] 
ID 0.239 0.886 
 [0.03,1.73] [0.25,3.20] 
IL 0.483 0.782 
 [0.10,2.39] [0.28,2.15] 
IN 0.272 0.955 
 [0.05,1.44] [0.36,2.53] 
KS 0.191** 0.394* 
 [0.04,1.00] [0.14,1.10] 
KY 0.362 2.179 
 [0.06,2.31] [0.71,6.70] 
LA 0.486 1.018 
 [0.08,3.14] [0.30,3.43] 
MA 1.189 3.286** 
 [0.27,5.22] [1.31,8.24] 
MD 1.385 1.654 
 [0.34,5.65] [0.63,4.32] 
ME 0.436 2.124 
 [0.05,3.95] [0.54,8.39] 
MI 0.296 0.825 
 [0.06,1.44] [0.33,2.04] 
MN 0.171** 0.402** 
 [0.04,0.76] [0.17,0.95] 
MO 0.165** 0.490 
 [0.03,0.89] [0.19,1.29] 
MS 0.313 0.676 





MT 0.118** 0.728 
 [0.02,0.66] [0.25,2.14] 
NC 0.421 1.296 
 [0.10,1.79] [0.56,2.99] 
ND 0.119*** 0.365** 
 [0.02,0.57] [0.14,0.96] 
NE 0.130** 0.282** 
 [0.02,0.75] [0.10,0.82] 
NH 0.327 1.781 
 [0.04,2.59] [0.50,6.30] 
NJ 1.238 2.651* 
 [0.24,6.49] [0.89,7.89] 
NM 9.217 24.63* 
 [0.10,861.06] [0.95,640.34] 
NV 1.286 1.817 
 [0.12,14.30] [0.34,9.71] 
NY 1.443 2.590* 
 [0.31,6.72] [0.94,7.13] 
OH 0.347 1.156 
 [0.07,1.84] [0.45,3.00] 
OR 0.472 1.467 
 [0.08,2.72] [0.47,4.59] 
PA 0.472 1.957 
 [0.09,2.40] [0.76,5.05] 
RI 1.266 5.432*** 
 [0.19,8.46] [1.55,19.00] 
SC 0.307 0.658 
 [0.05,1.76] [0.23,1.90] 
SD 0.0901*** 0.171*** 
 [0.02,0.37] [0.07,0.41] 
TX 1.616 2.533 
 [0.05,54.86] [0.22,29.33] 
UT 0.778 1.086 
 [0.13,4.61] [0.33,3.54] 
VA 0.393 0.994 
 [0.12,1.32] [0.50,1.99] 
VT 0.543 3.109 
 [0.06,5.24] [0.74,13.06] 
WA 0.733 1.484 
 [0.22,2.48] [0.68,3.24] 
WI 0.222* 0.681 
 [0.04,1.18] [0.25,1.83] 
WV 0.237 2.460 
 [0.03,2.07] [0.63,9.62] 
Year   
   2015 1 1 
 [1.00,1.00] [1.00,1.00] 
   2016 1.164*** 1.120*** 
 [1.12,1.21] [1.08,1.16] 
   2017 1.305*** 1.313*** 
 [1.19,1.43] [1.23,1.41] 
   2018 1.666*** 1.571*** 
 [1.44,1.93] [1.41,1.75] 
   2019 2.303*** 1.871*** 





Observations 960 960 
Exponentiated coefficients; 95% confidence intervals in brackets 
















































Appendix B, Table 4.  
Falsification test: Prescriptions of Metoprolol (blood pressure) Dispensed in Broad vs. Narrow 
SOP States Before and After CARA (DID),  
 
 Prescriptions of Metoprolol /100k 
Marginal Effects 
  
Broad SOP (ref=Narrow SOP) 11.51 
 [-106.58,129.60] 
Post-CARA (ref=pre-CARA) 17.39 
 [-10.08,44.86] 
Broad SOP x CARA 4.242 
 [-70.40,78.88] 




SUD 1115 Waiver 39.75 
 [-17.28,96.79] 
State Prior Auth Law for BUP -34.31 
 [-82.21,13.59] 
Opioid Rx/100,000(1yr lag) -1.417 
 [-5.24,2.41] 
Fair/Poor Health(%) -6.880 
 [-24.03,10.27] 
Poor MH (%, 1yr lag) 14.04 
 [-18.32,46.40] 
Black/African American (%) 2.903 
 [-47.99,53.79] 
Hispanic (%) 62.75 
 [-104.73,230.22] 
Other Race(%) 35.27 
 [-37.81,108.36] 
Age 0 to 18(%) 3.434 
 [-58.56,65.43] 
Age 65+(%) 11.58 
 [-24.09,47.25] 

























































































































95% confidence intervals in brackets 















Appendix B. Table 5. 
Effect of CARA (Comprehensive Addiction and Recovery Act) on Buprenorphine Dispensing per 
100,000 population in Broad SOP states (Narrow SOP is reference), 2015-2019 




Ref=Quarter of CARA 
passage 
-9 -.064 ** -.047 
-8 -.063** -.047 
-7 -.051** -.035** 
-6 -.052*** -.036** 
-5 -.045 -.028 
-4 -.016 -.0006 
-3 (CARA Enactment) -.017 Reference 
-2 -.016 .0007 
-1 Reference .016 
0 CARA Implementation (Q2, 2017) .005 .021 
+1 .029*** .046*** 
+2 .034** .050** 
+3 .031 .046 
+4 .025 0.041 
+5 .030 .047 
+6 .046 .062** 
+7 .054** .069** 
+8 .061** .077** 
+9 .062** .078** 
+10 .062 .080** 
Notes: This figure shows the difference in difference coefficient for narrow and broad SOP states for each quarter before and 
after CARA legislation implementation (Q2 of 2017). Analysis adjusted for state and year fixed effects as well as area level 


























Appendix B. Table 6.  
Sensitivity tests to examine SOP specifications: Buprenorphine Dispensing (grams) Before and After CARA in various 
specifications of SOP (DID), Incident Rate Ratio 
 Model 1 Model 2 Model 3 Model 4 Model 5 
Incident Rate Ratio 
Broad vs Narrow 
SOP, all states 
(specification used 
in main analysis) 
Full vs  
Reduced vs  
Restricted 













      
Various Specifications of DID term      
 Model 1 DID      
   Broad SOP x CARA 1.067**     
 [1.01,1.12]     
 Model 2 DID      
   Transition SOP x CARA  1.023    
  [0.98,1.07]    
   Full SOP x CARA  1.071**    
  [1.01,1.14]    
 Model 3 DID      
    Full SOP x CARA   1.062**   
   [1.00,1.12]   
 Model 4 DID      
    Full/transition x CARA    1.052**  
    [1.00,1.10]  
 Model 5 DID      
   Broad SOP x CARA     1.067** 
     [1.01,1.13] 
CARA term      
   Post-CARA (ref=Pre-CARA) 1.050*** 1.047*** 1.055*** 1.045*** 1.051*** 
 [1.03,1.07] [1.02,1.08] [1.04,1.07] [1.02,1.07] [1.03,1.07] 
SOP Term, without interaction      
   Broad SOP (ref=Narrow SOP) 1.016    0.563 
 [0.94,1.10]    [0.14,2.29] 
   Transition (ref= Restricted SOP)  1.028    
  [0.95,1.12]    
   Full (ref= Restricted SOP)  0.523    
  [0.15,1.85]    
   Full SOP (ref=Reduced/Restricted)   0.574   
   [0.15,2.20]   
   Full/transition (ref=Restricted)    1.005  
    [0.92,1.10]  
Policies      
   Mandatory PDMP 0.986 0.985 0.983 0.984 0.988 
 [0.95,1.03] [0.95,1.03] [0.94,1.02] [0.95,1.02] [0.95,1.03] 
   SUD 1115 Waiver 0.940*** 0.937*** 0.938*** 0.935*** 0.938*** 
 [0.90,0.98] [0.90,0.98] [0.90,0.98] [0.90,0.97] [0.90,0.98] 
   State prior auth law 0.997 0.995 1.002 0.995 0.997 
 [0.95,1.05] [0.95,1.05] [0.95,1.05] [0.95,1.05] [0.95,1.05] 
OUD Risk      
   Opioid Prescribing/100k 1.002 1.003* 1.003 1.003 1.002 





   Fair/Poor Health (%) 0.995 0.996 0.995 0.996 0.992 
 [0.98,1.01] [0.98,1.01] [0.98,1.01] [0.98,1.01] [0.98,1.01] 
   Poor MH (%) 1.001 1.000 1.001 1.002 1.002 
 [0.99,1.01] [0.99,1.01] [0.99,1.01] [0.99,1.01] [0.99,1.02] 
Demographics      
Black/AA (%) 0.995 1.000 1.004 0.998 0.989 
 [0.95,1.05] [0.95,1.05] [0.95,1.06] [0.95,1.05] [0.94,1.04] 
Hispanic (%) 0.923** 0.930** 0.926** 0.937* 0.927** 
 [0.86,0.99] [0.87,1.00] [0.86,1.00] [0.87,1.01] [0.86,1.00] 
Other Race (%) 0.981 0.983 0.980 0.990 0.979 
 [0.94,1.03] [0.94,1.03] [0.94,1.02] [0.95,1.03] [0.94,1.02] 
Age: 0 to 18 (%) 1.047*** 1.049*** 1.049*** 1.052*** 1.049*** 
 [1.01,1.08] [1.02,1.08] [1.02,1.08] [1.02,1.09] [1.01,1.09] 
Age: 65+ (%) 0.992 0.985 0.988 0.985 0.991 
 [0.96,1.02] [0.96,1.01] [0.96,1.01] [0.96,1.01] [0.96,1.02] 
Under 100% FPL (%) 0.984** 0.983** 0.985** 0.982** 0.985** 
 [0.97,1.00] [0.97,1.00] [0.97,1.00] [0.97,1.00] [0.97,1.00] 
      
Supply      
APRN/100k 1.000 1.000 1.000 1.000 1.000 
 [1.00,1.00] [1.00,1.00] [1.00,1.00] [1.00,1.00] [1.00,1.00] 
MD Waiver/100k 1.004** 1.004** 1.004** 1.004** 1.004** 
 [1.00,1.01] [1.00,1.01] [1.00,1.01] [1.00,1.01] [1.00,1.01] 
OTP/100k 0.945 0.935 0.939 0.939 0.948 
 [0.84,1.06] [0.83,1.05] [0.84,1.05] [0.84,1.05] [0.84,1.07] 
States      
AL 1.305 0.629 0.578 1.584 0.837 
 [0.38,4.42] [0.20,1.99] [0.18,1.86] [0.56,4.48] [0.24,2.87] 
AR 0.622 0.313*** 0.304*** 0.736 0.368** 
 [0.23,1.68] [0.15,0.64] [0.15,0.63] [0.32,1.70] [0.17,0.80] 
AZ 2.904 2.574 2.657 2.503 2.568 
 [0.40,21.03] [0.33,19.96] [0.34,20.85] [0.32,19.68] [0.33,19.74] 
CA 5.141 2.143 2.549 3.534 2.463 
 [0.52,50.83] [0.14,32.12] [0.16,41.66] [0.32,39.29] [0.15,39.61] 
CO 1.121 0.553 0.626 1.125  
 [0.26,4.89] [0.13,2.31] [0.14,2.76] [0.25,5.01]  
CT 2.733* 1.337 1.431 2.870** 1.468 
 [0.93,8.04] [0.49,3.62] [0.51,4.03] [1.00,8.20] [0.53,4.08] 
DC 2.035 1.696 1.341 2.212 2.438 
 [0.44,9.33] [0.40,7.15] [0.28,6.41] [0.55,8.90] [0.49,12.03] 
DE 1.472 0.714 0.705 1.666 0.883 
 [0.59,3.65] [0.29,1.76] [0.28,1.79] [0.79,3.53] [0.34,2.31] 
FL 3.797* 1.748 1.820 3.601* 2.049 
 [0.85,17.01] [0.35,8.74] [0.35,9.45] [0.79,16.51] [0.40,10.43] 
GA 0.611 0.275* 0.256* 0.649 0.383 
 [0.20,1.85] [0.07,1.14] [0.06,1.09] [0.25,1.70] [0.08,1.79] 
HI 1.662 1.604 1.750 1.214 1.732 
 [0.34,8.04] [0.36,7.15] [0.37,8.32] [0.28,5.17] [0.35,8.58] 
IA 0.128*** 0.139*** 0.128*** 0.168*** 0.125*** 
 [0.04,0.41] [0.05,0.41] [0.04,0.40] [0.06,0.48] [0.04,0.41] 
ID 0.729 0.740 0.717 0.839 0.681 
 [0.20,2.67] [0.21,2.63] [0.20,2.62] [0.24,2.94] [0.18,2.56] 
IL 0.828 0.394 0.406 0.835 0.453 
 [0.30,2.27] [0.13,1.23] [0.13,1.32] [0.31,2.22] [0.14,1.49] 





 [0.31,2.31] [0.27,0.74] [0.26,0.74] [0.43,2.47] [0.27,0.82] 
KS 0.356* 0.181*** 0.190*** 0.394* 0.192*** 
 [0.13,1.01] [0.08,0.39] [0.09,0.42] [0.15,1.06] [0.09,0.43] 
KY 1.725 0.948 0.928 2.282 0.992 
 [0.55,5.40] [0.70,1.28] [0.69,1.24] [0.84,6.20] [0.72,1.37] 
LA 1.126 0.529 0.474 1.329 0.729 
 [0.31,4.11] [0.13,2.23] [0.11,2.03] [0.43,4.09] [0.16,3.42] 
MA 2.890** 1.556 1.593 3.354*** 1.565 
 [1.14,7.34] [0.70,3.48] [0.69,3.65] [1.41,7.99] [0.69,3.57] 
MD 1.845 0.883 0.851 2.028  
 [0.70,4.89] [0.22,3.59] [0.20,3.58] [0.86,4.77]  
ME 1.450 0.851 0.875 2.061 0.807 
 [0.37,5.65] [0.64,1.13] [0.66,1.16] [0.59,7.14] [0.60,1.09] 
MI 0.735 0.391*** 0.376*** 0.928 0.428** 
 [0.28,1.92] [0.21,0.72] [0.20,0.69] [0.42,2.05] [0.22,0.82] 
MN 0.320** 0.179*** 0.186*** 0.404**  
 [0.13,0.78] [0.11,0.30] [0.11,0.32] [0.19,0.88]  
MO 0.419* 0.223*** 0.218*** 0.531 0.243*** 
 [0.15,1.13] [0.14,0.37] [0.13,0.36] [0.23,1.24] [0.14,0.42] 
MS 0.775 0.355 0.308 0.932 0.526 
 [0.16,3.79] [0.06,1.96] [0.05,1.74] [0.23,3.83] [0.08,3.29] 
MT 0.537 0.606 0.559 0.718 0.527 
 [0.18,1.58] [0.22,1.65] [0.19,1.61] [0.27,1.91] [0.17,1.61] 
NC 1.366 0.661 0.635 1.535 0.816 
 [0.56,3.35] [0.25,1.74] [0.24,1.71] [0.74,3.20] [0.29,2.32] 
ND 0.273*** 0.300*** 0.277*** 0.355** 0.268** 
 [0.10,0.73] [0.12,0.75] [0.11,0.73] [0.15,0.86] [0.10,0.74] 
NE 0.237*** 0.125*** 0.135*** 0.275**  
 [0.08,0.71] [0.06,0.25] [0.06,0.28] [0.10,0.77]  
NH 1.214 1.394 1.278 1.715 1.193 
 [0.34,4.34] [0.43,4.53] [0.37,4.44] [0.54,5.42] [0.32,4.44] 
NJ 2.967** 1.407 1.475 2.825* 1.605 
 [1.04,8.44] [0.35,5.70] [0.35,6.25] [0.98,8.17] [0.37,6.88] 







NV 2.198 0.966 1.127 1.799  
 [0.45,10.80] [0.14,6.53] [0.16,8.17] [0.34,9.60]  
NY 2.841** 1.373 1.406 2.828** 1.546 
 [1.06,7.62] [0.38,5.02] [0.37,5.34] [1.06,7.52] [0.41,5.90] 
OH 0.980 0.533** 0.512** 1.275 0.567** 
 [0.36,2.65] [0.31,0.91] [0.30,0.87] [0.56,2.93] [0.32,1.00] 
OR 1.229 1.275 1.227 1.419 1.174 
 [0.39,3.86] [0.42,3.88] [0.39,3.85] [0.47,4.29] [0.36,3.79] 
PA 1.676 0.914 0.893 2.115* 0.948 
 [0.63,4.49] [0.55,1.53] [0.53,1.50] [0.92,4.88] [0.56,1.61] 
RI 4.574** 4.725** 4.469** 5.304*** 4.347** 
 [1.28,16.30] [1.37,16.33] [1.25,15.98] [1.56,18.06] [1.18,16.07] 
SC 0.686 0.336* 0.308** 0.832 0.429 
 [0.22,2.17] [0.11,1.05] [0.10,0.98] [0.32,2.16] [0.13,1.46] 
SD 0.135*** 0.0765*** 0.0804*** 0.168***  
 [0.06,0.32] [0.05,0.13] [0.05,0.14] [0.08,0.37]  
TX 3.633 1.426 1.641 2.543 1.772 
 [0.34,38.74] [0.10,20.25] [0.11,25.00] [0.21,30.15] [0.12,26.72] 





 [0.31,3.36] [0.19,1.40] [0.19,1.61] [0.33,3.41] [0.18,1.53] 
VA 1.027 0.499 0.496 1.117 0.605 
 [0.49,2.16] [0.18,1.37] [0.18,1.40] [0.61,2.06] [0.20,1.80] 
VT 2.069 1.252 1.268 3.015* 1.126 
 [0.50,8.53] [0.86,1.82] [0.87,1.85] [0.83,11.01] [0.76,1.67] 
WA 1.356 1.369 1.329 1.464 1.309 
 [0.62,2.96] [0.64,2.95] [0.60,2.93] [0.69,3.13] [0.59,2.92] 
WI 0.573 0.313*** 0.314*** 0.712 0.315*** 
 [0.21,1.56] [0.20,0.50] [0.19,0.51] [0.29,1.74] [0.19,0.51] 
WV 1.744 1 1 2.441 1 
 [0.45,6.79] [1.00,1.00] [1.00,1.00] [0.72,8.27] [1.00,1.00] 
AL 1.305 0.629 0.578 1.584 0.837 
 [0.38,4.42] [0.20,1.99] [0.18,1.86] [0.56,4.48] [0.24,2.87] 
AR 0.622 0.313*** 0.304*** 0.736 0.368** 
 [0.23,1.68] [0.15,0.64] [0.15,0.63] [0.32,1.70] [0.17,0.80] 
AZ 2.904 2.574 2.657 2.503 2.568 
 [0.40,21.03] [0.33,19.96] [0.34,20.85] [0.32,19.68] [0.33,19.74] 
CA 5.141 2.143 2.549 3.534 2.463 
 [0.52,50.83] [0.14,32.12] [0.16,41.66] [0.32,39.29] [0.15,39.61] 
CO 1.121 0.553 0.626 1.125  
 [0.26,4.89] [0.13,2.31] [0.14,2.76] [0.25,5.01]  
CT 2.733* 1.337 1.431 2.870** 1.468 
 [0.93,8.04] [0.49,3.62] [0.51,4.03] [1.00,8.20] [0.53,4.08] 
DC 2.035 1.696 1.341 2.212 2.438 
 [0.44,9.33] [0.40,7.15] [0.28,6.41] [0.55,8.90] [0.49,12.03] 
DE 1.472 0.714 0.705 1.666 0.883 
 [0.59,3.65] [0.29,1.76] [0.28,1.79] [0.79,3.53] [0.34,2.31] 
FL 3.797* 1.748 1.820 3.601* 2.049 
 [0.85,17.01] [0.35,8.74] [0.35,9.45] [0.79,16.51] [0.40,10.43] 
GA 0.611 0.275* 0.256* 0.649 0.383 
 [0.20,1.85] [0.07,1.14] [0.06,1.09] [0.25,1.70] [0.08,1.79] 
HI 1.662 1.604 1.750 1.214 1.732 
 [0.34,8.04] [0.36,7.15] [0.37,8.32] [0.28,5.17] [0.35,8.58] 
IA 0.128*** 0.139*** 0.128*** 0.168*** 0.125*** 
 [0.04,0.41] [0.05,0.41] [0.04,0.40] [0.06,0.48] [0.04,0.41] 
ID 0.729 0.740 0.717 0.839 0.681 
 [0.20,2.67] [0.21,2.63] [0.20,2.62] [0.24,2.94] [0.18,2.56] 
Year      
2015 0 0 0 0 0 
 [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] [0.00,0.00] 
2016 1.113*** 1.117*** 1.119*** 1.115*** 1.113*** 
 [1.08,1.15] [1.08,1.15] [1.08,1.16] [1.08,1.15] [1.08,1.15] 
2017 1.236*** 1.246*** 1.248*** 1.239*** 1.237*** 
 [1.16,1.32] [1.17,1.33] [1.17,1.33] [1.16,1.32] [1.16,1.32] 
2018 1.452*** 1.481*** 1.479*** 1.468*** 1.449*** 
 [1.31,1.61] [1.34,1.64] [1.33,1.64] [1.32,1.63] [1.30,1.61] 
2019 1.729*** 1.780*** 1.774*** 1.758*** 1.719*** 
 [1.50,2.00] [1.53,2.07] [1.53,2.06] [1.52,2.03] [1.47,2.01] 
Constant 1.113*** 1.117*** 1.119*** 1.115*** 1.113*** 
 [1.08,1.15] [1.08,1.15] [1.08,1.16] [1.08,1.15] [1.08,1.15] 
Observations 960 960 960 960 840 
95% confidence intervals in brackets 







Appendix B Table 8. 
Scope of Practice (SOP) Specifications 
 2015 2016 2017 2018 2019 
Broad vs Narrow SOP 
  Broad. Full SOP     
  and transition  
  states <=18 month  
  transition 
(n=13) AK  AZ  
DC  HI  IA  ID  
MT  ND  NH  
NM  OR  RI  WA   
 
(n=15) AK  AZ  
CO  DC  HI  IA  
ID  MD  MT  ND  
NH  NM  OR  RI  
WA   
 
(n=17) AK  AZ  
CO  DC  HI  IA  
ID  MD  MN  MT  
ND  NE  NH  NM  
OR  RI  WA   
(n=19) AK  AZ  
CO  DC  HI  IA  
ID  MD  MN  MT  
ND  NE  NH  NM  
NV  OR  RI  SD  
WA   
(n=19) AK  AZ  
CO  DC  HI  IA  
ID  MD  MN  MT  
ND  NE  NH  NM  
NV  OR  RI  SD  
WA   
  Narrow.     
  Restricted SOP     
  and transition  
  states <=18 month  
  transition 
(n=35) AL  AR  
CA  CO  CT  DE  
FL  GA  IL  IN  
KS  KY  LA  MA  
MD  ME  MI  
MN  MO  MS  
NC  NE  NJ  NV  
NY  OH  PA  SC  
SD  TX  UT  VA  
VT  WI  WV   
(n=33) AL  AR  
CA  CT  DE  FL  
GA  IL  IN  KS  
KY  LA  MA  ME  
MI  MN  MO  MS  
NC  NE  NJ  NV  
NY  OH  PA  SC  
SD  TX  UT  VA  
VT  WI  WV   
(n=31) AL  AR  
CA  CT  DE  FL  
GA  IL  IN  KS  
KY  LA  MA  ME  
MI  MO  MS  NC  
NJ  NV  NY  OH  
PA  SC  SD  TX  
UT  VA  VT  WI  
WV   
(n=29) AL  AR  
CA  CT  DE  FL  
GA  IL  IN  KS  
KY  LA  MA  ME  
MI  MO  MS  NC  
NJ  NY  OH  PA  
SC  TX  UT  VA  
VT  WI  WV   
 
(n=29) AL  AR  
CA  CT  DE  FL  
GA  IL  IN  KS  
KY  LA  MA  ME  
MI  MO  MS  NC  
NJ  NY  OH  PA  
SC  TX  UT  VA  
VT  WI  WV   
 
Full | Reduced | Restricted 
  Full (n=13) AK  AZ  
DC  HI  IA  ID  
MT  ND  NH  
NM  OR  RI  WA   
(n=13) AK  AZ  
DC  HI  IA  ID  
MT  ND  NH  
NM  OR  RI  WA   
(n=13) AK  AZ  
DC  HI  IA  ID  
MT  ND  NH  
NM  OR  RI  WA   
(n=13) AK  AZ  
DC  HI  IA  ID  
MT  ND  NH  
NM  OR  RI  WA   
(n=13) AK  AZ  
DC  HI  IA  ID  
MT  ND  NH  NM  
OR  RI  WA   
  Reduced (n=6) CO  CT  
ME  MN  NV  
VT   
(n=9) CO  CT  
DE  MD  ME  
MN  NE  NV  VT 
(n=10) CO  CT  
DE  MD  ME  
MN  NE  NV  VT  
WV   
(n=11) CO  CT  
DE  MD  ME  
MN  NE  NV  SD  
VT  WV   
 
(n=13) CO  CT  
DE  IL  MD  ME  
MN  NE  NV  SD  
VA  VT  WV   
  Restricted (n=29) AL AR 
CA DE FL GA IL 
IN KS KY LA 
MA MD MI MO 
MS NC NE NJ 
NY OH PA SC 
SD TX UT VA 
WI WV 
(n=26) AL AR 
CA FL GA IL IN 
KS KY LA MA 
MI MO MS NC 
NJ NY OH PA 
SC SD TX UT 
VA WI WV 
 
(n=25) AL AR 
CA FL GA IL IN 
KS KY LA MA 
MI MO MS NC 
NJ NY OH PA 
SC SD TX UT 
VA WI  
 
(n=24) AL  AR  
CA  FL  GA  IL  
IN  KS  KY  LA  
MA  MI  MO  MS  
NC  NJ  NY  OH  
PA  SC  TX  UT  
VA  WI   
 
(n=22) AL  AR  
CA  FL  GA  IN  
KS  KY  LA  MA  
MI  MO  MS  NC  
NJ  NY  OH  PA  
SC  TX  UT  WI   
 
Full vs Reduced/Restricted 
  Full (n=13) AK  AZ  
DC  HI  IA  ID  
MT  ND  NH  
NM  OR  RI  WA   
(n=13) AK  AZ  
DC  HI  IA  ID  
MT  ND  NH  
NM  OR  RI  WA   
(n=13) AK  AZ  
DC  HI  IA  ID  
MT  ND  NH  
NM  OR  RI  WA   
(n=13) AK  AZ  
DC  HI  IA  ID  
MT  ND  NH  
NM  OR  RI  WA   
(n=13) AK  AZ  
DC  HI  IA  ID  
MT  ND  NH  NM  
OR  RI  WA   
   
Reduced/Restricted 
  
(n=35) AL  AR  
CA  CO  CT  DE  
FL  GA  IL  IN  
KS  KY  LA  MA  
MD  ME  MI  
MN  MO  MS  
NC  NE  NJ  NV  
NY  OH  PA  SC  
(n=35) AL  AR  
CA  CO  CT  DE  
FL  GA  IL  IN  
KS  KY  LA  MA  
MD  ME  MI  MN  
MO  MS  NC  NE  
NJ  NV  NY  OH  
PA  SC  SD  TX  
(n=35) AL  AR  
CA  CO  CT  DE  
FL  GA  IL  IN  
KS  KY  LA  MA  
MD  ME  MI  MN  
MO  MS  NC  NE  
NJ  NV  NY  OH  
PA  SC  SD  TX  
(n=35) AL  AR  
CA  CO  CT  DE  
FL  GA  IL  IN  
KS  KY  LA  MA  
MD  ME  MI  MN  
MO  MS  NC  NE  
NJ  NV  NY  OH  
PA  SC  SD  TX  
(n=35) AL  AR  
CA  CO  CT  DE  
FL  GA  IL  IN  KS  
KY  LA  MA  MD  
ME  MI  MN  MO  
MS  NC  NE  NJ  





SD  TX  UT  VA  




UT  VA  VT  WI  
WV   
UT  VA  VT  WI  
WV   
UT  VA  VT  WI  
WV   
SC  SD  TX  UT  
VA  VT  WI  WV   
Full/Reduced vs Restricted 
  Full/Reduced (n=19) AK  AZ  
CO  CT  DC  HI  
IA  ID  ME  MN  
MT  ND  NH  
NM  NV  OR  RI  
VT  WA 
(n=22) AK  AZ  
CO  CT  DC  DE  
HI  IA  ID  MD  
ME  MN  MT  
ND  NE  NH  NM  
NV  OR  RI  VT  
WA   
(n=23) AK  AZ  
CO  CT  DC  DE  
HI  IA  ID  MD  
ME  MN  MT  
ND  NE  NH  NM  
NV  OR  RI  VT  
WA  WV 
(n=24) AK  AZ  
CO  CT  DC  DE  
HI  IA  ID  MD  
ME  MN  MT  
ND  NE  NH  NM  
NV  OR  RI  SD  
VT  WA  WV   
(n=26) AK  AZ  
CO  CT  DC  DE  
HI  IA  ID  IL  MD  
ME  MN  MT  ND  
NE  NH  NM  NV  
OR  RI  SD  VA  
VT  WA  WV   
  Restricted (n=29) AL  AR  
CA  DE  FL  GA  
IL  IN  KS  KY  
LA  MA  MD  MI  
MO  MS  NC  NE  
NJ  NY  OH  PA  
SC  SD  TX  UT  
VA  WI  WV    
(n=26) AL  AR  
CA  FL  GA  IL  
IN  KS  KY  LA  
MA  MI  MO  MS  
NC  NJ  NY  OH  
PA  SC  SD  TX  
UT  VA  WI  WV 
(n=25) AL  AR  
CA  FL  GA  IL  
IN  KS  KY  LA  
MA  MI  MO  MS  
NC  NJ  NY  OH  
PA  SC  SD  TX  
UT  VA  WI    
 
(n=24) AL  AR  
CA  FL  GA  IL  
IN  KS  KY  LA  
MA  MI  MO  MS  
NC  NJ  NY  OH  
PA  SC  TX  UT  
VA  WI   
 
(n=22) AL  AR  
CA  FL  GA  IN  
KS  KY  LA  MA  
MI  MO  MS  NC  
NJ  NY  OH  PA  
































































Appendix C Table 2. Predicted probability of Treatment type, Full and MH Subsample, Multinomial 
Logistic Regression  
Full  MH Subsample 
 
No Treatmenta PCP Specialist  No Treatmenta PCP Specialist 
Low HILa 0.742 0.159 0.097  0.689 0.191 0.118 
High HIL 0.69 0.154 0.155**  0.629 0.187 0.182** 
        
Female 0.749 0.14 0.11  0.702 0.162* 0.135 
Malea 0.688 0.173 0.137  0.629 0.213 0.159 
        
Non-whitea 0.744 0.155 0.1  0.679 0.195 0.124 
White 0.654 0.165 0.179**  0.615 0.179 0.205** 
        
Unmarrieda 0.707 0.16 0.132  0.646 0.191 0.161 
Married 0.789 0.136 0.074*  0.764 0.17 0.064** 
        
21-35a 0.684 0.163 0.152  0.64 0.203 0.156 
36-50 0.734 0.166 0.098*  0.676 0.194 0.129 
51-64 0.719 0.144 0.135  0.657 0.177 0.164 
        
Less than HSa 0.694 0.154 0.15  0.643 0.192 0.164 
HS 0.723 0.18 0.096*  0.667 0.22 0.112 
More than HS 0.728 0.143 0.127  0.666 0.166 0.166 
        
Income, <$1500a 0.717 0.157 0.124  0.658 0.193 0.148 
Income, $1500+ 0.721 0.164 0.113  0.709 0.136 0.154 
        
Unemployeda 0.708 0.168 0.123  0.651 0.197 0.151 
Employed 0.743 0.127 0.129  0.694 0.164 0.14 
        
Insurance history 0.688 0.122 0.189  0.653 0.132 0.214 
No historya 0.724 0.167 0.108**  0.661 0.205 0.133 
    
 
   
 0 Chronic conda 0.732 0.17 0.097  0.665 0.192 0.141 
 1 Chronic cond 0.73 0.169 0.1  0.663 0.219 0.116 
 2 Chronic cond 0.71 0.153 0.135  0.659 0.183 0.157 
        
Not Incentivea 0.715 0.143 0.141  0.646 0.188 0.165 
Incentive 0.718 0.165 0.115  0.668 0.191 0.139 
        
Moderate/High 
MH 





        
No SUD Dxa 0.726 0.153 0.119  0.675 0.18 0.144 
SUD Dx 0.67 0.18 0.148  0.595 0.236 0.168 
        
No Previous MH 
Dxa 
0.873 0.067 0.059  0.861 0.065 0.073 
Previous MH Dx 0.597 0.229*** 0.172***  0.571 0.246*** 0.182*** 










































Appendix C, Table 3. Association between PROMIS and BH diagnosis or BH visit, full sample 
 BH Diagnosis in claims 
Depression 
BH Diagnosis in claims 
Anxiety 
PROMIS Depression 1.024**  
 (0.0123)  
PROMIS Anxiety  1.027** 
  (0.0128) 
Female 1.481** 1.460* 
 (0.286) (0.283) 
Race (ref=non-white) 1.815*** 1.680** 
 (0.380) (0.354) 
Married/Partnered 0.588 0.579 
 (0.199) (0.197) 
Age Group (ref=21-35)   
36-50 0.794 0.799 
 (0.208) (0.210) 
51-64 0.851 0.906 
 (0.230) (0.248) 
Education (Less than HS=Ref)   
High school 0.836 0.847 
 (0.206) (0.212) 
More than HS 0.850 0.851 
 (0.206) (0.204) 
Income, 1500+ (Ref=<$1500) 0.988 0.951 
 (0.453) (0.433) 
Employed 0.834 0.849 
 (0.192) (0.197) 
Any history of insurance 0.842 0.791 
 (0.203) (0.192) 
Chronic Conditions (ref = 0 conditions)   
1 1.041 1.105 
 (0.374) (0.403) 
2+ 1.092 1.166 
 (0.356) (0.383) 
MH symptom severity, moderate/mild 
(ref=severe) 
1.377 1.368 
 (0.372) (0.386) 
Self-Reported MH diagnosis 4.376*** 4.362*** 
 (1.025) (1.054) 
Self-Reported Alcohol diagnosis 1.347 1.349 
 (0.345) (0.353) 
Incentive group 0.976 0.968 
 (0.192) (0.190) 
Constant 0.0392*** 0.0325*** 
 (0.0294) (0.0242) 
   
Observations 714 711 
Robust standard error in parentheses 








Appendix C, Table 4: Specification to examine various HIL specifications in Unmet MH need outcome 
analyses, Logistic Regression 
 
 Full Sample MH Sample 
























HIL, binary (ref=less 
than 50th percentile) 
      
  High HIL 0.712*   0.642**   
 (0.143)   (0.141)   
       
HIL, thirds (ref= Lower 
third) 
      
   Middle Third  0.756   0.734  
  (0.179)   (0.189)  
   Top Third  0.572**   0.555**  
  (0.144)   (0.153)  
HIL, continuous   0.963**   0.960** 
   (0.0183)   (0.0199) 
Female 0.938 0.957 0.955 0.942 0.961 0.957 
 (0.195) (0.201) (0.200) (0.211) (0.217) (0.216) 
White (ref=non-white) 0.755 0.758 0.764 0.820 0.821 0.824 
 (0.170) (0.170) (0.172) (0.202) (0.200) (0.201) 
Married/Partnered 1.128 1.129 1.118 1.203 1.206 1.199 
 (0.359) (0.361) (0.357) (0.413) (0.417) (0.413) 
Age Group (ref=21-35)       
36-50 1.206 1.198 1.195 1.182 1.169 1.169 
 (0.328) (0.327) (0.324) (0.345) (0.344) (0.341) 
51-64 1.027 1.030 1.020 1.030 1.032 1.019 
 (0.279) (0.283) (0.278) (0.311) (0.315) (0.308) 
Education       
High School 0.536** 0.541** 0.556** 0.514** 0.519** 0.536** 
 (0.142) (0.144) (0.148) (0.145) (0.147) (0.152) 
More than HS 0.705 0.715 0.722 0.703 0.705 0.717 
 (0.168) (0.172) (0.174) (0.181) (0.183) (0.187) 
Income, 1500+ 
(ref=<$1500) 
0.652 0.631 0.636 0.568 0.523 0.538 
 (0.330) (0.329) (0.330) (0.347) (0.328) (0.336) 
Employed 0.864 0.873 0.869 0.825 0.845 0.839 
 (0.211) (0.214) (0.213) (0.223) (0.229) (0.227) 
Insurance history 0.974 0.969 0.967 0.876 0.859 0.862 
 (0.237) (0.237) (0.235) (0.230) (0.226) (0.226) 
Chronic conditions 
(ref=0) 
      
1 0.552* 0.556 0.555 0.498* 0.496* 0.497 
 (0.199) (0.201) (0.201) (0.211) (0.209) (0.211) 
2+ 0.627 0.635 0.638 0.543* 0.550 0.554 
 (0.194) (0.197) (0.199) (0.201) (0.205) (0.207) 
Incentive group 0.900 0.904 0.902 0.823 0.823 0.818 






symptoms  (ref=severe) 
2.033*** 1.980*** 2.020*** 1.743** 1.714** 1.740** 
 (0.446) (0.436) (0.443) (0.392) (0.385) (0.389) 
Hx drug/alcohol 1.102 1.081 1.081 1.131 1.108 1.103 
 (0.303) (0.300) (0.297) (0.320) (0.316) (0.310) 
Hx MH Dx 3.900*** 3.940*** 3.849*** 2.726*** 2.786*** 2.707*** 
 (0.923) (0.939) (0.918) (0.700) (0.721) (0.699) 
Constant 0.297*** 0.321*** 0.480 0.634 0.672 1.042 
 (0.122) (0.134) (0.238) (0.284) (0.305) (0.555) 
       
Observations 675 675 675 481 481 481 
Robust standard error in parentheses 





Appendix C, Table 5: Sensitivity tests of HIL specifications in BH utilization multinomial logistic regressions.    
 Full Sample MH Sample 
 HIL split at Median 
(primary specification) 
HIL split into top, 
middle, and bottom 
percentiles 
HIL specified as 
continuous 
HIL split at Median 
(primary specification) 
HIL split into top, 
middle, and bottom 
percentiles 
HIL specified as 
continuous 
HIL, binary 
(ref=less than 50th 
percentile) 
            
  High HIL 1.105 1.876**     1.141 1.822**     
 (0.254) (0.501)     (0.297) (0.527)     
HIL, thirds (ref= 
Lower third) 
            
   Middle Third   1.239 1.090     1.356 1.093   
   (0.329) (0.354)     (0.398) (0.380)   
   Top Third   1.054 1.719*     0.948 1.529   
   (0.304) (0.559)     (0.313) (0.540)   
HIL, continuous     1.015 1.038     1.018 1.028 
     (0.0218) (0.0283)     (0.0239) (0.0306) 
Female 1.425 1.460 1.434 1.426 1.413 1.436 1.570* 1.425 1.610* 1.400 1.556* 1.414 
 (0.316) (0.397) (0.322) (0.386) (0.314) (0.392) (0.390) (0.424) (0.408) (0.414) (0.388) (0.423) 
White (ref=non-
white) 
1.328 2.288*** 1.329 2.298*** 1.323 2.279*** 1.056 1.948** 1.042 1.985** 1.055 1.959** 
 (0.345) (0.597) (0.347) (0.595) (0.345) (0.591) (0.314) (0.559) (0.311) (0.566) (0.314) (0.561) 
Married/Partnered 0.692 0.445* 0.687 0.458* 0.688 0.461* 0.676 0.296** 0.673 0.305** 0.671 0.307** 
 (0.265) (0.206) (0.265) (0.213) (0.264) (0.213) (0.297) (0.161) (0.299) (0.166) (0.295) (0.165) 
Age Group 
(ref=21-35) 
            
36-50 0.918 0.560 0.921 0.585 0.911 0.587 0.885 0.755 0.877 0.783 0.873 0.791 
 (0.290) (0.199) (0.292) (0.206) (0.288) (0.208) (0.307) (0.295) (0.308) (0.305) (0.304) (0.309) 
51-64 0.820 0.811 0.822 0.827 0.815 0.842 0.846 1.013 0.854 1.026 0.837 1.060 
 (0.278) (0.277) (0.279) (0.281) (0.276) (0.289) (0.304) (0.400) (0.309) (0.403) (0.301) (0.418) 
Education             
High 
School 
1.055 0.580 1.039 0.604 1.037 0.581 1.057 0.637 1.029 0.670 1.036 0.647 
 (0.311) (0.195) (0.306) (0.200) (0.307) (0.193) (0.346) (0.237) (0.338) (0.247) (0.342) (0.238) 
More 
than HS 
0.852 0.773 0.860 0.816 0.838 0.817 0.787 0.954 0.801 1.024 0.774 1.020 







0.989 0.894 0.997 0.926 0.993 0.920 0.580 0.935 0.562 0.998 0.588 0.958 
 (0.509) (0.583) (0.513) (0.614) (0.510) (0.605) (0.385) (0.701) (0.373) (0.769) (0.388) (0.731) 
Employed 0.703 0.969 0.699 0.961 0.701 0.966 0.764 0.838 0.760 0.824 0.759 0.839 
 (0.199) (0.305) (0.196) (0.305) (0.198) (0.305) (0.258) (0.305) (0.253) (0.303) (0.255) (0.306) 
Insurance history 1.241 0.499** 1.231 0.520** 1.241 0.512** 1.537 0.593 1.530 0.613 1.539 0.608 
 (0.372) (0.153) (0.371) (0.157) (0.373) (0.157) (0.520) (0.202) (0.519) (0.206) (0.524) (0.205) 
Chronic 
conditions (ref=0) 
0.966 1.033 0.970 1.065 0.954 1.082 1.128 0.814 1.159 0.871 1.113 0.881 
1 (0.418) (0.526) (0.418) (0.545) (0.410) (0.552) (0.608) (0.476) (0.622) (0.514) (0.595) (0.519) 
 0.915 1.490 0.907 1.486 0.907 1.488 0.939 1.126 0.939 1.159 0.929 1.158 
 (0.348) (0.706) (0.347) (0.700) (0.345) (0.706) (0.440) (0.606) (0.444) (0.626) (0.435) (0.630) 
Incentive group 1.135 0.804 1.149 0.779 1.143 0.791 0.957 0.799 0.969 0.777 0.972 0.786 
 (0.275) (0.210) (0.279) (0.205) (0.276) (0.205) (0.256) (0.229) (0.260) (0.224) (0.260) (0.223) 
Moderate/Mild 
MH symptoms  
(ref=severe) 
1.932** 2.154*** 1.917** 2.217*** 1.948*** 2.145*** 1.927** 2.247*** 1.872** 2.260*** 1.942** 2.213*** 
 (0.495) (0.616) (0.491) (0.642) (0.498) (0.616) (0.522) (0.660) (0.507) (0.671) (0.526) (0.653) 
Hx drug/alcohol 1.338 1.445 1.364 1.418 1.353 1.453 1.585 1.420 1.642 1.387 1.608 1.422 
 (0.414) (0.484) (0.425) (0.477) (0.418) (0.493) (0.525) (0.513) (0.550) (0.504) (0.532) (0.521) 
Hx MH Dx 5.326*** 4.781*** 5.341*** 4.568*** 5.364*** 4.708*** 6.327*** 4.218*** 6.385*** 3.956*** 6.357*** 4.092*** 
 (1.585) (1.617) (1.590) (1.532) (1.606) (1.579) (2.475) (1.663) (2.498) (1.544) (2.502) (1.593) 
Constant 0.0480*** 0.0606*** 0.0456*** 0.0656*** 0.0396*** 0.0411*** 0.0376*** 0.0651*** 0.0355*** 0.0716*** 0.0300*** 0.0499*** 
 (0.0270) (0.0361) (0.0263) (0.0401) (0.0259) (0.0301) (0.0248) (0.0439) (0.0240) (0.0495) (0.0222) (0.0396) 
             
Observations 718 718 718 718 718 718 513 513 513 513 513 513 
Robust standard error in parentheses 














Appendix C, Table 6. Sensitivity tests exploring BH utilization outcomes as continuous. Poisson Regression.  
 Full Sample MH Subsample 
VARIABLES MH Outpatient 
Visits (no.) 










       
High HIL, baseline 1.090 1.192 0.910 1.073 1.192 0.875 
 (0.252) (0.333) (0.327) (0.263) (0.353) (0.328) 
Female 1.517 1.348 1.986* 1.633* 1.489 2.029* 
 (0.404) (0.459) (0.748) (0.458) (0.535) (0.819) 
White (ref=non-white) 1.021 0.899 1.341 1.006 0.855 1.397 
 (0.216) (0.211) (0.496) (0.223) (0.204) (0.554) 
Married/Partnered 0.740 0.919 0.460* 0.759 0.976 0.401* 
 (0.254) (0.383) (0.214) (0.281) (0.420) (0.212) 
Age Group (ref=21-35)       
   36-50 0.817 1.112 0.540 0.850 1.112 0.616 
 (0.236) (0.274) (0.320) (0.268) (0.292) (0.405) 
   51-64 1.069 1.345 0.858 1.165 1.475 0.922 
 (0.348) (0.428) (0.573) (0.407) (0.481) (0.669) 
Education (ref=less than HS)       
   High school 0.857 0.843 0.964 0.872 0.846 1.033 
 (0.240) (0.277) (0.367) (0.264) (0.302) (0.420) 
   More than HS 1.221 0.769 3.304*** 1.296 0.795 3.816*** 
 (0.349) (0.263) (1.490) (0.385) (0.279) (1.823) 
Income, 1500+ (ref=<$1500) 0.850 0.362** 2.136 0.744 0.215** 2.290 
 (0.437) (0.185) (1.517) (0.452) (0.143) (1.838) 
Employed 0.942 1.064 0.701 1.075 1.278 0.687 
 (0.300) (0.421) (0.345) (0.369) (0.524) (0.379) 
Insurance History 0.918 1.042 0.651 0.957 1.092 0.665 
 (0.293) (0.403) (0.366) (0.335) (0.460) (0.422) 
Chronic conditions (ref=0)       
 1.174 0.924 1.751 1.067 0.857 1.506 
   1 (0.416) (0.337) (1.164) (0.413) (0.352) (1.025) 
 1.383 1.177 1.763 1.257 1.101 1.520 
   2+ (0.439) (0.365) (1.185) (0.439) (0.363) (1.112) 
Incentive Group 1.613** 1.862** 1.307 1.642** 1.878** 1.335 
 (0.347) (0.480) (0.473) (0.372) (0.507) (0.493) 
Moderate/Mild MH symptoms (ref=severe) 1.406 1.173 2.053* 1.271 1.073 1.837 
 (0.332) (0.309) (0.806) (0.311) (0.291) (0.752) 





 (0.324) (0.376) (0.551) (0.343) (0.414) (0.539) 
Hx MH Dx 8.403*** 8.790*** 7.989*** 9.279*** 10.69*** 6.751*** 
 (2.648) (3.493) (3.405) (3.271) (4.827) (2.956) 
Constant 0.0995*** 0.0681*** 0.0199*** 0.0902*** 0.0544*** 0.0247*** 
 (0.0533) (0.0455) (0.0179) (0.0516) (0.0394) (0.0226) 
       
Observations 718 718 718 513 513 513 
Robust standard error in parentheses 







Appendix C, Table 7. Sensitivity test removing multiple imputation for Unmet MH needs 
analysis.  
Logistic Regression, listwise deletion 
 Full Sample Subsample 










Unmet MH  
Fully adjust 
       
High HIL 0.618*** 0.615** 0.722 0.575*** 0.564*** 0.632** 
 (0.115) (0.119) (0.147) (0.118) (0.122) (0.141) 
Female  1.284 0.975  1.153 0.974 
  (0.251) (0.205)  (0.246) (0.220) 
White (ref=non-white)  0.948 0.709  0.979 0.799 
  (0.207) (0.160)  (0.239) (0.198) 
Married/Partnered  1.119 1.169  1.275 1.246 
  (0.332) (0.373)  (0.427) (0.431) 
Age Group (ref=21-35)       
36-50  1.246 1.220  1.168 1.233 
  (0.318) (0.337)  (0.319) (0.366) 
51-64  0.867 1.084  0.905 1.096 
  (0.229) (0.299)  (0.257) (0.338) 
Education       
High School  0.531*** 0.529**  0.534** 0.510** 
  (0.127) (0.141)  (0.139) (0.144) 
More than HS  0.719 0.702  0.745 0.708 
  (0.164) (0.168)  (0.192) (0.184) 
Income, 1500+ 
(ref=<$1500) 
 0.530 0.655  0.524 0.567 
  (0.252) (0.333)  (0.300) (0.346) 
Employed  0.759 0.893  0.664 0.839 
  (0.172) (0.218)  (0.172) (0.228) 
Insurance history  1.073 0.929  0.904 0.852 
  (0.243) (0.228)  (0.226) (0.225) 
Chronic conditions 
(ref=0) 
      
1   0.580   0.499 
   (0.213)   (0.214) 
2+   0.627   0.505* 
   (0.198)   (0.189) 
Incentive group   0.877   0.806 
   (0.186)   (0.186) 
Moderate/Mild MH 
symptoms  (ref=severe) 
  2.041***   1.723** 
   (0.450)   (0.389) 
Hx drug/alcohol   1.072   1.090 
   (0.296)   (0.309) 
Hx MH Dx   4.014***   2.718*** 
   (0.966)   (0.704) 
Constant 0.377*** 0.465** 0.289*** 0.530*** 0.787 0.664 
 (0.0454) (0.144) (0.121) (0.0700) (0.266) (0.299) 
       








Appendix C, Table 8. Sensitivity test removing multiple imputation for BH utilization analysis.  
Logistic Regression, listwise deletion 













High HIL  1.109 1.866**  1.091 1.790** 
  (0.258) (0.499)  (0.288) (0.519) 
Female  1.510* 1.447  1.641** 1.402 
  (0.340) (0.395)  (0.413) (0.419) 
White (ref=non-white)  1.335 2.278***  1.112 1.968** 
  (0.352) (0.594)  (0.336) (0.565) 
Married/Partnered  0.721 0.447*  0.695 0.296** 
  (0.279) (0.208)  (0.310) (0.161) 
Age Group (ref=21-35)       
   36-50  0.786 0.538*  0.771 0.730 
  (0.249) (0.193)  (0.269) (0.291) 
   51-64  0.735 0.781  0.747 0.968 
  (0.252) (0.270)  (0.271) (0.387) 
Education       
   High School  1.080 0.577  1.088 0.634 
  (0.321) (0.194)  (0.358) (0.236) 
   More than HS  0.797 0.765  0.760 0.956 
  (0.234) (0.250)  (0.243) (0.340) 
Income, 1500+ (ref=<$1500)  1.049 0.893  0.612 0.927 
  (0.543) (0.583)  (0.407) (0.694) 
Employed  0.695 0.961  0.727 0.831 
  (0.202) (0.302)  (0.253) (0.301) 
Insurance history  1.295 0.506**  1.675 0.605 
  (0.395) (0.156)  (0.571) (0.207) 
Chronic conditions (ref=0)  1.152 1.043  1.313 0.823 
   1  (0.525) (0.535)  (0.734) (0.489) 
       
   2+  1.153 1.521  1.148 1.152 
  (0.460) (0.727)  (0.553) (0.628) 
Incentive group  1.155 0.793  0.982 0.789 
  (0.286) (0.208)  (0.269) (0.226) 
Moderate/Mild MH 
symptoms (ref=severe) 
 1.954** 2.129***  1.934** 2.210*** 
  (0.511) (0.609)  (0.534) (0.650) 
Hx drug/alcohol  1.454 1.493  1.713 1.459 
  (0.455) (0.500)  (0.574) (0.528) 
Hx MH Dx  5.164*** 4.775***  5.727*** 4.201*** 
  (1.555) (1.614)  (2.234) (1.660) 
Constant  0.0395*** 0.0627***  0.0329*** 0.0673*** 
  (0.0231) (0.0377)  (0.0221) (0.0457) 
Observations 710 710 710 507 507 507 
Robust se in parentheses 









Appendix C, Table 9. Sensitivity to examine potential endogeneity of HIL term.  
Bivariate Probit Regression 
 Unmet Need vs.  
No Unmet Need 
Any Treatment  
vs No Treatment 
Primary Care  
vs No Treatment 
Specialist  
vs. No Treatment 
VARIABLES (1) (2) (1) (2) (1) (2) (1) (2) 
         
High HIL, baseline -0.961  -0.328  -1.329**  -1.281***  
 (0.638)  (0.815)  (0.655)  (0.253)  
Female 0.0298 0.203 0.260** 0.163 0.353** 0.240* 0.209 0.148 
 (0.145) (0.125) (0.130) (0.122) (0.141) (0.131) (0.132) (0.132) 
White (ref=non-white) -0.0988 0.0955 0.238* 0.105 0.122 0.0977 0.309** 0.0529 
 (0.149) (0.142) (0.141) (0.135) (0.159) (0.155) (0.153) (0.150) 
Married/Partnered 0.138 0.0721 -0.384 0.104 -0.139 0.0723 -0.457* 0.0119 
 (0.200) (0.203) (0.238) (0.191) (0.256) (0.212) (0.255) (0.214) 
Age Group (ref=21-35)         
   36-50 0.195 0.195 -0.110 0.164 -0.108 0.0805 0.0166 0.0788 
 (0.171) (0.167) (0.184) (0.159) (0.218) (0.172) (0.192) (0.176) 
   51-64 0.116 0.166 -0.0644 0.129 -0.0840 0.123 0.0623 0.0115 
 (0.179) (0.172) (0.177) (0.167) (0.229) (0.181) (0.185) (0.182) 
Education (ref=less than HS)        
   High school -0.314* 0.167 -0.0594 0.202 0.203 0.206 -0.118 0.0909 
 (0.186) (0.156) (0.178) (0.152) (0.171) (0.163) (0.173) (0.168) 
   More than HS -0.0521 0.533*** 0.00323 0.555*** 0.165 0.540*** 0.315* 0.494*** 
 (0.216) (0.150) (0.249) (0.146) (0.267) (0.161) (0.173) (0.166) 
Income, 1500+ 
(ref=<$1500) 
-0.299 0.0237 -0.160 0.0168 -0.280 -0.123 -0.0396 0.106 
 (0.315) (0.271) (0.319) (0.262) (0.327) (0.270) (0.355) (0.293) 
Employed -0.141 -0.191 -0.186 -0.196 -0.205 -0.188 -0.232 -0.335** 
 (0.155) (0.146) (0.165) (0.141) (0.171) (0.154) (0.160) (0.150) 
Insurance History -0.0608 0.184 0.0463 0.212 0.383** 0.333** -0.142 0.0509 
 (0.161) (0.147) (0.171) (0.144) (0.164) (0.164) (0.165) (0.157) 
Chronic conditions 
(ref=0) 
        
   1 -0.201 0.716*** 0.155 0.704*** 0.487 0.583** 0.313 0.898*** 
 (0.331) (0.242) (0.334) (0.236) (0.309) (0.254) (0.283) (0.254) 
   2+ -0.319 0.258 0.103 0.235 0.224 0.175 0.219 0.388* 
 (0.241) (0.216) (0.244) (0.208) (0.266) (0.232) (0.235) (0.222) 
Incentive Group -0.131 -0.0682 -0.0822 -0.0798 -0.0372 -0.0668 -0.104 -0.0234 
 (0.131) (0.129) (0.130) (0.126) (0.138) (0.147) (0.132) (0.134) 
Moderate/Mild MH 
symptoms (ref=severe) 
0.243 -0.245* 0.406** -0.140 0.277 -0.0182 0.137 -0.262* 
 (0.166) (0.134) (0.163) (0.132) (0.208) (0.160) (0.160) (0.151) 
Hx Drug/Alcohol Dx 0.00842 -0.130 0.254 -0.105 0.146 -0.270 0.104 0.0706 
 (0.171) (0.166) (0.172) (0.164) (0.240) (0.211) (0.199) (0.203) 
Hx MH Dx 0.524*** -0.146 0.870*** -0.171 0.588 -0.224 0.418* -0.0868 
 (0.180) (0.139) (0.218) (0.136) (0.436) (0.143) (0.216) (0.153) 
Constant -.100 -0.769*** -
1.202*** 
-0.752*** -1.273 -0.806*** -0.616* -0.633** 
 (0.314) (0.279) (0.409) (0.271) (0.797) (0.288) (0.362) (0.309) 
Rho .430  
(.502) 
0.430 
0.317 0.845 0.935 
 (0.478) (0.419) (0.103) 
Wald test of rho=0 0.381 0.712 4.27** 
Observations 475 475 507 507 431 431 412 412 





Appendix C, Table 10. Behavioral Health ICD-9 and ICD-10 codes 
Code ICD-9 ICD-10 
Depression "29620", "29621", "29622","29623", 
"29624", "29625", "29626", 29630", 
“29631", "29632","29633","29634", 
"29635", "29636", "29651","29652", 
"29653", "29654", "29655","29656", 
"29660", "29661", "29662","29663", 
"29664", "29665", "29666", 29689", "2980", 
"3004", "3091", "311" 
"F3130", "F3131", "F3132", "F314", "F315", "F3160", 
"F3161", "F3162", "F3163", "F3164", "F3175", "F3176", 
"F3177", "F3178", "F3181", "F320", "F321", "F322", "F323", 
"F324", "F325", "F329", "F330", "F331", "F332", "F333", 
"F3340", "F3341",  "F3342", "F338", "F339", "F341", "F4321", 
"F4323" 
Anxiety "29384", "30000", "30001","30002", 
"30009", "30010", "30020", 30021", 
"30022", "30023", "30029", "3003", "3005", 
"30089", "3009", "3080", "3081", "3082", 
"3083", "3084", "3089", "30981", "3130", 
"3131", "31321", "31322", "3133", "31382", 
"31383" 
"F064", "F4000", "F4001", "F4002", "F4010", "F4011", 
"F40210", "F40218", "F40220", "F40228", "F40230", 
"F40231", "F40232", "F40233", "F40240", "F40241", 
"F40242", "F40243", "F40248", "F40290", "F40291", 
"F40298", "F408", "F409", "F410", "F411", "F413", "F418", 
"F419", "F42", "F422", "F423", "F424", "F428", "F429", 
"F430", "F4310", "F4311", "F4312", "F449", "F458", "F488", 
"F489", "F938", "F99", "R452", "R455", "R456", "R457" 
ADHD "31200", "31201", "31202","31203", 
"31210", "31211", "31212","31213", 
"31220", "31221", "31222","31223", 
"31230", "31231", "31232","31233", 
"31234", "31235", "31239", "3124", 
"31281", "31282", "31289", "3129", 
"31400", "31401", "3141", "3142", "3148", 
"3149" 
"F630", "F631", "F632", "F633", "F6381", "F6389", "F639", 
"F900", "F901", "F902", "F908", "F909", "F910", "F911", 
"F913", "F912", "F918", "F919" 
Bipolar "29600", "29601", "29602","29603", 
"29604", "29605", "29606","29610", 
"29611", "29612", "29613","29614", 
"29615", "29616", "29640","29641", 
"29642", "29643", "29644","29645", 
"29646", "29650", "29651","29652", 
"29653", "29654", "29655","29656", 
"29660", "29661", "29662","29663", 
"29664", "29665", "29666", "2967", 
"29680", "29681", "29682","29689", 
"29690", "29699" 
"F3010", "F3011", "F3012", "F3013", "F302", "F303", "F304", 
"F308", "F309", "F310", "F3110", "F3111", "F3112", "F3113", 
"F312", "F3130", "F3131", "F3132", "F314", "F315", "F3160", 
"F3161", "F3162", "F3163", "F3164", "F3170", "F3171", 
"F3172", "F3173", "F3174", "F3175", "F3176", "F3177", 
"F3178", "F3181", "F3189", "F319", "F338", "F3481", 
"F3489", "F349", "F39" 
Personality 
Disorders 
"3010", "30110", "30111", "30112", 
"30113", "30120", "30121","30122", "3013", 
"3014", "30150", "30151", "30159", "3016", 
"3017", "30181", "30182", "30183", 
"30184", "30189", "3019" 
"F21", "F340", "F341", "F600", "F601", "F602", "F603", 
"F604", "F605", "F606", "F607", "F6081", "F6089", "F609", 





"30981" "F4310", "F4311", "F4312" 
Schizophrenia "29381", "29382", "29500","29501", 
"29502", "29503", "29504","29505", 
"29510", "29511", "29512","29513", 
"29514","29515","29520","29521","29522", 
"29523", "29524","29525","29530","29531" 
"F060", "F062", "F200", "F201", "F202", "F203", "F205", 
"F2081", "F2089", "F209", "F21", "F22", "F23", "F24", "F250", 






, "29532", "29533", "29534", "29535", 
"29540", "29541", "29542", "29543", 
"29544", "29545", "29550", "29551", 
"29552", "29553", "29554", "29555", 
"29560", "29561", "29562", "29563", 
"29564", "29565", "29570", "29571", 
"29572", "29573", "29574", "29575", 
"29580", "29581", "29582", "29583", 
"29584", "29585", "29590", "29591", 
"29592", "29593", "29594", "29595", 
"2970", "2971", "2972", "2973", "2978", 
"2979", "2980", "2981", "2982", "2983", 
"2984", "2988", "2989" 
Other "30011", "30012", "30013", "30014", 
"30015", "30016", "30019", "3004", "3006", 
"3007","30081", "30082", "30270", "30271", 
"3090", "30924", "30928", "30929", "3093", 
"3094", "30982", "30983", "30989", "3099", 
"29700", "3071", "30750", "30751" 
"F348", "O906", "F5000", "F5001", "F5002", "F502", "F508", 
"F5081", "F5089", "F509", "F9821", "F9829", "F983", 
"F4521", "F4522", "R4681", "F070", "F688","F061", "F444", 
"F445", "F446", "F447", "F450", "F451", "F4520", "F4529", 
"F4541", "F4542", "F458", "F459", "F54", "F430", "F4310", 
"F4320", "F4321","F4322", "F4323", "F4324", "F4325", 
"F4329", "F348", "F439", "F440", "F441", "F442", "F4481", 
"F4489", "F449", "F941", "F942", "F068", "F09", "F481", 
"F488", "F489", "F939", "F99", "O99340", "O99341", 
"O99342", "O99343", "O99344", "O99345", "R45850", 
"F6810" 
Self-Injury "V6284", "E9500", "E9501", "E9502", 
"E9503", "E9504", "E9505", "E9506", 
"E9507", "E9508", "E9509",  
"E9510","E9511", "E9518", "E9520", 
"E9521", "E9528", "E9529","E9530", 
"E9530", "E9531", "E9538","E9539", 
"E954","E9550", "E9552", "E9554", "E9555", 
"E9556", "E9559","E956", "E9570", "E9571",  
"E9572", "E9579", "E9580", "E9581", 
"E9582", "E9583", "E9584", "E9585", 
"E9587", "E9588", "E9589" 
"R45851", "T1491", "T360X2A", "T361X2A", "T362X2A", 
"T363X2A", "T364X2A", "T365X2A", "T366X2A", "T367X2A", 
"T368X2A", "T3692XA", "T370X2A", "T371X2A", "T372X2A", 
"T373X2A", "T374X2A", "T375X2A", "T378X2A", "T3792XA", 
"T380X2A", "T381X2A", "T382X2A", "T383X2A", "T384X2A", 
"T385X2A", "T386X2A", "T387X2A", "T38802A", "T38812A", 
"T38892A", "T38902A", "T38992A", "T39012A", "T39092A", 
"T391X2A", "T392X2A", "T39312A", "T39392A", "T394X2A", 
"T398X2A", "T3992XA", "T400X2A", "T401X2A", "T402X2A", 
"T403X2A", "T404X2A", "T405X2A", "T40602A", "T40692A", 
"T407X2A", "T408X2A", "T40902A", "T40992A", "T410X2A", 
"T411X2A", "T41202A", "T41292A", "T413X2A", "T4142XA", 
"T415X2A", "T420X2A", "T421X2A", "T422X2A", "T423X2A", 
"T424X2A", "T425X2A", "T426X2A", "T4272XA", "T428X2A", 
"T43012A", "T43022A", "T431X2A", "T43202A", "T43212A", 
"T43222A", "T43292A", "T433X2A", "T434X2A", "T43502A", 
"T43592A", "T43602A", "T43612A", "T43622A", "T43632A", 
"T43692A", "T438X2A", "T4392XA", "T440X2A", "T441X2A", 
"T442X2A", "T443X2A", "T444X2A", "T445X2A", "T446X2A", 
"T447X2A", "T448X2A", "T44902A", "T44992A", "T450X2A", 
"T451X2A", "T452X2A", "T453X2A", "T454X2A", "T45512A", 
"T45522A", "T45602A", "T45612A", "T45622A", "T45692A", 
"T457X2A", "T458X2A", "T4592XA", "T460X2A", "T461X2A", 
"T462X2A", "T463X2A", "T464X2A", "T465X2A", "T466X2A", 
"T467X2A", "T468X2A", "T46902A", "T46992A", "T470X2A", 
"T471X2A", "T472X2A", "T473X2A", "T474X2A", "T475X2A", 





"T481X2A", "T48202A", "T48292A", "T483X2A", "T484X2A", 
"T485X2A", "T486X2A", "T48902A", "T48992A", "T490X2A", 
"T491X2A", "T492X2A", "T493X2A", "T494X2A", "T495X2A", 
"T496X2A", "T497X2A", "T498X2A", "T4992XA", "T500X2A", 
"T501X2A", "T502X2A", "T503X2A", "T504X2A", "T505X2A", 
"T506X2A", "T507X2A", "T508X2A", "T50902A", "T50992A", 
"T50A12A", "T50A22A", "T50A92A", "T50B12A", "T50B92A", 
"T50Z12A", "T50Z92A", "T510X2A", "T511X2A", "T512X2A", 
"T513X2A", "T518X2A", "T5192XA", "T520X2A", "T521X2A", 
"T522X2A", "T523X2A", "T524X2A", "T528X2A", "T5292XA", 
"T530X2A", "T531X2A", "T532X2A", "T533X2A", "T534X2A", 
"T535X2A", "T536X2A", "T537X2A", "T5392XA", "T540X2A", 
"T541X2A", "T542X2A", "T543X2A", "T5492XA", "T550X2A", 
"T551X2A", "T560X2A", "T561X2A", "T562X2A", "T563X2A", 
"T564X2A", "T565X2A", "T566X2A", "T567X2A", "T56812A", 
"T56892A", "T5692XA", "T570X2A", "T571X2A", "T572X2A", 
"T573X2A", "T578X2A", "T5792XA", "T5802XA", "T5812XA", 
"T582X2A", "T588X2A", "T5892XA", "T590X2A", "T591X2A", 
"T592X2A", "T593X2A", "T594X2A", "T595X2A", "T596X2A", 
"T597X2A", "T59812A", "T59892A", "T5992XA", "T600X2A", 
"T601X2A", "T602X2A", "T603X2A", "T604X2A", "T608X2A", 
"T6092XA", "T6102XA", "T6112XA", “T61772A", "T61782A", 
"T618X2A", "T6192XA", "T620X2A", "T621X2A", "T622X2A", 
"T628X2A", "T6292XA", "T63002A", "T63012A", "T63022A", 
"T63032A", "T63042A", "T63062A", "T63072A", "T63082A", 
"T63092A", "T63112A", "T63122A", "T63192A", "T632X2A", 
"T63302A", "T63312A", "T63322A", "T63332A", "T63392A", 
"T63412A", "T63422A", "T63432A", "T63442A", "T63452A", 
"T63462A", "T63482A", "T63512A", "T63592A", "T63612A", 
"T63622A", "T63632A", "T63692A", "T63712A", "T63792A", 
"T63812A", "T63822A", "T63832A", "T63892A", "T6392XA", 
"T6402XA", "T6482XA", "T650X2A", "T651X2A", "T65212A", 
"T65222A", "T65292A", "T653X2A", "T654X2A", "T655X2A", 
"T656X2A", "T65812A", "T65822A", "T65832A", "T65892A", 
"T6592XA", “T71112A", "T71122A", "T71132A", "T71152A", 
"T71162A", "T71192A", "T71222A", "T71232A", "X710XXA", 
"X711XXA", "X712XXA", "X713XXA", "X718XXA", "X719XXA", 
"X72XXXA", "X730XXA", "X731XXA", "X732XXA", "X738XXA", 
"X739XXA", "X7401XA", "X7402XA", "X7409XA", "X748XXA", 
"X749XXA", "X75XXXA", "X76XXXA", "X770XXA", "X771XXA", 
"X772XXA", "X773XXA", "X778XXA", "X779XXA", "X780XXA", 
"X781XXA", "X782XXA", "X788XXA", "X789XXA", "X79XXXA", 
"X80XXXA", "X810XXA", "X811XXA", "X818XXA", "X820XXA", 
"X821XXA", "X822XXA", "X828XXA", "X830XXA", "X831XXA", 
"X832XXA", "X838XXA" 
SUD "291.0", "291.1", "291.2", "291.3", "291.4", 
"291.5", "291.81", "291.82", "291.89", 
"291.9", "303.0", "303.01", "303.02", 
"303.03", "303.90", "303.91", "303.92", 
"303.93", "305.00", "305.01", "305.02", 
"305.03", "790.3", "980.0", "980.9", "292.0", 
"F1010", "F10120", "F10121", "F10129", "F1014", "F10150", 
"F10151", "F10159", "F10180", "F10181", "F10182", 
"F10188", "F1019", "F1020", "F10220", "F10221", "F10229", 
"F10230", "F10231", "F10232", "F10239", "F1024", "F10250", 
"F10251", "F10259", "F1026", "F1027", "F10280", "F10281", 





"292.11", "292.12", "292.2", "292.81", 
"292.82", "292.83", "292.84", "292.85", 
"292.89", "292.9", "304.0", "304.01", 
"304.02", "304.03", "304.10", "304.11", 
"304.12", "304.13", "304.20", "304.21", 
"304.22", "304.23", "304.30", "304.31", 
"304.32", "304.40", "304.41", "304.42", 
"304.43", "304.50", "304.51", "304.60", 
"304.61", "304.62", "304.63", "304.70",  
"304.71", "304.72", "304.73", "304.80", 
"304.81", "304.82", "304.83", "304.90", 
"304.91", "304.92", "304.93", "305.20", 
"305.21", "305.22", "305.23", "305.30", 
"305.31", "305.32", "305.40", "305.41",  
"305.42", "305.43", "305.50", "305.51", 
"305.52", "305.53", "305.60", "305.61", 
"305.62", "305.63", "305.70", "305.71", 
"305.72", "305.73", "305.80", "305.81", 
"305.82", "305.90", "305.91", "305.92",  
"305.93", "965.00", "965.01", "965.02", 
"965.09", "968.2", "968.3", "968.4", "969.4", 
"969.6", "969.72", "969.73", "967.0", 
"970.81", "975.4", "981", "V65.42", "E850.0 
"E850.1", "E850.2", "E850.8", "E851",  
"E852.0", "E852.1", "E852.2", "E852.3", 
"E852.4", "E852.5", "E852.8", "E852.9", 
"E853.0", "E853.1", "E853.2", "E853.8", 
"E853.9", "E854.1", "E854.2", "E854.3", 
"E855.1", "E858.0", "E858.6", "E860.0", 
"E860.1", "E860.9", "E862.0", "E862.1", 
"E862.4", "E862.9" 
"F1094", "F10950", "F10951", "F10959", "F1096", "F1097", 
"F10980", "F10981", "F10982", "F10988", "F1099", "G621", 
"I426", "K2920", "K2921", "K700", "K7010", "K7011", "K702", 
"K7030", "K7031", "K7040", "K7041", "K709", "O354XX0", 
"O354XX1", "O354XX2", "O354XX3", "O354XX4", "O354XX5", 
"O354XX9", "O99310", "O99311", "O99312", "O99313", 
"O99314", "O99315", "F1210", "F12120", "F12121", 
"F12122", "F12129", "F12150", "F12151", "F12159", 
"F12180", "F12188", "F1219", "F1220", "F12220", "F12221", 
"F12222", "F12229", "F12250", "F12251", "F12259", 
"F12280", "F12288", "F1229", "F1290", "F12920", "F12921", 
"F12922", "F12929", "F12950", "F12951", "F12959", 
"F12980", "F12988", "F1299", "T407X1A", "T407X3A", 
"T407X4A", "T407X5A", "F1110", "F11120", "F11121", 
"F11122", "F11129", "F1114", "F11150", "F11151", "F11159", 
"F11181", "F11182", "F11188", "F1119", "F1120", "F11220", 
"F11221", "F11222", "F11229", "F1123", "F1124", "F11250", 
"F11251", "F11259", "F11281", "F11282", "F11288", "F1129", 
"F1190", "F11920", "F11921", "F11922", "F11929", "F1193", 
"F1194", "F11950", "F11951", "F11959", "F11981", "F11982", 
"F11988", "F1199", "T400X1A", "T400X3A", "T400X4A", 
"T400X5A", "T401X1A", "T401X3A", "T401X4A", "T402X1A", 
"T402X3A", "T402X4A", "T402X5A", "T403X1A", "T403X3A", 
"T403X4A", "T403X5A", "T404X1A", "T404X3A", "T404X4A", 
"T404X5A", "T40601A", "T40603A", "T40604A", "T40605A", 
"T40691A", "T40693A", "T40694A", "T40695A", "F1310", 
"F13120", "F13121", "F13129", "F1314", "F13150", "F13151", 
"F13159", "F13180", "F13181", "F13182", "F13188", "F1319", 
"F1320", "F13220", "F13221", "F13229", "F13230", "F13231", 
"F13232", "F13239", "F1324", "F13250", "F13251", "F13259", 
"F1326", "F1327", "F13280", "F13281", "F13282", "F13288", 
"F1329", "F1390", "F13920", "F13921", "F13929", "F13930", 
"F13931", "F13932", "F13939", "F1394", "F13950", "F13951", 
"F13959", "F1396", "F1397", "F13980", "F13981", "F13982", 
"F13988", "F1399", "F1410", "F14120", "F14121", "F14122", 
"F14129", "F1414", "F14150", "F14151", "F14159", "F14180", 
"F14181", "F14182", "F14188", "F1419", "F1420", "F14220", 
"F14221", "F14222", "F14229", "F1423", "F1424", "F14250", 
"F14251", "F14259", "F14280", "F14281", "F14282", 
"F14288", "F1429", "F1490", "F14920", "F14921", "F14922", 
"F14929", "F1494", "F14950", "F14951", "F14959", "F14980", 
"F14981", "F14982", "F14988", "F1499", "F1510", "F15120", 
"F15121", "F15122", "F15129", "F1514", "F15150", "F15151", 
"F15159", "F15180", "F15181", "F15182", "F15188", "F1519", 
"F1520", "F15220", "F15221", "F15222", "F15229", "F1523", 
"F1524", "F15250", "F15251", "F15259", "F15280", "F15281", 
"F15282", "F15288", "F1529", F1590", "F15920", "F15921", 
"F15922", "F15929", "F1593", "F1594", "F15950", "F15951", 
"F15959", "F15980", "F15981", "F15982", "F15988", "F1599", 
"T405X1A", "T405X3A", "T405X4A", "T405X5A", "T43601A", 





"T43624A", "T43625A", "T43631A", "T43633A", "T43634A", 
"T43635A", "T43691A", "T43693A", "T43694A", "T43695A", 
"F1610", "F16120", "F16121", "F16122", "F16129", "F1614", 
"F16150", "F16151", "F16159", "F16180", "F16183", 
"F16188", "F1619", "F1620", "F16220", "F16221", "F16229", 
"F1624", "F16250", "F16251", "F16259", "F16280", "F16283", 
"F16288", "F1629", "F1690", "F16920", "F16921", "F16929", 
"F1694", "F16950", "F16951", "F16959", "F16980", "F16983", 
"F16988", "F1699", "F1810", "F18120", "F18121", "F18129", 
"F1814", "F18150", "F18151", "F18159", "F1817", "F18180", 
"F18188", "F1819", "F1820", "F18220", "F18221", "F18229", 
"F1824", "F18250", "F18251", "F18259", "F1827", "F18280", 
"F18288", "F1829", "F1890", "F18920", "F18921", "F18929", 
"F1894", "F18950", "F18951", "F18959", "F1897",  
"F18980", "F18988", "F1899", "F1910", "F19120", "F19121", 
"F19122", "F19129", "F1914", "F19150", "F19151", "F19159", 
"F1916", "F1917", "F19180", "F19181", "F19182", "F19188", 
"F1919", "F1920", "F19220", "F19221", "F19222", "F19229", 
"F19230", "F19231", "F19232", "F19239", "F1924", "F19250", 
"F19251", "F19259", "F1926", "F1927", "F19280", "F19281", 
"F19282", "F19288", "F1929", "F1990", "F19920", "F19921", 
"F19922", "F19929", "F19930", "F19931", "F19932", 
"F19939", "F1994", "F19950", "F19951", "F19959", "F1996", 
"F1997", "F19980", "F19981", "F19982", "F19988", "F1999", 
"F550", "F551", "F552", "F553", "F554", "F558", "F630", 
"O355XX0", "O355XX1", "O355XX2", "O355XX3", "O355XX4", 
"O355XX5", "O355XX9", "O99320", "O99321", "O99322", 
"O99323", "O99324", "O99325", "T408X1A", "T408X3A", 
"T408X4A", "T40901A", "T40903A", "T40904A", "T40905A", 




























Heather (Guiffre) Saunders 
Richmond, VA 




• Skills: Quasi-experimental research methods; Insurance claims analysis; Survey design; Survey 
analysis; Qualitative design and data collection; Qualitative analysis; IRB; Program evaluation; 
Discrete choice experiments 
 
• Data Types: Healthcare claims—medical claims, prescription, enrollment (Medicaid; Virginia 
Coordinated Care; Medical Expenditure Panel); Healthcare claims linked to primary surveys and 
public data sources; National, state, and local surveys; Randomized controlled trial; National and state 
registries; National drug reporting systems; Qualitative 
 
• Computer skills: STATA, SAS and SAS Enterprise (working), Excel, NVivo 
 
• Management skills: Program management; Staff management; Regulatory affairs 
 
Education 
Virginia Commonwealth University, Healthcare Policy and Research, Doctor of Philosophy (2016-
2021, anticipated) 
• Dissertation: Access to Behavioral Health Services: Workforce, Coverage, and Health Insurance 
Literacy 
• Relevant coursework: Health Economics, Econometrics I, Econometrics II, Economic 
Evaluation and Decision Analysis, Panel and Nonlinear Methods, Statistical Methods, Survey 
Research Methods, Health Services Research and Policy I & II, Economics of Health Disparities, 
Program Evaluation 
 
Virginia Commonwealth University, Master of Social Work, clinical concentration (2010-2012)  
 
Christopher Newport University, Bachelor of Psychology (2002-2007) 
 
 
Publications in Peer Reviewed Journals 
1. Saunders, H., Britton, E., Cunningham, P., Walker, L., Harrell, A., Scialli, A., & Lowe, J. (2021, 
In Press). Medicaid participation among practitioners authorized to prescribe buprenorphine. 
Journal of Substance Abuse Treatment. 
 
2. Bradley, C & Saunders, H. (2021, In Press). Impact of cash incentives for low-income  
individuals to seek a primary care visit on mental health outcomes: evidence from a randomized 
controlled trial. Social Science and Medicine.   
 
3. Cartwright, K. B., Bock, A. M., Clause, J. H., Coppage August, E. A., Saunders, H., & Schmidt, 
K. J. (2020). Near-and far-transfer effects of an executive function intervention for 2nd to 5th-
grade struggling readers. Cognitive Development. 
 
4. Mason, M., Light, J., Campbell, L., Keyser-Marcus, L., Crewe, S., Way, T., Saunders, H., King, 
L., Zaharakis, N., & McHenry, C. (2015). Peer Network Counseling with Urban Adolescents: A 
Randomized Controlled Trial with Moderate Substance Users. Journal of Substance Abuse 






5. Lynn, L. & Guiffre, H. (2009). Computer science outreach in an elementary school. Journal of 
Computing Sciences in Colleges, 24, 118-124. 
 
Publications Submitted or in Preparation 
1. Marks, S., Saunders, H., Shadowden, H., Cunningham, P. Substantial Coverage Gaps and 
Inequities in Voluntary Medicaid Managed Care Coverage of Dental, Vision, and Hearing 
Services.   
 
2. Salehian S., Saunders, H., Cunningham, P. Health Plan switching in a Medicaid managed long-
term services and supports (MLTSS) program.  
 
3. Saunders, H., Marks, S., Shadowden, H., Walker, L., Cunningham, P. Unmet social needs in 
Medicaid Managed Long-Term Services and Supports (MLTSS).   
 
4. Saunders, H., Cunningham, P. Bradley, C., Barnes, A., Moeller, G. The impact of CARA and 
nurse practitioner scope-of-practice laws on access to medications for opioid use disorders.  
 
5. Saunders, H., Barnes, A., Cunningham, P., Moeller, G., Bradley, C., Health insurance literacy in 
low-income individuals and subsequent mental health utilization.  
 
6. Saunders, H., & Cunningham, P., Mellor, J., Mittler, J., & Walker, L. Are member experiences 





1. Saunders, H., Cunningham, P., Mellor, J., Britton, E., Guerra, L., Salehian, S., Marks, S., 
Shadowen, H., Mittler, J., & Barnes, A. (2021). Commonwealth Coordinated Care 
Comprehensive Report (2017-2020). Delivered to Virginia Medicaid.  
 
2. Cunningham, P., Mueller, M., Britton, E., Pham, H., Guerra, L., Saunders, H., Zhao, X., Barnes, 
A., & Dihwa, V. (2021).  Addiction and Recovery Treatment Services. Access, Utilization, and 
Quality of Care 2016-2019. Delivered to Virginia Medicaid and published online.  
 
3. Marks, S., Saunders, H., Cunningham, P. (2020). Unmet Health and LTSS Needs among 
members enrolled in Commonwealth Coordinated Care Plus. Delivered to Virginia Medicaid 
 
4. Mellor, J., Saunders, H. Commonwealth Coordinated Care Plus Evaluation Design. Delivered to 
Virginia Medicaid.   
 
5. Salehian, S. Saunders, H., Guerra, L., Cunningham. Survey of caregivers of members enrolled in  
Commonwealth Coordinated Care Plus (2020). Delivered to Virginia Medicaid. 
 
6. Saunders, H. & Cunningham, P. (2019). Member experiences with care coordinators and 
subsequent utilization. Delivered to Virginia Medicaid.  
 
7. Saunders, H., Snell, L., Mittler, J., Guerra, L., & Cunningham, P. (2019). Key Facts about Care  
Coordinators serving in the Commonwealth Coordinated Care Plus Members. An Evaluation 
Report of the Commonwealth Coordinated Care Plus Program Prepared for the Virginia 
Department of Medical Assistance Services. 
 
8. Saunders, H., Cunningham, P., Guerra, L., Britton, E., & Barnes, A. (2019). Commonwealth  
Coordinated Care Plus. Survey of Member Experiences with Care Coordination and Health Plans. 
An Evaluation Report of the Commonwealth Coordinated Care Plus Program Prepared for the 






9. Mittler, J., Saunders, H., Snell, M. (2019). Understanding MLTSS Care Coordination in 
Virginia’s CCC Plus Program: The view from the care coordinator. An Evaluation Report of the 
Commonwealth Coordinated Care Plus Program Prepared for the Virginia Department of Medical 
Assistance Services 
 
10. Saunders, H., Walker, L., & Cunningham, P. (2019). Number of Buprenorphine Prescribers Have  
Increased Since ARTS. Delivered to Virginia Medicaid. 
 
11. Barnes, A., Snell, M., Guerra, L., Mueller, M., Pham, H., Britton, E., Saunders, H., Brooks, M., 
Krist, A., & Cunningham, P. (2019). Experiences Prior to Enrollment in Medicaid. New Medicaid 
Expansion Members Describe Health and Healthcare experiences from the Year before Enrolling. 
A report delivered to Virginia Medicaid and published online.  
 
12. Cunningham, P., Barnes, A., Sheng, Y., Walker, L., Saunders, H., Brooks, M., & Tong, S. 
(2018). Addiction and Recovery Treatment Services. Access and Utilization during the First Year 
(April 2017 to March 2018). An Evaluation Report Prepared for the Virginia Department of 
Medical Assistance Services. Delivered to Virginia Medicaid. 
 
13. Brooks, M., Tong, S., Walker, L., Saunders, H., Sheng, F., Barnes, A., & Cunningham, P. (2018). 
Preferred OBOT Implementation Experiences, Clinic Models and Treatment Strategies during the 
First Year (April 2017 to June 2018). Addiction and Recovery Treatment Services. An Evaluation 
Report Prepared for the Virginia Department of Medical Assistance Services.  
 
14. Cunningham, P., Barnes, A., Tong, S., Brooks, M., Aycock, R., Sheng, Y., Saunders, H., & 
Walker, L. (December 2017). Addiction and Recovery Treatment Services. Access, Utilization, 
and Spending for the Period of April 1-August 31, 2017. Report prepared for the Virginia 
Department of Medical Assistance Services.  
 
15. Cunningham, P., Barnes, A., Saunders, H., Walker, L., Sheng, Y., Tong, S., Brooks, M., Aycock, 
R. (2017). Treatment for addiction disorders increases during first three months of new Medicaid  
program. VCU ARTS Evaluation Update. Published by the Department of Health Behavior and 
Policy at Virginia Commonwealth University.   
 
16. Mason, M., Nay, Wilkinson, C., Ickes, A., Saunders, H., Markowicz, M., Zhang, J., & Campbell, 
L (2013). Project MOST (Measuring Outcomes Study) feasibility study outcome report. Report to 
the Department of Psychiatry, Virginia Commonwealth University, Richmond, VA.  
 
Invited Presentations 
Medicaid or Community Presentations 
1. Results from Qualitative Interviews with Virginia Medicaid Addiction Recovery Treatment 
Services (ARTS) receiving Opioid Use Disorder Services.  
a. Presentation to BRAVO Equity workgroup. December 2021 
b. Presentation to SUPPORT grant stakeholder group. November 2021 
c. Presentation to Virginia Medicaid. September 2021 
2. Virginia’s OUD Brightspots: Preliminary Findings. Presentation to SUPPORT grant stakeholder 








1. Exploring the Black Box of MLTSS Care Coordination: Are Member Experiences with Care 
Coordinators Associated with Subsequent Utilization? State-University Partnership Learning 
Network; AcademyHealth. June 2020.  
2. Increase in Buprenorphine Waivered Prescribers Following Expanded Coverage for Addiction 
Treatment Services in Virginia Medicaid. Presented at Addiction Health Services Research 
Conference. Park City, Utah. June 2019 
3. Increase in Buprenorphine Waivered Prescribers Following Expanded Coverage for Addiction 
Treatment Services in Virginia Medicaid. Presented at Department Health Behavior and Policy, 
Virginia Commonwealth University, Department Seminar.  
 
Poster Presentations (select) 
1. Saunders, H., Cunningham, P., Barnes, A., Moeller, G. (June 2021). Does Health Insurance 
Literacy in those Experiencing Depression/Anxiety Predict Subsequent Access to Mental Health 
Services and Unmet Mental Health Needs? Academy Health. 
2. Saunders, H., Cunningham, P., Mellor, J., Mittler, J., Walker, L. (June 2020). Exploring the Black 
Box of MLTSS Care Coordination: Are Member Experiences with Care Coordinators Associated 
with Subsequent Utilization. Academy Health, 2020, Abstract accepted but not presented due to 
COVID-19.  
3. Saunders, H., Britton, E., Cunningham, P., Rachel, J., Berhans, M. (June 2019). Intention to 
switch  
health plans at open enrollment: The pivotal role of patient experiences with care coordinators, 
Academy Health, June 2019.  
4. Miller, C., Guidry, J., Saunders, H. (February 2019). A tale of two diverse Qualtrics samples: 
Information for online survey researchers, American Academy of Cancer Research, San Diego, 
CA. 
5. Saunders, H., Cunningham, P., & Tong, S. (June 2018). Combatting the Opioid Crisis: 
Characteristics of buprenorphine providers in Virginia who accept Medicaid. Presented at 
Academy Health, Seattle Washington.  
6. Saunders, H., Walker, L., Thomson, M., Bradley, C. (November 2017). Healthcare Utilization 
Patterns in Individuals with Symptoms of Anxiety and/or Depression, American Public Health 
Association, Atlanta, GA. 
7. Walker, L., Saunders, H., Thomson, M., Bradley, C. (October 2017). The "Difficult Patient": Are 
Substance Use Disorder Patients Really Harder to Please? American Public Health Association, 
Atlanta, GA  
8. Saunders, H., Walker, L., Sheng, Y., Cunningham, P., Neuhausen, K., Barnes, A., Tong, S., 
Brooks, M., & Aycock, R. (2017, October). Impact of Virginia Medicaid’s Addiction and 
Recovery Treatment Services (ARTS) reform on opioid use disorder (OUD) providers and the 
change in waivered buprenorphine providers for all payers across Virginia. Poster session 
presented at the meeting of the Virginia Society of Addiction Medicine, Norfolk, VA. 
9. Saunders, H. (2012). Traumatic events: A secondary data analysis. School of Social Work 





10. Cartwright, K., Guiffre, H., Bock, A., Montano, M., Coppage, E. (2007). A cross-sectional 
comparison of general and reading-specific cognitive flexibility in second to fifth grad struggling 
readers. (Poster Session). Society for Research in Child Development. 
11. Bock, A., Guiffre, H. Coppage, E., Montaño, M., & Cartwright, K. B. (2007, April). Effects of a 
flexibility intervention on reading comprehension. Poster presented at the sixth annual Paideia 
Conference for Student Research, Christopher Newport University, Newport News, VA.  
12. Guiffre, H., Bock, A. M., Montaño, M. J., Cartwright, K. B., & Marshall, T. R. (2007, March).  
Cognitive inflexibility: a potential relation between children’s sex-typed reading choices and 
reading skill. Poster presented at the 78th annual meeting of the Eastern Psychological 
Association, Philadelphia, PA. 
13. Guiffre, H., Martenak, L., Frederick, J., Cartwright, K. B., & Marshall, T. R. (2006, March). Sex 
differences in first and second grade children's book choices. Poster presented at the 77th annual 
meeting of the Eastern Psychological Association, Baltimore, MD. 
 
Professional and Research Experience 
Graduate Research Assistant, Health Behavior and Policy, Virginia Commonwealth University, 2016-  
Advisor: Peter Cunningham, Ph.D. 
• Led and participated in studies evaluating Virginia Medicaid waiver programs and a federal 
needs assessment grant. Addiction Recovery and Treatment Services (1115 waiver) | 
Commonwealth Coordinated Care Plus Program (1915b waiver) | Opioid Needs Assessment 
(CMS SUPPORT Act Grant) 
• Presentation of Medicaid program evaluation findings to Medicaid policymakers and 
stakeholders in presentations, reports, and peer-reviewed journal articles. 
• Managed or participated in all aspects of study conceptualization, design, analysis, and 
execution of various studies involving multiple faculty from internal and external 
departments/universities. 
• Led survey development, data collection, analysis, and dissemination of results for multiple 
large surveys. Populations include patients who receive Medicaid long-term services and 
supports, medical providers, and facility-level surveys. Excellent response rates.  
• Designed and developed novel databases by linking Medicaid claims data to multiple sources 
of survey and publicly available data. Requests for linking methods by external researchers.   
• Led Institutional Review Board submissions and maintenance.  
• Developed a proposal for subsequent evaluation activities that was adopted. Program 
evaluation logic model and driver diagram development. 
• Qualitative lead or assistant for multiple qualitative studies: MLTSS care coordinators, 
Medicaid members receiving opioid treatment services, and Office Based Opioid Treatment 
facilities.  
• Led the comprehensive report for 3-years of evaluation activities for Virginia’s Long-term 
services and supports (MLTSS) program. This detailed report summarized evaluation 
findings, identified program strengths, and identified opportunities for improvement.  
• Led several studies to evaluate the shortage of buprenorphine waivered providers, including 
developing a survey with a discrete choice experiment for Virginia physicians, nurse 








Research Consultant, University of Colorado, 2016-2018 
 Supervisor: Cathy Bradley, Ph.D. 
• Data analysis of secondary outcomes for an AHRQ-funded randomized controlled trial 
• Dissemination of findings in a peer reviewed journal. 
 
Research Manager, Healthcare Policy and Research, Virginia Commonwealth University, 2014-2016 
Supervisor: Cathy Bradley, Ph.D. 
• Managed a team of 10 research assistants. 
• Data collection and data quality assurance for an AHRQ-funded randomized controlled trial 
to examine patient incentives to encourage primary care visits. 
 
Research Coordinator, Psychiatry, Virginia Commonwealth University, 2012-2014 
• Managed data collection and research assistant oversight for a randomized controlled trial to 
reduce substance abuse in teens in a primary care. Findings disseminated in a peer review 
journal. 
• Maintenance and development of regulatory documentation. 
• Delivered motivational interviewing intervention to teens with substance use disorder. 
• Provided oversight and data analysis of patient-reported outcome measurement pilot in 
pediatric and adult psychiatric clinics.  
 
 
Research Coordinator, Psychology, Virginia Commonwealth University, 2008-2010 
• Oversight of 8 research assistants. 
• Data collection and data quality assurance for an NIH-funded randomized controlled trial to 
increase parental involvement in the management of type 1 diabetes in a teenage population. 
 
 
Laboratory Coordinator, Psychology, College of William and Mary, 2007-2008 
 




Clinical Social Worker, Pediatric oncology, Children’s Hospital of the King’s Daughters, 2012 
• Provided supportive counseling for pediatric oncology patients and families. Connected 
patients to resources. 
• Wrote grants to obtain funding for pediatric families with financial needs.  
• Functioned as the social component of a medical oncology team in a pediatric hospital.  
 
Clinical Social Worker Intern, Center for Family Services, 2011-2012 
 




An Introduction to Survey Methods. Invited class lecture. Virginia State University, 2020. 
 
Introduction to STATA workshop. Presented to first-year PhD students. Virginia Commonwealth 
University, 2019. 
 












President, Student AcademyHealth. Virginia Commonwealth University Chapter, 2019-2021 
 





Healthcare Policy and Research Academic Program Review, Office of the Provost, Virginia 
Commonwealth University. 2021 
 





Changing the Face of the Public Health Ph.D. Workforce: Outreach Panel to Increase the Diversity of 
Ph.D. Applicants and Leaders. Event development/organization. Event moderator. AcademyHealth 
Event. Professional and Community Engagement, 2021 
 
Post Ph.D. Graduate Panel. Event Development/organization. Event moderator. AcademyHealth Event, 
2020 
 




CC Clayton Student Achievement Award, School of Medicine, Virginia Commonwealth University, 
2019 
 
Susan G Komen Scholar in Training Travel Award, American Association for Cancer Research, 2019 
  
VCU Travel Awards, School of Medicine, Virginia Commonwealth University, 2017 and 2018 
 
  
 
